Attorney's Docket No. 16153-5587 ***PATENT***

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s): William S. M. Wold

WARNING: *Patent must be applied for in the name(s) of all of the actual inventor(s). 37 CFR 1.41(a) and 1.53(b).*

For (title): INHIBITING APOPTOSIS WITH ADENOVIRUS RID PROTEIN

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date July 8, 1998, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EM001013589US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Mary Ogolin
(type or print name of person mailing paper)

Mary Ogolin
Signature of person mailing paper

NOTE: Each paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 CFR 1.10(b).

WARNING: *Certificate of mailing (first class) or facsimile transmission procedures of 37 CFR 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.*

1. Type of Application

This new application is for a(n)

(check one applicable item below)

☒ Original (nonprovisional)

☐ Design

☐ Plant

WARNING: ***Do not*** *use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4), unless the International Application is being filed as a divisional, continuation or continuation-in-part application.*

WARNING: ***Do not*** *use this transmittal for the filing of a provisional application.*

NOTE: If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.

☐ Divisional.

☐ Continuation.

☐ Continuation-in-part (C-I-P).

2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

WARNING: *If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.*

WARNING: *When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional application* ***must*** *be filed prior to the Saturday, Sunday, or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).*

☒ The new application being transmitted claims the benefit of prior U.S. application(s). Enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

3. Papers Enclosed That Are Required for Filing Date under 37 C.F.R. 1.53(b) (Regular) or 37 C.F.R. 1.153 (Design) Application

37 Pages of specification (including claims)

2 Pages of claims

1 Pages of Abstract

81 Sheets of drawing

☒ formal

☐ informal

WARNING: ***DO NOT*** *submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. Comments on proposed new 37 CFR 1.84. Notice of March 9, 1988 (1990 O.G. 57-62).*

NOTE: "Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (5/8 inch) down from the top of the page." 37 C.F.R. 1.84(c)).

(complete the following, if applicable)

☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. 1.84(b).

4. Additional papers enclosed

☐ Preliminary Amendment

☐ Information Disclosure Statement (37 C.F.R. 1.98)

☐ Form PTO–1449 (PTO/SB/08A and 08B)

☐ Citations

☐ Declaration of Biological Deposit

☐ Submission of "Sequence Listing," computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative

☐ Special Comments

☐ Other

5. Declaration or oath

☒ Enclosed

Executed by

(check **all** *applicable boxes)*

☒ inventor(s).

☐ legal representative of inventor(s). 37 CFR 1.42 or 1.43.

☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.

☐ This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. *See* item 13 below for fee.

☐ Not Enclosed.

WARNING: *Where the filing is a completion in the U.S. of an International Application, but where a declaration is not available, or where the completion of the U.S. application contains subject matter in addition to the International Application, the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.*

☐ Application is made by a person authorized under 37 C.F.R. 1.41(c) on behalf of *all* the above named inventor(s).

(The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently).

NOTE: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b).

☐ Showing that the filing is authorized.
(not required unless called into question. 37 CFR 1.41(d))

6. Inventorship Statement

WARNING: *If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.*

The inventorship for all the claims in this application are:

☒ The same.

or

☐ Not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,

☐ is submitted.

☐ will be submitted.

7. Language

NOTE: An application including a signed oath or declaration may be filed in a language other than English. A verified English translation of the non-English language application and the processing fee of $130.00 required by 37 CFR 1.17(k) is required to be filed with the application, or within such time as may be set by the Office. 37 CFR 1.52(d).

NOTE: A non-English oath or declaration in the form provided or approved by the PTO need not be translated. 37 CFR 1.69(b).

☐ English

☐ Non-English

☐ The attached translation is a verified translation. 37 C.F.R. 1.52(d).

8. Assignment

☒ An assignment of the invention to Saint Louis University

☒ is attached. A separate ☐ "COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING NEW PATENT APPLICATION" or ☒ FORM PTO 1595 is also attached.

☐ will follow.

NOTE: "If an assignment is submitted with a new application, send two separate letters-one for the application and one for the assignment." Notice of May 4, 1990 (1114 O.G. 77-78).

WARNING: *A newly executed "CERTIFICATE UNDER 37 CFR 3.73(b)" must be filed when a continuation-in-part application is filed by an assignee. Notice of April 30, 1993, 1150 O.G. 62-64.*

9. Certified Copy

Certified copy(ies) of application(s)

Country	Appln. no.	Filed
Country	Appln. no.	Filed
Country	Appln. no.	Filed

from which priority is claimed

☐ is (are) attached.

☐ will follow.

NOTE: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application, then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 C.F.R. 1.16)

A. ☒ Regular application

CLAIMS AS FILED				
Number filed	Number Extra		Rate	Basic Fee 37 C.F.R. 1.16(a) $ 790.00
Total Claims (37 CFR 1.16(c)) 25	− 20 = 5	×	$ 22.00	$110.00
Independent Claims (37 CFR 1.16(b)) 4	− 3 = 1	×	$ 82.00	$ 82.00
Multiple dependent claim(s), if any (37 CFR 1.16(d))		+	$ 270.00	-0-

☐ Amendment cancelling extra claims is enclosed.

☐ Amendment deleting multiple-dependencies is enclosed.

☐ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(d).

Filing Fee Calculation $ 982.00

B. ☐ Design application
($320.00—37 CFR 1.16(f))

Filing Fee Calculation $_____

C. ☐ Plant application
($530.00—37 CFR 1.16(g))

Filing fee calculation $_____

11. Small Entity Statement(s)

☒ Verified Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is (are) attached.

WARNING: *"Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. A nonprovisional application claiming benefit under 35 U.S.C. 119(e), 120, 121 or 365(c) of a prior application may rely on a verified statement filed in the prior application if the nonprovisional application includes a reference to a verified statement in the prior application or includes a copy of the verified statement filed in the prior application if status as a small entity is still proper and desired." 37 C.F.R. § 1.28(a).*

(complete the following, if applicable)

☐ Status as a small entity was claimed in prior application

_____ / _____, filed on _____, from which benefit is being claimed for this application under:

35 U.S.C. ☐ 119(e),
☐ 120,
☐ 121,
☐ 365(c),

and which status as a small entity is still proper and desired.

☐ A copy of the verified statement in the prior application is included.

Filing Fee Calculation (50% of **A, B** or **C** above)

$ 491.00

NOTE: Any excess of the full fee paid will be refunded if a verified statement and a refund request are filed within 2 months of the date of timely payment of a full fee. The two-month period is not extendable under § 1.136. 37 CFR 1.28(a).

12. Request for International-Type Search (37 C.F.R. 1.104(d))

(complete, if applicable)

☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

13. Fee Payment Being Made at This Time

☐ Not Enclosed

☐ No filing fee is to be paid at this time.
(This and the surcharge required by 37 C.F.R. 1.16(e) can be paid subsequently.)

☒ Enclosed

☒ Basic filing fee	$ 491.00
☒ Recording assignment ($40.00; 37 C.F.R. 1.21(h)) (See attached "COVER SHEET FOR ASSIGNMENT ACCOMPANYING NEW APPLICATION".)	$ 40.00
☐ Petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached ($130.00; 37 C.F.R. 1.47 and 1.17(h))	$ _____
☐ For processing an application with a specification in a non-English language ($130.00; 37 C.F.R. 1.52(d) and 1.17(k))	$ _____
☐ Processing and retention fee ($130.00; 37 C.F.R. 1.53(d) and 1.21(l))	$ _____
☐ Fee for international-type search report ($40.00; 37 C.F.R. 1.21(e))	$ _____

NOTE: 37 CFR 1.21(l) establishes a fee for processing and retaining any application that is abandoned for failing to complete the application pursuant to 37 CFR 1.53(d) and this, as well as the changes to 37 CFR 1.53 and 1.78, indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid, or the processing and retention fee of § 1.21(l) must be paid, within 1 year from notification under § 53(d).

Total fees enclosed $ 531.00

14. Method of Payment of Fees

☒ Checksin the amount of $491.00 and $40.00 are enclosed

☐ Charge Account No. _____ in the amount of $_____.

A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

15. Authorization to Charge Additional Fees

WARNING: *If no fees are to be paid on filing, the following items should not be completed.*

WARNING: *Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.*

☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 18-1829 :

☒ 37 C.F.R. 1.16(a), (f) or (g) (filing fees)

☒ 37 C.F.R. 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

☒ 37 C.F.R. 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)

☒ 37 C.F.R. 1.17 (application processing fees)

WARNING: *While 37 CFR 1.17(a), (b), (c) and (d) deal with extensions of time under § 1.136(a), this authorization should be made only with the knowledge that: "Submission of the appropriate extension fee under 37 C.F.R. 1.136(a) is to no avail unless a request or petition for extension is filed." (Emphasis added). Notice of November 5, 1985 (1060 O.G. 27).*

☐ 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).

NOTE: 37 CFR 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . issue fee." From the wording of 37 CFR 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

16. Instructions as to Overpayment

☒ Credit Account No. 18-1829

☐ Refund

SIGNATURE OF ATTORNEY

Reg. No. 35,197

Donald R. Holland

(type or print name of attorney)

Tel. No. (314) 727-5188

Howell & Haferkamp, L.C.
7733 Forsyth, Suite 1400

P.O. Address

St. Louis, Missouri 63105

☒ **Incorporation by reference of added pages**

(check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)

☒ Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added 5

☐ Plus Added Pages for Papers Referred to in Item 4 Above

Number of pages added _____

☒ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added 3

☐ **Statement Where No Further Pages Added**

(if no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item)

☐ This transmittal ends with this page.

Attorney's Docket No. 16153-5587 **PATENT**

ADDED PAGES FOR APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED

NOTE: "In order for an application to claim the benefit of a prior filed copending national application, the prior application must name as an inventor at least one inventor named in the later filed application and disclose the named inventor's invention claimed in at least one claim of the later filed application in the manner provided by the first paragraph of 35 U.S.C. 112." 37 CFR 1.78(a).

NOTE: "In addition the prior application must be (1) complete as set forth in § 1.51, or (2) entitled to a filing date as set forth in § 1.53(b) and include the basic filing fee set forth in § 1.16; or (3) entitled to a filing date as set forth in § 1.53(b) and have paid therein the processing and retention fee set forth in § 1.21(l) within the time period set forth in § 1.53(d)." 37 CFR 1.78(a).

17. Relate Back

WARNING: *If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.*

(complete the following, if applicable)

☒ Amend the specification by inserting, before the first line, the following sentence:

A. 35 U.S.C. 119(e)

NOTE: "Any nonprovisional application claiming the benefit of one or more prior filed copending provisional applications must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior provisional application, identifying it as a provisional application, and including the provisional application number (consisting of series code and serial number)." 37 C.F.R. § 1.78(a)(4).

☒ "This application claims the benefit of U.S. Provisional Application(s) No(s).:

APPLICATION NO(S).:	FILING DATE
60 / 088/993	7/9/97 "
/	"
/	"

B. 35 U.S.C. 120, 121 and 365(c)

NOTE: "Any nonprovisional application claiming the benefit of one or more prior filed copending nonprovisional applications or international applications designating the United States of America must contain or be amended to contain in the first sentence of the specification following the title a reference to each such prior application, identifying it by application number (consisting of the series code and serial number) or international application number and international filing date and indicating the relationship of the applications. Cross-references to other related applications may be made when appropriate. (See § 1.14(b))." 37 C.F.R. § 1.78(2).

☐ "This application is a

- ☐ continuation
- ☐ continuation-in-part
- ☐ divisional

of copending application(s)

☐ application number 0 /_____ filed on _____"

☐ International Application _____ filed on _____ and which designated the U.S."

NOTE: The proper reference to a prior filed PCT application that entered the U.S. national phase is the U.S. serial number and the filing date of the PCT application that designated the U.S.

NOTE: (1) Where the application being transmitted adds subject matter to the International Application, then the filing can be as a continuation-in-part or (2) if it is desired to do so for other reasons then the filing can be as a continuation.

☐ "The nonprovisional application designated above, namely application _____ / _____, filed _____, claims the benefit of U.S. Provisional Application(s) No(s).:

APPLICATION NO(S).:	**FILING DATE**
_____ /_____	_____"
_____ /_____	_____"
_____ /_____	_____"

NOTE: The deadline for entering the national phase in the U.S. for an international application was clarified in the Notice of April 28, 1987 (1079 O.G. 32 to 46) as follows:

"The Patent and Trademark Office considers the International application to be pending until the 22nd month from the priority date if the United States has been designated and no Demand for International Preliminary Examination has been filed prior to the expiration of the 19th month from the priority date and until the 32nd month from the priority date if a Demand for International Preliminary Examination which elected the United States of America has been filed prior to the expiration of the 19th month from the priority date, provided that a copy of the international application has been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively. If a copy of the international application has not been communicated to the Patent and Trademark Office within the 20 or 30 month period respectively, the international application becomes abandoned as to the United States 20 or 30 months from the priority date respectivley. These periods have been placed in the rules as paragraph (h) of § 1.494 and paragraph (i) of § 1.495. A continuing application under 35 U.S.C. 365(c) and 120 may be filed anytime during the pendency of the international application."

18. Relate Back—35 U.S.C. 119 Priority Claim for Prior Application

The prior U.S. application(s), including any prior International Application designating the U.S., identified above in item 17B, in turn itself claim(s) foreign priority(ies) as follows:

country	appln. no.	filed on

The certified copy(ies) has (have)

☐ been filed on _____, in prior application 0 /_____, which was filed on _____.

☐ is (are) attached.

WARNING: *The certified copy of the priority application that may have been communicated to the PTO by the International Bureau may* ***not*** *be relied on without any need to file a certified copy of the priority application* ***in the continuing application.*** *This is so because the certified copy of the priority application communicated by the International Bureau is placed in a folder and is not assigned a U.S. serial number unless the national stage is entered. Such folders are disposed of if the national stage is not entered. Therefore, such certified copies may not be available if needed later in the prosecution of a continuing application. An alternative would be to physically remove the priority documents from the folders and transfer them to the continuing application. The resources required to request transfer, retrieve the folders, make suitable record notations, transfer the certified copies, enter and make a record of such copies in the Continuing Application are substantial. Accordingly, the priority documents in folders of international applications that have not entered the national stage may not be relied on. Notice of April 28, 1987 (1079 O.G. 32 to 46).*

19. Maintenance of Copendency of Prior Application

NOTE: The PTO finds it useful if a copy of the petition filed in the prior application extending the term for response is filed with the papers constituting the filing of the continuation application. Notice of November 5, 1985 (1060 0.G. 27).

A. ☐ Extension of time in prior application

(This item ***must*** *be completed and the papers filed* ***in the prior application,*** *if the period set in the prior application has run.)*

☐ A petition, fee and response extends the term in the pending **prior** application until _____.

☐ A **copy** of the petition filed in prior application is attached.

B. ☐ Conditional Petition for Extension of Time in Prior Application

(complete this item, if previous item not applicable)

☐ A conditional petition for extension of time is being filed in the pending **prior** application.

☐ A **copy** of the conditional petition filed in the prior application is attached.

20. Further Inventorship Statement Where Benefit of Prior Application(s) Claimed

NOTE: *"If the continuation, continuation-in-part, or divisional application is filed by less than all the inventors named in the prior application a statement* ***must*** *accompany the application when filed requesting deletion of the names of the person or persons who are not inventors of the invention being claimed in the continuation, continuation-in-part, or divisional application." 37 CFR 1.62(a) [emphasis added]. (dealing with the file wrapper continuation situation).*

NOTE: *"In the case of a continuation-in-part application which adds and claims additional disclosure by amendment, an oath or declaration as required by § 1.63 must be filed. In those situations where a new oath or declaration is required due to additional subject matter being claimed, additional inventors may be named in the continuing application. In a continuation or divisional application which discloses and claims only subject matter disclosed in a prior application, no additional oath or declaration is required and the application must name as inventors the same or less than all the inventors in the prior application." 37 CFR 1.60(c) (dealing with the continuation situation).*

(complete applicable item (a), (b) and/or (c) below)

(a) ☐ This application discloses and claims only subject matter disclosed in the prior application whose particulars are set out above and the inventor(s) in this application are

- ☐ the same.
- ☐ less than those named in the prior application. It is requested that the following inventor(s) identified for the prior application be deleted:

_____

(type name(s) of inventor(s) to be deleted)

(b) ☐ This application discloses and claims additional disclosure by amendment and a new declaration or oath is being filed. With respect to the prior application, the inventor(s) in this application are

- ☐ the same.
- ☐ the following additional inventor(s) have been added:

_____

(type name(s) of inventor(s) to be added)

(c) The inventorship for all the claims in this application are

- ☐ the same.
- ☐ not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made
  - ☐ is submitted.
  - ☐ will be submitted.

21. Abandonment of Prior Application *(if applicable)*

☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

NOTE: According to the Notice of May 13, 1983 (103, TMOG 6-7), the filing of a continuation or continuation-in-part application is a proper response with respect to a petition for extension of time or a petition to revive and should include the express abandonment of the prior application conditioned upon the granting of the petition and the granting of a filing date to the continuing application.

22. Petition for Suspension of Prosecution for the Time Necessary to File an Amendment

WARNING: *"The claims of a new application may be finally rejected in the first Office action in those situations where (1) the new application is a continuing application of, or a substitute for, an earlier application, and (2) all the claims of the new application (a) are drawn to the same invention claimed in the earlier application, and (b) would have been properly finally rejected on the grounds of art of record in the next Office action if they had been entered in the earlier application." MPEP, § 706.07(b).*

NOTE: Where it is possible that the claims on file will give rise to a first action final for this continuation application and for some reason an amendment cannot be filed promptly (e.g., experimental data is being gathered) it may be desirable to file a petition for suspension of prosecution for the time necessary.

(check the next item, if applicable)

☐ There is provided herewith a Petition To Suspend Prosecution for the Time Necessary to File An Amendment (New Application Filed Concurrently)

23. Small Entity (37 CFR § 1.28(a))

☐ Applicant has established small entity status by the filing of a verified statement in parent application /_____ on _____ .

☐ A copy of the verified statement previously filed is included.

WARNING: *"Status as a small entity in one application or patent does not affect any other application or patent, including applications or patents which are directly or indirectly dependent upon the application or patent in which the status has been established. Applications filed as continuations, divisions or continuations-in-part of a parent application must include a reference to a verified statement filed in the parent application if status as a samll entity is still proper and desired." 37 CFR § 1.28(a).*

24. NOTIFICATION IN PARENT APPLICATION OF THIS FILING

☐ A notification of the filing of this
(check one of the following)

- ☐ continuation
- ☐ continuation-in-part
- ☐ divisional

is being filed in the parent application, from which this application claims priority under 35 U.S.C. § 120.

PATENT

Inhibiting Apoptosis with Adenovirus RID Protein

Reference to Government Grant

This invention was made with government support under Grant Number RO1 CA58538. The government has certain rights in this invention.

Related Application

This application claims priority to U.S. Provisional Application serial number 60/088,993, filed July 9, 1997, which is incorporated herein in its entirety by reference.

Background of the Invention

(1) Field of the Invention

This invention relates generally to the regulation of apoptosis and, more particularly, to a method for inhibiting apoptosis using the Adenovirus RID protein and to applications of this method, including promoting survival of tissue transplants, treating autoimmune disease, and promoting tumor destruction in cancer patients.

(2) Description of the Related Art

Apoptosis, or programmed cell death, plays a fundamental role in regulation of the immune system. For review, see White, E. *Genes & Development 10*:1-15, 1996; van Parijs. L. and Abbas, A.K., *Curr. Opin. Immunol. 8*:355-361, 1996; Nagata, S., *Cell 88*:355-365, 1997. In recent years researchers have shown that some members of the tumor necrosis factor (TNF) family of cytokines can induce apoptosis by binding to their specific receptors on

target cells. Nagata, *supra*; Baker , S.J. and Reddy, E.P., *Oncogene 12*:1-9, 1996. The receptors for the TNF family of cytokines belong to a family of proteins referred to as the TNFR family, which is characterized by an extracellular domain of highly conserved cysteine residues contained in cysteine-rich pseudorepeats (Chaudhary et al., *Immunity 7*:821-830, 1997). In addition, several members of the TNFR family possess a conserved cytoplasmic domain of approximately 80 amino acids called the death domain, which functions to initiate an intracellular apoptotic signaling cascade upon binding of the appropriate cytokine. (*See* Chaudhary et al., *supra*; Walczak et al., *EMBO J. 16*:5386-5397, 1997.) TNFR proteins containing death domains comprise a death receptor subfamily which includes: TNFR1 (Tartiglia et al., *Cell 74*:845-853, 1993); Fas (also called CD95 and Apo-1) (Itoh and Nagata, *J.Biol. Chem. 268*:10932-10937, 1993); death receptor 3 (DR3, also called TRAMP, Apo-3, Wsl-1, and LARD) (Chinnaiyan et al., *Science 274*:990-992,1996; Kiston et al., *Nature 384*:372-375, 1996); TRAIL-R1 (also known as DR4) (Pan et al., *Science 276*:111-113, 1997); and TRAIL-R2 (also called DR5) (Pan et al., *Science 277*:815-818, 1997). The death domains of these proteins are shown in Figure 1.

Fas, the most studied death receptor, is expressed on the surface of most cell types, including epithelial cells, fibroblasts, T and B cells, liver hepatocytes and some tumor cells (Nagata, *Nature Medicine 2*:1306-1307, 1996; French et al., *Nature Medicine 3*:387-388, 1997). However, FasL is primarily expressed by activated leukocytes of the immune system, including cytotoxic T lymphocytes (CTL's) and natural killer (NK) cells (Nagata, *Cell, supra)*. It is believed that the Fas ligand (FasL) plays a role in the immune response of these cells to induce apoptosis in target cells expressing Fas. Such target cells include virus-infected cells and tumor cells. On the other hand, leukocytes also express Fas, which can result in down regulation of the immune response due to activated leukocytes killing each other (Nagata, *Cell, supra)*.

Recently, it was discovered that FasL is also expressed in immune-privileged sites such as the eye chamber, parts of the nervous system, and testis and it is believed that any activated leukocytes entering such sites are immediately killed through the FasL-Fas apoptotic pathway, thereby preventing a potentially crippling immune response (Nagata, *Cell, supra)*. This finding could potentially be applied to preventing transplant rejection and, indeed, one group has reported that islet allografts were protected from immune rejection by cotransplantation with syngeneic myoblasts expressing functional FasL (Lau et al., *Science 273*:109-112, 1996).

The discovery of FasL expression in immune-privileged sites led a number of groups to examine whether the means by which tumor cells avoid destruction is through expression of FasL. A number of tumor cell types were subsequently reported to constitutively express

FasL, including lymphoma and leukemia cells (Tanake, et al., *Nature Med. 2*:317-322, 1996) various nonlymphoid carcinoma cells, including colon cancer (O'Connell, et al., *J. Exp. Med. 184*:1075-1082, 1996), hepatocellular carcinoma (Strand et al., *Nature Med. 2*1361-1366, 1996) and melanoma (Hahne et al., *Science 274*:1363-1366, 1996). As a result of expressing FasL, many tumor cells have the ability to kill attacking CTL and NK cells thereby reducing the immune response against the tumor. In addition, it has been reported that some types of tumors become resistant to Fas-mediated apoptosis, either by downregulation of Fas expression or by other unknown mechanisms, and thereby avoid being killed by the infiltrating leukocytes (Nagata, *Nat. Med., supra.*; Strand et al., *supra;* Hahne et al., *supra).* Because alterations in Fas-FasL regulation, including upregulation of FasL expression and downregulation of Fas expression, may be involved in tumor cells avoiding destruction by the immune system, it would be desirable to devise an approach that would reduce the effect of such changes in Fas-FasL regulation. In one such approach it was recently reported that the anti-cancer drug doxorubicin enhances expression of both Fas and Fasl in tumor cells (Friesen et al., *Nature Med.* 2:574-577, 1996).

Recent reports have associated other disease states with dysfunction of the Fas system, including hypereosinophilic syndromes in humans (Lenardo et al., *J. Exp. Med. 183*:721-724, 1996), hepatitis (Kondo et al., *Nat. Med. 3*:409-413, 1997) and the autoimmune disease Hashimoto's thyroiditis (HT) (Giordano et al., *Science 175*:960-963, 1997). Consequently, it has been suggested that inappropriate upregulation of Fas may be a causal factor in other autoimmune diseases involving tissues which constitutively express FasL (French et al., *supra).*

Human adenoviruses (used interchangeably herein with Ad), which cause disease in the respiratory tract, conjunctiva, intestine, urinary tract and liver, have evolved elaborate mechanisms to overcome host antiviral defenses, including at least four of the seven known proteins encoded by the early region 3 (E3) transcription unit which have been reported to inhibit the host immune response to Ad-infected cells (Fejer et al., *J. Virol. 68*:5871-5881, 1994; Sparer et al., *J. Virol. 770*:2431-2439, 1996). One of these proteins is a 19kDa glycoprotein (gp19K), which inhibits CTL-mediated lysis of Ad-infected cells *in vitro* (Efrat et al., *Proc. Natl. Acad. Sci. 92*:6947-6951, 1995). Three other E3 proteins, the 14.7K protein and 10.4K protein in combination with the 14.5K protein (referenced hereinafter as the 10.4K/14.5K complex), protect adenovirus-infected cells against cytolysis and the inflammatory response induced by tumor necrosis factor-α (TNF-α) both *in vitro* and *in vivo* (Sparer et al., *supra*; Krajcsi et al., *J. Virol.* 70:4904-4913, 1996; Dimitrov et al., *J. Virol.* 71:2830-2837, 1997). Although the exact stoichiometry of 10.4K and 14.5K proteins in this complex is not known, it is believed to consist of one 14.5K polypeptide in physical

association with a dimer formed by full-length and short forms of the 10.4K polypeptide joined in disulfide linkage. Stewart et al, *supra*.

Efrat et al. have reported that the expression of the one of the Ad E3 genes, i.e. the gene encoding the 19kDa glycoprotein (gp19K), can prolong survival of pancreatic islet allografts. The islets were obtained from transgenic animals prepared to contain the entire E3 genomic DNA from human Ad, however, the gp19K mRNA was prominently expressed with little or no expression of the 10.4K protein which makes up a portion of the 10.4/14.5 complex. The islet allografts survived reportedly due to the expression of the gp19K protein and there was no suggestion in this reference that the 10.4K or 14.5K proteins either separately or in the 10.4K/14.5K complex played any role in the survival of the allografts.

Nevertheless, the 10.4/14.5 complex can protect Ad-infected cells from the inflammatory response in the context of Ad infection (Sparer et al., *supra*) and, although it has not been heretofore recognized, it is possible that the 10.4K/14.5K complex could also provide a novel basis for modulating the immune system in certain disease processes.

Summary of the Invention

In accordance with the present invention, the inventor herein has succeeded in discovering that the Ad 10.4K/14.5K complex inhibits apoptosis mediated by death receptors, in particular Fas or TNFR-1, by removing the death receptor from the cell surface. The present invention, thus, provides a method for inhibiting apoptosis of a cell comprising treating the cell with an effective amount of a 10.4K/14.5K complex referenced herein as RID (Receptor Internalization and Death) or as RID complex. The RID complex reduces the number of molecules of one or more death receptors on the surface of the cell. This down-regulation of the death receptor results from internalization of the receptor to endosomes and degradation of the internalized death receptor by lysozymes. The RID complex is obtained from or derived from the RIDα and RIDβ proteins encoded by the Ad E3 region DNA. Other E3 region-encoded proteins, including the gp19K and 14.7K proteins, are not required to remove the death receptor from the cell surface or to induce apoptosis. Due to the similar structure of TNFR death receptors, and in the common pathway by which they mediate apoptosis, it is believed that RID can inhibit apoptosis mediated by all death receptor members of the TNFR family by promoting their removal from the cell surface.

In one embodiment of the present invention, the cell is treated with RID by administering to the cell a polynucleotide encoding the RID complex, through which the RID complex is expressed in the cell. Alternatively, the treating step comprises administering the RID complex to the cell, preferably in a carrier that facilitates delivery of the complex into the cell. The method can be used to inhibit apoptosis of cells expressing one or more death

receptors of the TNFR family, including but not limited to Fas, TNFR-1, DR3, TRAIL-R1 and TRAIL-R2. Where the cell comprises a tissue, the method is useful for promoting survival of a tissue transplant in a patient or in promoting survival of a tissue under attack in a patient suffering from a degenerative disease, an immunodeficiency disease, an autoimmune disorder or other diseases associated with disregulation of apoptosis mediated by the TNFR death receptors. The method is also useful in inhibiting apoptosis of leukocytes mediated by tumor cells in cancer patients, thereby promoting leukocyte destruction of the patient's tumor cells.

Accordingly, in another embodiment, the present invention provides a method for decreasing apoptosis of target cells in a patient comprising treating the patient with an effective amount of a RID complex. The target cells express a death receptor which is downregulated when RID enters the cells.

In yet another embodiment, the invention provides a method for inhibiting leukocyte apoptosis in a patient comprising withdrawing leukocytes from the patient, treating the leukocytes with an effective amount of a RID complex, and administering the treated leukocytes to the patient.

In another embodiment, the present invention provides a composition comprising a RID complex in a carrier suitable for facilitating entry of the RID complex into a cell. As illustrated in Figure 3, a RID complex comprises at least three polypeptides: a full-length Ad E3 10.4K protein having two transmembrane domains (RIDα-L), a short form of the 10.4K protein with only one transmembrane domain (RIDα-S), and a 14.5K protein (RIDβ). RID compositions intended for treating humans preferably contain a pharmaceutically acceptable carrier. In one embodiment, the carrier component of the composition comprises a liposome.

The present invention also provides an Ad vector for expressing a RID complex in a cell and to cells transfected with this vector. The vector comprises a nucleotide sequence encoding the RIDα and RIDβ polypeptide components of the complex operably linked to a promoter capable of directing expression of the nucleotide sequence in the cell. A preferred vector consists of 231-10 (SEQ ID NO:2), which expresses functional polypeptides for all of the E3 genes other than *adp*.

Among the several advantages found to be achieved by the present invention, therefore, may be noted the provision of compositions and methods for inhibiting apoptosis of a cell expressing a death receptor; the provision of compositions and methods for promoting tissue transplant survival in patients; the provision of compositions and methods for treating patients suffering from an autoimmune disease and other disorders associated with

dysfunction of apoptosis regulation; and the provision of compositions and methods for promoting tumor destruction in cancer patients.

Brief Description of the Drawings

Figure 1 shows an alignment of the amino acid sequences of the death domains of the death receptor subfamily of TNFR proteins, with residues identical in more than 30% of sequences shaded black and residues conserved in more than 30% of sequences shaded in gray;

Figure 2 is a schematic representation of apoptosis mediated by death domain-containing members of the TNF receptor superfamily, with the death receptors Fas, TNFR1, TRAIL-R1, TRAIL-R2 and DR3 depicted by the bars on the extreme right and left sides of the figure, the ligands for these receptors indicated in parenthesis, and showing the association of the death receptors with intracellular proteins in the apoptotic singling cascade at the bottom of the figure;

Figure 3 is a schematic representation of a preferred RID complex showing one mature 14.5K polypeptide having an O-glycosylated residue in the extracellular (or lumenal) domain and an O-phosphorylated residue in the cytoplasmic domain, and two covalently-linked 10.4K polypeptides, one of which is an uncleaved, full-length form of 10.4K (10.4K-L) having two membrane-spanning regions (diagonal stripes) and the other a cleaved, short form of 10.4K (10.4K-S) with only one transmembrane region;

Figure 4 illustrates the amino acid sequences and various domains of preferred embodiments of the RIDα and RIDβ polypeptides, showing in Fig. 4A-4B the long and short forms of the E3 10.4K polypeptides (RIDα-L and RIDα-S) from Ad serotype 2, Fig. 4C the pre-14.5K (RIDβ) polypeptide of Ad serotype 5, and in Fig. 4D the mature 14.5K (RIDβ) polypeptide of Ad serotype 5, with the signal sequences and transmembrane domains underlined and the asterisks indicating sites for disulfide linkage in RIDα or for O-phosphorylation in RIDβ;

Figure 5 is a schematic representation of a model for RID-induced internalization and degradation of Fas and TNFR1 death receptors, showing RID and the death receptor in the plasma membrane, entry of RID and the death receptor into endosomes, transport of these endosomes to lysosomes where the death receptor is degraded, and recycling of RID in endosomes to the cell surface, where it can internalize another death receptor molecule;

Figure 6 shows photographs of MCF7-Fas cells (Figs. 6A and 6B) infected with *rec*700 Ad ("wild-type") or (Figs. 6C and 6D) transiently transfected with pMT2-RIDα plus pMT2-RIβ which were then treated with an agonist monoclonal antibody to Fas and double-

stained for the adenovirus-encoded DNA binding protein (anti-ADP) (Fig. 6A) and for DNA 4, 6-diamidino-2-phenylindole (DAPI) (Fig. 6B) or double-stained for RIDβ (Fig. 6C) and DNA (Fig. 6D), with the photographs taken using a 100X Plan apo objective lens;

Figure 7 shows flow cytometry tracings of MCF7-Fas cells which were mock-infected (Fig. 7A) or infected with wild-type Ad (Ad5 and *rec*700) (Figs. 7B-7C) or with the indicated Ad E3 mutant (Figs. 7D-7H) and then incubated with antibodies to Fas (bold trace), transferrin receptor (dashed trace), or control IgG (light trace);

Figure 8 shows flow cytometry tracings of A549 cells which were mock-infected (Fig. 8B) or infected with wild-type Ad (*rec*700) (Fig. 8C) or with the indicated Ad E3 mutant (Figs. 7D-7H) and then incubated with antibodies to Fas (red trace), transferrin receptor (blue trace), or control IgG (black trace), with the cell pattern for mock-infected cells shown in Fig. 8A and R1 indicating the cells that were gated for the analysis;

Figure 9 shows photographs of mock-infected MCF7 cells (Fig. 9A) or MCF7-Fas cells mock-infected (Fig. 9B) or infected with the indicated viruses (Figs. 9C-9H) and then analyzed for Fas by immunofluorescence, with the speckled pattern in Figs. 9C, 9G, and 9H representing putative endosomes and lysosomes containing Fas;

Figure 10 shows an immunoblot of proteins extracted from MCF-7 Fas cells following mock-infection or infection with the indicated wild-type and mutant Ads and stained for Fas (Fig. 10A), transferrin receptor (Fig. 10B) or Ad E1A (Fig. 10C), with molecular weight markers indicated on the right;

Figure 11 shows photographs of COS7 cells transfected with expression plasmids for Fas and RIDα (Fig. 11A, 11B), Fas and RIDβ (Fig. 11C, 11D), or Fas, RIDα, and RIDβ (Fig. 11E-11H) and double-stained for RIDα and Fas (Fig. 11A, 11B, 11E, 11F) or for RIDβ and Fas (Fig. 11C, 11D, 11G, 11H) with arrow in Figs. 11G and H indicate vesicles that appear to contain both RIDβ and Fas;

Figure 12 shows photographs of rec700-infected A549 cells double-stained for Fas and a lysosomal protein, LAMP1 and examined by confocal microscopy, with Fig. 12A showing cells labeled with rabbit anti-Fas antibody and fluoroscein isothiocyanate (FITC), Fig. 12B showing cells labeled with mouse anti-LAMP-1 antibody and rhodamine isothiocyanate (RITC), Fig. 12C showing the combined images of Fig. 12A and 12 B, and Fig. 12D showing a perpendicular view of the image in Fig. 12C (arrows), 1 μm thick, where green indicates Fas, red indicates LAMP-1 and yellow indicates colocalization of Fas and LAMP1 and the bar indicating a distance of 10 μm;

Figures 13A-13C show photographs of immunofluorescence labeling of Fas in *rec*700-infected cells treated (Fig. 13A) or not treated (Fig. 13B) with bafilomycin A1 (Baf), or in *dl*309 (RID^-)-infected cells treated with Baf (Fig. 13C);

Figure 13D shows an immunoblot of proteins extracted from mock-, *rec*700- or *dl*309-infected cells treated (+) or not treated (-) with bafilomycin A1 (Baf) and stained for Fas, ERp72, or Ad protein E1B-19K;

Figure 13E shows the immunoblot of Fig. 13D following removal of antibody and restaining for transferrin receptor (TfR);

Figure 14 shows an immunoblot of proteins extracted from COS7 cells transfected with various combinations of plasmids expressing Fas, Shp-1, RIDα or RIDβ as indicated by the "-" and "+" signs and stained for Fas, Erp72 or Shp-1 using appropriate antisera, with the arrows indicating two groupings of bands which correspond to differently glycosylated species of Fas;

Figure 15 shows an immunoblot of proteins extracted from COS7 cells transfected with various combinations of plasmids expressing Fas, chloramphenical acetyl-transferase (CAT), RIDα or RIDβ as indicated by the "-" and "+" signs and stained for Fas, Erp72 or CAT using appropriate antisera, with the arrows indicating two groupings of bands which correspond to differently glycosylated species of Fas;

Figures 16A and 16B are graphs of the amount of lysis of mock-, *rec*700- or *dl*7001-infected Fas-positive mouse P815 cells by activated cytotoxic lymphocyetes (CTL) from peforin (-/-) mice (Fig. 16A) or matched perforin (+/+) mice (Fig. 16B) at effector lymphocyte:target ratios of 60:1 (black bars), 20:1 (stippled bars), or 6:1 (open bars);

Figure 16C shows flow cytometry tracings of P815 cells infected with *rec*700 (middle plot) or *dl*7000 (right dark plot) and then stained for Fas, with the left plot showing the IgG control;

Figure 17 is a graph of the amount of lysis of mock- or Ad-infected Fas-positive human A549 cells by natural killer (NK) cells at NK:A549 cell ratios of 10:1(black bar) and 5:1 (striped bar);

Figure 18 shows flow cytometry tracings of human HeLa cells mock-infected (green trace) or infected with *rec*700 (red trace) or *dl*712, a mutant that overexpresses RID and E3-14.7K (blue trace) and then stained for TNFR1 (Fig. 18A) or Fas (Fig. 18B), with the percentage of cells that stained positive for TNFR1 or Fas indicated at the bottom;

Figure 19 shows flow cytometry tracings of human HeLa cells mock-infected (black trace) or infected with *rec*700 (red trace), *dl*753 (light blue trace), *dl*764 (dark blue trace), *dl*712 (green trace), *dl*309 (pink trace) and then stained for TNFR1 (Fig. 19A) or Fas (Fig.

19B), with the genotype of each virus and the percentage of cells that stained positive for TNFR1 or Fas indicated at the bottom;

Figure 20 shows flow cytometry tracings of human HeLa cells mock-infected (black trace) or infected with the 231-10 vector, which expresses only the E3 proteins, and then stained for TNFR1 at 24 hr. p.i. (red trace) or 48 hr. p.i. (blue trace);

Figure 21 shows an immunoblot of TNFR1 extracted from A549 cells mock-infected or infected with rec700 in which cell surface proteins were labeled by incubation with biotin at the indicated hour p.i.;

Figure 22 shows an immunoblot of TNFR1 (Fig. 22A) and RIDβ (Fig. 22B) extracted from A549 cells mock-infected or infected with *rec*700 or the 231-10 vector in which cell surface proteins were labeled by incubation with biotin at the indicated hour p.i.;

Figure 23A shows an immunoblot of TNFR1 extracted from A549 cells mock-infected or infected with the indicated virus in which cell surface proteins were labeled by incubation with biotin at 26 h p.i.;

Figure 23B shows an immunoblot of Ad E1B-19K protein extracted from the same cells used in Fig. 23A;

Figure 24 shows a photograph of exposed skin and muscle of the hind flanks of a female C57Bl/6 mouse sacrificed 18 days after the flanks were subcutaneously injected with human cancer A549 cells infected with the 231-10 vector, with A549 tumors appearing as whitish-tan masses on each flank;

Figure 25 shows a closer view of the tumor on the right flank of the mouse in Fig. 24;

Figure 26 shows an immunoblot of proteins extracted from an A549 tumor grown in a mouse such as described in Fig. 24;

Figure 27 is a schematic illustration of the structure of the genome of the Ad 231-10 vector, with the black horizontal bar representing the backbone of the Ad5 genome, from which the E1 and E3 regions are deleted, as indicated by the triangles below the black bar, and containing an expression cassette with the CMV promoter controlling the E3 genes inserted into the deleted E1 region, as indicated by the triangle to the left, above the black bar, with the transcription unit oriented from right to left as indicated by the arrowhead and restriction endonuclease cleavage sites flanking the CMV-E3 cassette indicated;

Figure 28 illustrates the nucleotide sequence of the 231-10 genome with the numbering beginning with the first base-pair on the conventional left side of the Ad5 genome as shown in Fig. 27 and proceeding to the last base-pair at the right side of the genome;

Figure 29 shows an immunoblot of E3 RIDβ, 14.7K, and gp19K proteins expressed in A549 cells infected with the 231-10 vector and detected at the days p.i. indicated, with lane A

containing proteins extracted from 231-10-infected cells at 1 day p.i. following treatment with 1-β-D-arabinofuransylcytosine (araC) at 2 h p.i.; and

Figure 30 shows a photograph of A549 cells infected with the 231-10 vector and gp19K, RIDβ, and 14.7K proteins detected by indirect immunoflourescence.

Detailed Description of the Invention

The present invention is based on the discovery that the Ad RID complex inhibits apoptosis mediated by death receptors, and in particular by Fas and TNFR1. Some of the molecular events involved in apoptosis induced through death receptors of the TNFR family are illustrated in Fig. 2. Fas (bar on the extreme right) is localized on the cell surface. When FasL engages Fas on the outside of the cell (top of Fig. 2), Fas associates with proteins within the cell (bottom of Fig. 2). First, Fas binds a protein named FADD through their corresponding death domains and then the Fas/FADD complex binds the protein named Caspase 8 through another region in FADD and Caspase 8 named the "death effector" domain. This binding activates the enzymatic activity of Caspase 8, an "initiator" caspase. Activated Caspase 8 cleaves other caspases (effector caspases), which then cleave other proteins, and apoptosis ensues. Apoptosis induced through TNFR is very similar, except that an additional protein, named TRADD, is involved. TNF engages TNFR1, causing it to bind TRADD through death domains in TNFR1 and TRADD (left part of Fig. 2). The TNFR1/TRADD complex then binds FADD through their death domains and this is followed by binding to Caspase 8, etc. TRAIL-R1, TRAIL-R2, and DR3 are believed to undergo a similar binding cascade to activate caspases, although the ligand that triggers apoptosis through DR3 is unknown.

RID inhibits apoptosis by means of an internalization and degradation mechanism common to all death receptors. As illustrated in Figure 2, RID shuttles the death receptor from the cell surface to lysosomes where the receptors are degraded. This model is supported in part by the fact that the RID complex has two motifs in its intracellular portion that are known to play a role in the internalization of some cell surface receptors and their transport to lysosomes. These motifs are a dileucine motif (LL), which is present in RIDα, and a tyrosine-based motif in RIDβ, which is YXXϕ, where Y is tyrosine, X is any amino acid, and ϕ is an aromatic or bulky hydrophobic amino acid such as phenylalanine, tyrosine, tryptophan and proline. It is believed that RID acts through the LL and YXXϕ motifs to cause Fas or TNFR1 to be internalized into early/sorting endosomes. Again, acting through the LL and YXXϕ motifs, RID mediates transport of the early endosomes to late endosomes and then to lysosomes where the receptors are degraded. RID then recycles back to the cell surface in

endosomes where it repeats this process. Additional evidence supporting this model is as follows: (1) RID co-localizes with Fas on the cell surface as well as in vesicles; (2) degradation of Fas is inhibited by bafilomycin A1, an inhibitor of late endosome function; (3) the RID proteins are very stable, as indicated by pulse-chase experiments, whereas Fas is very unstable in the presence of RID; and (4) mutation of the LL motif severely reduces the function of RID, and conversion of the Y in the YXXϕ motif abolishes the function of RID.

Because of their similar structures and common apoptotic pathway, it is believed that all death receptors of the TNFR family can be removed from the cell surface by RID via internalization into endosomes and subsequent degradation in lysozymes. Thus, RID will inhibit apoptosis mediated by any member of the TNFR death receptor family. As such, RID should be useful to promote survival of cells and tissues in the treatment of diseases such as degenerative diseases, immune disorders including autoimmune disorders, ischemic injury such as caused by myocardial infarction, stroke induced neuron death and reperfusion injury, alcohol-induced hepatitis, diseases caused by viral infection, such as AIDS and fulminant hepatitis, and cancer. RID is also useful in promoting survival of tissue transplants in transplant recipients.

Thus, in one embodiment the invention provides a method for inhibiting apoptosis of a cell comprising treating the cell with an effective amount of a Receptor Internalization and Degradation (RID) complex. Cells which can be treated by this method express one or more death receptors of the TNFR family, which includes Fas, TNFR1, DR3, TRAIL-R1, TRAIL-R2 and any subsequently discovered family member characterized by the presence of a death domain. Cells expressing a death receptor can be identified by methods known in the art, such as incubating the cells with one or more death receptor ligands followed by evaluating the cells for apoptosis, detecting death receptor molecules on the cell surface with an antibody against the death receptor, or detecting mRNA molecules that encode the death receptor. Cell death by apoptosis is readily recognizable and includes cytoplasmic and nuclear condensation, loss of membrane integrity and extensive fragmentation of chromosomal DNA, which forms a characteristic ladder when analyzed by gel electrophoresis. Vaux, D., *Proc. Natl.Acad. Sci 90*:786-789, 1993. Antibodies against the TNFR death receptors are either commercially available or can be readily prepared using standard techniques.

The RID complex used in the method comprises at least one of each of the following polypeptides: a RIDα-L polypeptide, a RIDα-S polypeptide, and a RIDβ polypeptide. RIDα and RIDβ are synonymous with the 10.4K and 14.5K proteins, respectively, which are encoded by two genes in the Ad E3 region. The basic structures of these polypeptides in a membrane are illustrated in Fig. 3. RIDα-L comprises a first transmembrane domain, which

is an uncleaved signal sequence, an extracellular domain, an internal transmembrane domain, and a cytoplasmic domain. RIDα-S lacks the signal sequence and thus comprises the extracellular domain, the internal transmembrane domain and the cytoplasmic domain. RIDβ comprises an extracellular domain, which preferably lacks the signal sequence as shown in Fig. 4D, a transmembrane domain and a cytoplasmic domain. When the RID complex is localized in membrane structures and vesicles within the cell, the extracellular domain is located in the lumen of these membranes and vesicles.

In preferred embodiments, the RIDα-S and RIDα-L polypeptides are covalently joined by a disulfide bond between cysteine residues in their extracellular domains which correspond by alignment with the Cys_{31} residue of the Ad2 10.4K protein (Fig. 4A). Also, RIDβ preferably has a mucin type O-linked oligosaccharide attached to one or more amino acids in the extracellular domain and/or is phosphorylated at one or two serines in the cytoplasmic domain. (See Krajcsi et al., *Virol.187*:492-498, 1992; Krajcsi et al., *Virol.*. *188*:570-579, 1992.) The location of these residues in RIDβ polypeptides encoded by E3 genes of different Ad serotypes can be determined by alignment with the amino acid sequence for the 14.5K protein of Ad5, which is shown in Fig. 4C.

A RID complex made by Ad *in vivo* is believed to contain RIDα-L, RID-αS and RIDβ (lacking the signal sequence) polypeptides in about a 1:1:1 ratio. However, it is possible that various ratios of these polypeptides will be functional or that in some cases different ratios will be required to provide a functional complex.

The amino acid sequences of the RIDα-L, RIDα-β and RIDβ polypeptides comprising the RID complex may be identical to those of naturally-occurring Ad RIDα (10.4K) and RIDβ (14.5K) proteins from any Ad serotype or may comprise functional variants of such naturally-occurring sequences. As stated above, the genes encoding the RIDα and RIDβ proteins are highly conserved among Ad serotypes. These genes are also conserved in Ads from some non-human species. Thus, it is believed that their encoded products should function very similar to the RIDα and RIDβ polypeptides from Ad2 and Ad5, which were used in the experiments described herein. In addition, the invention includes the use of RID complexes in which the RIDα-L, RIDα-S, and RIDβ polypeptides comprise homologous amino acid sequences, i.e., encoded by the same Ad serotype, or that comprises heterologous sequences, i.e., encoded by two or more Ad serotypes. Thus, for example, a RID complex may comprise (1) a RIDα-L polypeptide comprising the RIDα-L amino acid sequence from Ad2, (2) a RIDα-S polypeptide comprising the RIDα-S amino acid sequence from Ad5, and (3) a RIDβ polypeptide comprising the RIDβ amino acid sequence from Ad9. Preferably, the RID complex comprises polypeptides whose amino acid sequences correspond

to serotypes from the same subgroup. More preferably, the RID complex comprises RIDα-S and RIDα-L polypeptides encoded by the RIDα gene of Ad2 and a RIDβ polypeptide encoded by the RIDβ gene of Ad5.

A functional variant of a naturally-occurring RIDα or RIDβ sequence contains one or more amino acid substitutions in that sequence which do not destroy the ability of the resulting polypeptide to function in a RID complex to inhibit apoptosis. Preferably, amino acid substitutions in functional variants are conservative amino acid substitutions, which refer to the interchangeability of residues having similar side chains. Conservatively substituted amino acids can be grouped according to the chemical properties of their side chains. For example, one grouping of amino acids includes those amino acids have neutral and hydrophobic side chains (A, V, L, I, P, W, F, and M); another grouping is those amino acids having neutral and polar side chains (G, S, T, Y, C, N, and Q); another grouping is those amino acids having basic side chains (K, R, and H); another grouping is those amino acids having acidic side chains (D and E); another grouping is those amino acids having aliphatic side chains (G, A, V, L, and I); another grouping is those amino acids having aliphatic-hydroxyl side chains (S and T); another grouping is those amino acids having amine-containing side chains (N, Q, K, R, and H); another grouping is those amino acids having aromatic side chains (F, Y, and W); and another grouping is those amino acids having sulfur-containing side chains (C and M). Preferred conservative amino acid substitutions groups are: R-K; E-D, Y-F, L-M; V-I, and Q-H. In addition, conservative amino acid substitutions as used herein is intended to include substitutions which are present at corresponding positions in sequences from different Ad serotypes.

A functional variant as used herein can also include modified sequences in which one or more amino acids have been inserted, deleted, or replaced with a different amino acid or a modified amino acid or unusual amino acid, as well as modifications such as glycosylation or phosphorylation so long as the polypeptide containing the modified sequence retains the biological activity of a RIDα or RIDβ polypeptide. By retaining the biological activity, it is meant that the modified polypeptide can function to form a RID complex with anti-apoptotic activity.

In one embodiment, the cell is treated with the RID complex by administering to the cell a polynucleotide encoding the RID complex. The polynucleotide comprises a nucleotide sequence encoding a RIDα polypeptide and a RIDβ polypeptide operably linked to a promoter that produces expression of the RID complex in the cell. In one variation of this embodiment, the polynucleotide can contain portions of the Ad E3 region in addition to that portion encoding RIDα and RIDβ. However, the polynucleotide predominantly expresses the

RIDα and RIDβ proteins over any other Ad proteins. Alternatively, actions on cell apoptosis resulting from expression of the polynucleotide are predominantly due to the RID complex rather than any other protein expressed by the polynucleotide. The polynucleotide can comprise an expression plasmid, a retrovirus vector, an Ad vector, an adenovirus associated vector (AAV) or other vector used in the art to deliver genes into cells. Alternatively, the polynucleotide can be administered to the cell by microinjection.

In embodiments where the cell being treated is in a patient, such as cells comprising a tissue transplant or a tissue involved in an autoimmune disorder, the polynucleotide encoding RID is administered to the patient. Any of the vectors discussed above can be used. It is also contemplated that the RID complex be administered by coinfection with a replication-defective Ad expressing RID and another replication competent Ad that complements the replication defective virus to increase the expression of RID in the infected cells.

Preferably, the polynucleotide is selectively delivered to target cells within the patient so as not to affect apoptosis in other tissues. Targeted delivery of the polynucleotide can be done for example by using delivery vehicles such as polycations, liposomes or viral vectors containing targeting moieties that recognizes and binds a specific marker on the target cell. Such methods are known in the art, see, e.g., U.S. Patent No. 5,635,383. Another targeted delivery approach uses viral vectors that can only replicate in specific cell types which is accomplished by placing the viral genes necessary for replication under the transcriptional control of a response element for a transcription factor that is only active in the target cell. See, e.g., U.S. Patent No. 5,698,443.

In other embodiments of the invention, the cell is treated by administering to the cell a composition comprising a RID complex. The RID complex for use in such embodiments can be prepared by a variety of means. For example, the RID complex can be isolated from the membranes of Ad-infected cells or cells transfected with a nucleotide sequence encoding the RIDα and RIDβ polypeptides. Alternatively, the polypeptide components of the complex can be expressed in separate cell cultures, extracted into an appropriate buffer and mixed *in vitro*. RIDα and RIDβ polypeptides can also be chemically synthesized and mixed to form the complex. The RID complex can then be tested for the ability to inhibit apoptosis of a cell expressing a death receptor as described herein for Fas and TNFR1.

Preferably, the RID complex is administered with a carrier that facilitates delivery of the RID complex into the cell, such as liposomes. Where the RID complex is being administered to a patient, the liposomes can have targeting moieties exposed on the surface such as antibodies, ligands or receptors to specific cell surface molecules to limit delivery of RID to targeted cells. Liposome drug delivery is known in the art (see, e.g., Amselem et al.,

Chem. Phys. Lipid 64:219-237, 1993). Alternatively, one or more of the polypeptides of the complex can be modified to include a specific transit peptide that is capable of delivering the peptide into the cytoplasm of a cell or the complex can be delivered directly into a cell by microinjection.

Compositions comprising a RID complex can be administered by any suitable route known in the art including, for example, intravenous, subcutaneous, intramuscular, transdermal, intrathecal or intracerebral or administration to cells in *ex vivo* treatment protocols. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of slow release formulation. For treating tissues in the central nervous system, administration can be by injection or infusion into the cerebrospinal fluid (CSF). When it is intended that the RID complex be administered to cells in the central nervous system, administration can be with one or more agents capable of promoting penetration of the protein complex across the blood-brain barrier.

The RID complex can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties, including for example, substances known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor (Friden et al., *Science 259*:373-377, 1993), a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties Davis et al. *Enzyme Eng 4:*169-73, 1978; Burnham, *Am J Hosp Pharm 51*:210-218, 1994).

For nonparental administration, the compositions can also include absorption enhancers which increase the pore size of the mucosal membrane. Such absorption enhancers include sodium deoxycholate, sodium glycocholate, dimethyl-β-cyclodextrin, lauroyl-1-lysophosphatidylcholine and other substances having structural similarities to the phospholipid domains of the mucosal membrane.

The compositions are usually employed in the form of pharmaceutical preparations. Such preparations are made in a manner well known in the pharmaceutical art. One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate

of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dosage or multi-dose form or for direct infusion by continuous or periodic infusion.

It is also contemplated that certain formulations comprising the RID complex are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the active ingredients after administration to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and/or substances which promote absorption such as, for example, surface active agents.

The RID complex is administered to patients in an amount effective to inhibit apoptosis of target cells within the patient. The specific dose is calculated according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity disclosed herein in cell death assays. Exact dosages are determined in conjunction with standard dose-response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration. Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

The compositions and methods of the invention are contemplated for use in promoting survival of tissue transplants. For example, the tissue can be treated *in vitro* with the RID complex and the treated tissue then introduced into the transplant. In addition,

previously transplanted tissues can be treated with RID by administering the RID complex to the transplant recipient. In either scenario, it is contemplated that the RID complex can be administered as a protein formulation or as a polynucleotide expressing the complex.

In another embodiment, the RID complex is used to promote the survival of leukocytes in cancer patients. The leukocytes can be treated *in vivo* by administering to the patient a polynucleotide expressing RID or a composition containing the RID complex. Preferably, the polynucleotide or RID complex is targeted to the leukocytes by one of the targeting methods discussed above. For example, cytotoxic T cells could be targeted by using an antibody against the CD8 marker and natural killer cells targeted by use of an antibody against the CD16 marker. Alternatively, the leukocytes can be removed from the patient, treated with the RID complex *ex vivo*, and the treated leukocytes then returned to the patient.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

Example 1

This example illustrates inhibition of Fas-mediated apoptosis by adenovirus E1B and E3 proteins.

Human breast adenocarcinoma cells expressing Fas (MCF7-Fas) (Jäättela et al., *Oncogene 10*:2297-2305, 1995) were infected with *rec*700 or with an adenovirus mutant lacking expression of one or more of the RIDα, RIDβ, E3-14.7K and E1B-19K proteins. *rec*700 is an Ad5-Ad2-Ad5 "wild-type" recombinant whose genome consists of the Ad5 *Eco*RI A (map positions 0 to 76), Ad2 *Eco*RI D (map positions 76 to 83), and Ad5 *Eco*RI B (map positions 83 to 100) fragments (Wold et al., *Virol. 148*:168-188, 1986). rec700 is the parental virus of E3 mutants with 700 or 7000 numbers. The infected cells were treated with a monoclonal antibody to Fas, CH-11, which acts as an agonist of Fas and induces apoptosis. The cells were then fixed and stained for DNA and for the adenovirus DNA binding protein (DBP). Experimental details are provided in the footnote to Table 1.

Examples of apoptotic and non-apoptotic nuclei in *rec*700-infected cells are shown in Figs. 6A and 6B. Most cells were infected as indicated by the speckled staining of DBP in the nucleus (Fig. 6A), and these nuclei were non-apoptotic (Fig. 6B). Two uninfected cells were apoptotic (arrows in Figs. 6A and 6B) as evidenced by the presence of shrunken and irregular nuclei with condensed DNA that often fluoresced very brightly above the plane of

focus for non-apoptotic nuclei. The percentage of apoptotic and non-apoptotic nuclei was scored in *rec*700- or mutant-infected cells staining for DBP and the quantitative results are shown in Table 1 below.

Table 1. Fas Agonist-induced Apoptosis in MCF7-Fas Cells Infected with Ad Mutants[1]

Virus Mutant	Ad DNA Binding Protein-Positive Cells[2]	
	Apoptotic	**Non-apoptotic**
*rec*700 (wild type)	0.1[3]	99.9[3]
*pm*760 (E1B-19K$^+$, RID$^+$)	0.7	99.3
*dl*309 (E1B-19K$^+$, RID$^-$)	0.1	99.9
*dl*748 (E1B-19K$^+$, RID$^-$)	0.6	99.4
*dl*764 (E1B-19K$^+$, RID$^-$)	0.2	99.8
*lp*5 (E1B-19K$^-$, RID$^+$)	9.9	90.2
*dl*250 (E1B-19K$^-$, RID$^+$)	10.4	89.6
*dl*111 (E1B-19K$^-$, RID$^-$)	87.2	12.8
*dl*118 (E1B-19K$^-$, RID$^-$)	94.1	5.9

[1]MCF7-Fas cells were infected with 250 PFU per cell of virus except for *lp*5, *dl*250, *dl*111, and *dl*118 where 10 PFU per cell was used. At 21 h post-infection (p.i.), cells were treated for 22 h with the CH-11 agonist mAb to Fas (200 ng/ml) (Panvera, Madison, WI) plus cycloheximide (25 μg/ml). Cells were fixed and stained for the Ad DNA binding protein (DBP) using a rabbit antiserum (obtained from Maurice Green, St. Louis University) and goat anti-rabbit IgG (fluorescein conjugate) and for DNA using 4, 6-diamidino-2-phenylindole (DAPI). Typical apoptotic and non-apoptotic nuclei are shown in Fig. 6B, which is from the same experiment. Nuclei of *dl*111- or *dl*118-infected cells not treated with Fas agonist were not apoptotic (not shown), indicating that the apoptosis observed was not due to the *cyt deg* phenotype of E1B-19K-negative mutants (Subramanian et al., *J. Virol.* *52*:336-343, 1984).

[2]At least 1000 DBP-positive cells were counted per sample.

[3]Percent of apoptotic and non-apoptotic nuclei in cells staining for DBP.

In cells infected with *rec*700 or mutant *pm*760, which expresses both E1B-19K and RID, very few nuclei were apoptotic. Cells infected with mutants expressing E1B-19K but lacking RIDα and E3-14.7K (*dl*748), or lacking RIDβ (*dl*764), or lacking each of RIDα, RIDβ, and E3-14.7K (*dl*309) also had very few apoptotic nuclei. However, only about 10% of cells infected with *lp*5 and *dl*250, which lack E1B-19K but express RID, had apoptotic nuclei, while about 90% of the nuclei were apoptotic in cells infected with *dl*111 and *dl*118, which lack expression of RIDα, RIDβ, E3 14.7 K and E1B-19K. These results indicate that adenovirus has two proteins that independently inhibit Fas-induced apoptosis, RID and/or E3-14.7K in the E3 transcription unit and E1B-19K in the E1B transcription unit. This result observed with E1B-19K is consistent with an earlier report (Hashimoto, S., et al., *Int. Immunol. 3*:343-351, 1991. Data below show that RID inhibits Fas-induced apoptosis.

Example 2

This example illustrates that the RID complex is sufficient to inhibit apoptosis.

To address whether RID is sufficient to inhibit Fas-induced apoptosis, plasmids expressing RIDα or RIDβ from the Ad major late promoter plus SV40 enhancer were prepared by cloning the gene for RIDα or RIDβ into the pMT2 vector (Mazzarella, R. A. & Green, M. *J. Biol. Chem. 262*: 8875-8883, 1987) to generate pMT2-RIDα and pMT2-RIDβ. MCF7-Fas cells were transiently transfected with pMT2-RIDα plus pMT2-RIDβ, pMT2-RIDβ alone, or pMT2 alone (2.5 μg for each plasmid). After 38 h, cells were treated for 9 h with the CH-11 agonist mAb to Fas (500 ng/ml) plus cycloheximide (25 μg/ml), fixed in methanol with DAPI, and stained for RIDβ using the rabbit P118-132 antipeptide antiserum (Tollefson et al., *Virology 175*:19-29, 1990).

Examples of apoptotic and non-apoptotic nuclei in the cells co-transfected with pMT2-RIDα and pMT2-RIDβ are shown in Figs. 6C and 6D. The cell transfected with RIDα plus RIDβ (arrow in Fig. 6C) was non apoptotic (arrow in Fig. 6D). RIDβ-negative cells usually had apoptotic nuclei (most cells in Fig. 6D). Of 2000 cells counted in random fields, 173 RIDβ-positive cells were seen, and only 26% of these had apoptotic nuclei. In the transfection with RIDβ alone, and with 2000 cells counted, 101 RIDβ-positive cells were seen, 80% of which had apoptotic nuclei. With pMT2 alone, 62% of the total nuclei were apoptotic. These results indicate that RID (i.e. RIDα plus RIDβ), but not RIDβ alone, is sufficient to inhibit Fas-induced apoptosis.

Example 3

This example illustrates that RID down-regulates Fas from the cell-surface of adenovirus-infected human breast carcinoma cells.

To investigate how RID inhibits apoptosis, MCF7-Fas cells were infected with adenovirus serotype 5 (Ad5), *rec*700, or an Ad mutant lacking expression of one or more of RIDα, RIDβ, and E3-14.7K proteins. At 28 h p.i., cells were detached using 0.025% EDTA, then resuspended in FACS buffer (1X PBS, 2% FBS). Approximately 1 X 10^6 cells were pelleted and resuspended in 50 µl FACS buffer containing antibodies against human Fas (UB2 IgG mAb) (Panvera) (10 µg/ml), the human transferrin receptor (Boehringer/Mannheim, Indianapolis, IN) (2.5 µg/ml) and purified mouse IgGγ (PharMingen, San Diego, CA) (5 µg/ml) as an iso-type control. In common with Fas, the transferrin receptor is a cell surface receptor. Cells were incubated with the primary antibodies, washed with cold FACS buffer, incubated with 20 µg/ml of goat anti-mouse FITC-conjugated antibody (ICN), washed, then analyzed on a FACScaliber flow cytometer (Becton Dickinson, Mountain View, CA). The data were analyzed with Cell Quest software (Becton Dickinson) and are shown in Figure 7.

Nearly all Fas (bold trace in Fig. 7) was cleared from cells infected with Ad5 or *rec*700 (Figs. 7B, 7C). Transferrin receptor (dashed trace) was not affected. Fas was not cleared from cells infected with mutants lacking RIDα and/or RIDβ, namely *dl*309 (lacks RIDα, RIDβ, E3-14.7K) (Fig. 7D), *dl*748 (lacks RIDα) (Fig. 7E), and *dl*764 (lacks RIDβ) (Fig. 7F). Fas was down-regulated by *dl*758 (RID-positive, lacks E3-14.7K) (Fig. 7G) and *pm*760 (overexpresses RIDα and RIDβ) (Fig.7H). These results indicate that RID (i.e. RIDα and RIDβ) is necessary to clear Fas from the surface of Ad-infected MCF7-Fas cells. Other Ad proteins, including E3-14.7K and E1B-19K, are not required.

Example 4

This example illustrates that RID down-regulates Fas from the cell-surface of adenovirus-infected human lung adenocarcinoma cells.

To determine if RID can remove Fas from the surface of other cell types, the human A549 cell line was examined. A549 cells are derived from a human lung adenocarcinoma. A549 cells were mock-infected or infected with *rec*700. At 26 h p.i., cells were suspended in FACS buffer containing mouse IgGγ, anti-human-Fas UB2 IgG monoclonal antibody (Panvera), or antibody against the human transferrin receptor (Boehringer/Mannheim), incubated with goat anti-mouse fluorescein isothiocyanate (FITC)-conjugated antibody, and

analyzed on a FACScaliber flow cytometer using Cell Quest software (Becton Dickinson). The results are shown in Fig. 8.

With mock-infected cells (Fig. 8B), there was strong staining for both Fas (the red trace in Fig. 8) and transferrin receptor (the blue trace in Fig. 8). With *rec*700 or *pm*760, a virus mutant that overexpresses RID (i.e., RIDα plus RIDβ) and underexpresses other Ad E3 proteins, Fas was completely cleared from the cell surface whereas the transferrin receptor was not affected (Figs. 8C, 8H). With three virus mutants that lack both RIDα and RIDβ (*dl*309), RIDβ only (*dl*764), or RIDα (*dl*748), Fas was not cleared from the cell surface (Fig. 8, Panels E, F, and G). With *dl*758, a mutant that lacks only E3-14.7K and that expresses RIDα and RIDβ, Fas was down-regulated to the same extent as with *rec*700 and *pm*760. Therefore, the E3-14.7K protein is not required to down-regulate cell surface Fas. Recently, RID was reported to clear Fas from the cell surface in two other human cell lines, HT-29.14S and ME-180 (Shisler et al., *J. Virol. 71*:8299-8306, 1997). These results have been confirmed with HT-29.14S and ME-180 cells (data not shown). Thus, RID stimulates the removal of Fas from the cell surface of at least four different cell types, MCF7-Fas, A549, HT-29.14S, and ME-180 cells.

Example 5

This example illustrates that Fas molecules removed from the cell surface by RID are internalized into vesicles and then degraded in lysosomes.

Many receptors are internalized into endosomes. Accordingly, MCF7-Fas cells were mock-infected or infected with *rec*700 or with an E3 Ad mutant. MCF7 cells were mock-infected as a control. At 19 h p.i., cells were fixed in methanol and stained for Fas using the ZB4 mAb (Panvera) and goat anti-mouse IgG (Texas red conjugate). The results are shown in Figure 9.

Fas was not detected in mock-infected parental MCF7 cells (Fig. 9A), but was readily apparent on the surface of MCF7-Fas cells (Fig. 9B). In cells infected with *rec*700, Fas was in numerous vesicles and there was no cell surface staining (Fig. 9C). These vesicles are likely to be endosomes and lysosomes containing Fas. These vesicles were not observed with *dl*309, *dl*748, or *dl*764 (lack RIDα and/or RIDβ), whereas in each case, strong Fas staining was apparent at the plasma membrane (Figs 9D-9F). Vesicles staining for Fas were seen with *dl*758 and *pm*760, both of which express RID (Figs. 9G, 9H).

Some receptor types internalized into endosomes are targeted to lysosomes where they are degraded. To determine whether Fas was degraded in Ad-infected cells expressing RID, MCF7-Fas cells were mock-infected or infected with wild-type Ad or an E3 mutant

lacking expression of one or more of RIDα, RIDβ, and 14.7K proteins, then at 27 h p.i. proteins were extracted, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and blotted onto an Immobilon-P membrane. After blocking, membranes were incubated with rabbit anti-Fas antiserum (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), mouse anti-transferrin receptor mAb OKT9 (ATCC), or mouse anti-E1A mAb M73. Membranes were incubated with the appropriate peroxidase-conjugated secondary antibody (ICN). Proteins were detected with ECL reagents (Amersham Life Sciences, Arlington Heights, IL) and the results are shown in Fig. 10.

Fas was degraded in cells infected with viruses that express both RIDα and RIDβ (Ad5, Ad2, *rec*700, *dl*758, *pm*760) (Fig. 10A). Transferrin receptor was not degraded in these same extracts (Fig. 10B). Fas expression was actually stimulated in cells infected with mutants that lack RIDα and/or RIDβ (Fig. 10A, compare Mock with *dl*309, *dl*748, and *dl*764). The Ad-coded E1A proteins were expressed at similar levels (Fig. 10C), indicating that all infections were equivalent. These and the above results establish that RID (i.e. RIDα and RIDβ) functions in the internalization of Fas into putative endosomes, the degradation of Fas, and the inhibition of Fas-induced apoptosis.

RID has been reported to stimulate the internalization of EGFR into vesicles and its degradation in lysosomes (Carlin et al., *Cell 57*:135-144, 1989; Tollefson et al., *J. Virol. 65*:3095-3105, 1991). When the epidermal growth factor receptor (EGFR) interacts with its ligand, EGF, EGFR is internalized into early endosomes which are transported to late endosomes which fuse with lysosomes, where EGFR is degraded. This process results in attenuation of signal transduction through EGFR. Many receptors are degraded by the endosome-lysosome pathway in response to ligand. To determine if RID-induced degradation of Fas is occurring through this pathway, the following experiments were performed.

The first experiment, which was described in the copending provisional application, examined Fas localization in COS cells transiently co-transfected with combinations of expression plasmids for Fas, RID α and RIDβ. The following plasmids were used, the pMT2-RIDα and pMT2-RIDβ plasmid vectors described in Example 2, and pcDNA3-Fas, which expresses Fas from the human cytomegalovirus promoter (CMV). C0S7 cells were transfected (Mazzarella, R. A. & Green, M. *J. Biol. Chem. 262*:8875-8883, 1987) with 1 μg each of pMT2-RIDα plus pcDNA3-Fas, pMT2-RIDβ plus pcDNA3-Fas, or pMT2-RIDα, pMT2-RIDβ, and pcDNA3-Fas. After 30 h, cells were fixed in methanol with DAPI and stained for Fas using the ZB4 mAb, for RIDα using the rabbit P77-91 antipeptide antiserum, or for RIDβ using the rabbit P118-132 antipeptide antiserum (Tollefson et al., *J. Virol.*

64:794-801, 1990; Tollefson et al., *Virology 175*:19-29, 1990). The results are shown in Figure 11.

With cells co-transfected with expression plasmids for RIDα plus Fas, or RIDβ plus Fas, Fas was localized on the cell surface (Fig. 11B, 11D). In contrast, with cells triple-transfected with expression plasmids for RIDα, RIDβ, and Fas, Fas was in vesicles rather than the cell surface (Fig. 11F, 11H). RIDβ staining was typical of the endoplasmic reticulum (ER) and plasma membrane, a probable site of RID action (Stewart et al., *J. Virol. 69*:172-181, 1995); many vesicles containing RIDβ appeared to co-localize with vesicles containing Fas (arrows in Fig. 11G and 11H). Distribution to the ER was also characteristic of RIDα (Fig. 11E), and in some cells the plasma membrane was stained (not shown). RIDα did not co-localize with Fas-containing vesicles. Thus, RID (i.e. RIDα plus RIDβ) is sufficient to internalize Fas into vesicles.

In a second experiment, Fas localization was examined in Ad-infected cells. Human A549 cells were infected with *rec*700 fixed using 3.7% paraformaldehyde followed by methanol/DAPI (4,6-diamidino-2-phenylindole). Cells were double-stained for Fas and LAMP1, which is a lysosomal protein (Carlsson et al., *J. Biol. Chem.* 15:18911-18919, 1988), using a rabbit anti-Fas antibody (Santa Cruz Biotechnology) and the BB6 mouse anti-human-LAMP-1 monoclonal antibody (Carlsson et al., supra), followed by goat anti-rabbit IgG-FITC and goat anti-mouse IgG-RITC (rhodamine isothiocyanate) (Cappel ICN). Cells were examined using a Zeiss LSM 410 scanning laser confocal microscope with LSM 410 software. The results are shown in Figure 12.

Green, red, and yellow vesicles contain Fas (Fig. 12A), LAMP1 (Fig. 12B), or both Fas and LAMP1 (Fig. 12C, 12D), respectively. The many yellow vesicles establish that Fas co-localizes with LAMP1 in lysosomes. The Fas-containing green vesicles may be endosomes. Similar results were obtained with another lysosomal protein, CD63 (data not shown).

To obtain additional evidence supporting the involvement of the endosome-lysosome pathway in RID-induced Fas degradation in Ad-infected cells, the effect of Bafilomycin A1 (Baf) treatment was investigated. Baf specifically inhibits the vacuolar-type H^+-ATPase, preventing vesicle acidification and trafficking of receptors from late endosomes to lysosomes (Yoshimori et al., *J. Biol. Chem.* 266:17707-17712, 1991; van Weert et al, *J. Cell. Biol.* 130:821-834, 1995). A549 cells were mock-infected or infected with rec700 or *dl*309 (lacks RID). At 13 h after infection, cells were treated with Baf (0.1 μM) for 12 h and then immunostained for Fas. In a separate experiment, cells were treated with Baf at 6 h after

infection and processed for immunoblot analysis 18 h later. The results are shown in Figure 13.

When wild-type Ad-infected cells were treated with Baf, Fas was cleared from the cell surface but it accumulated in vesicles (Fig. 13A) rather than being degraded as in untreated cells (Fig. 13B). Baf did not affect cell surface Fas in cells infected with a mutant lacking RID (*dl*309) (Fig. 13C). Immunoblot analysis of proteins extracted from these cells indicated that Baf blocked the degradation of Fas in wild-type Ad-infected cells (Fig. 13D). Baf did not affect the abundance of Fas in mock-infected cells or in cells infected with the RID-minus mutant. Neither virus infection nor Baf affected the abundance of Erp72 (Fig. 13D), a cellular protein localized in the endoplasmic reticulum (Mazzarella et al., 1990). Also, neither virus infection nor Baf significantly affected the level of another cellular protein, the transferrin receptor (Fig. 13E). The infections were equivalent as indicated by the E1B-19K levels of the Ad-encoded protein (Fig. 13D). These confocal microscopy and Baf data provide strong evidence that RID causes Fas to be degraded in lysosomes in Ad-infected cells.

Example 6

This example illustrates that the RID proteins are sufficient to promote the degradation of Fas.

COS cells were transiently transfected with different combinations of pMT2-RIDα, MT2-RIDβ, pcDNA3-Fas, and pBUC-Shp-1, which expresses a mammalian cell protein named Shp-1. At 36 h post-transfection, cells were treated with cycloheximide (25 μg/ml) for 12 h and at 48 h post-transfection, proteins were extracted and analyzed for Fas, Shp-1, or ERp72 by immunoblot using rabbit antisera to Fas (Santa Cruz), Erp72 (Mazzarella et al., 1990), or Shp-1 (Plas et al., 1996) (Tollefson et al., Nature 392:726-730 (1998)). The results are shown in Fig. 14.

In cells transfected with pcDNA3-Fas and/or pBUC-Shp-1, expression of Fas and/or Shp-1 proteins was readily detected by immunoblot (Fig. 14, lanes b-d). For Fas, two groupings of bands were detected (indicated by the arrows), which represent differentially glycosylated species of Fas. The anti-Fas antibody also reacted with an unknown cellular protein that migrated between the two sets of Fas protein bands. When pMT2-RIDα or pMT2-RIDβ were co-transfected with pcDNA3-Fas and pBUC-Shp-1, there was a marginal decrease in Fas and Shp-1 (Fig. 14, lanes e and f). However, when both pMT2-RIDα and pMT2-RIDβ were co-transfected with pcDNA3-Fas and pBUC-Shp-1, the Fas bands were reduced to nearly undetectable levels, whereas the Shp-1 band was only marginally decreased

(Fig. 14, lane g). The levels of the endogenous cellular protein, Erp72, were equivalent in all of the transfected cells. These results indicate that the RID complex (i.e. RIDα plus RIDβ), but not RIDα or RIDβ alone, is sufficient to induce degradation of Fas.

A similar experiment was conducted except that cells were transfected with the pcDNA3.1-CAT (InVitrogen, Carlsbad, CA) plasmid expressing chloramphenicol acetyl transferase (CAT) instead of pBUC-Shp-1. Since CAT is a bacterial protein, it is not possible for RID to have evolved in Ad to exert a specific biological effect on CAT. Expression of this protein was detected by immunoblot using anti-CAT antiserum obtained from 5 prime-3 prime. The results of the experiment were similar to those with Shp-1, i.e. Fas was greatly reduced in the presence of RID, whereas CAT was only marginally affected (Fig. 15).

These experiments demonstrate that the RID complex is sufficient to induce the internalization of cell-surface Fas into vesicles, presumably endosomes and lysosomes, to induce degradation of Fas, presumably in lysosomes, and to inhibit apoptosis triggered by an anti-Fas agonist monoclonal antibody.

Example 7

This example illustrates that RID inhibits killing of Ad-infected cells by natural killer cells and cytotoxic lymphocytes.

Natural killer (NK) cells and cytotoxic T-lymphocytes (CTL) play an important role in the destruction of virus-infected cells during the early innate phase and the late immune-specific stages, respectively, of the host anti-viral response. Both NK and CTL kill targets via two major pathways. In one major pathway, perforin generates holes in the target and granzymes are introduced to induce apoptosis of the target cell. In another major pathway, Fas ligand on the surface of the CTL engages Fas on the target cell and induces apoptosis through activation of the pro-apoptotic caspases. CTL can also kill cells through a third minor pathway, in which TNF expressed on the surface of CTL (or secreted by CTL) engages TNFR1 on targets and induces apoptosis via the caspases. In cell culture, TNF-mediated killing by CTL is observable in long term (> 24 h) killing assays. To investigate whether RID inhibits NK- and CTL-killing through Fas, the following experiments were conducted.

In the first experiment, which was described in the copending provisional application, the effect of Ad proteins on CTL-killing was assessed by performing a short-term CD3-dependent redirected cell assay (Azuma et al., *J. Exp. Med.175*:353-360, 1992), using lymphocytes from perforin (-/-) mice (Kagi et al., *Science 265*:528-530, 1994) and from wild-type perforin (+/+) C57BL/6J mice acutely infected with influenza virus. Influenza virus enhances the expression of Fas ligand in activated lymphocytes (Clark et al., *Immunol. Rev. 146*:33-44, 1995). In brief, mice were primed by intranasal infection of 50 HAU of HkX31

influenza A virus (Topham et al., *J. Virol. 70*:1288-1291, 1996; Tripp et al., *J. Immunol. 154*:6013-6021, 1995). CTL were isolated from the spleens of the infected mice, irradiated, and effector CTL generated by secondary *in vitro* re-stimulation. These CTL were further activated by incubation with the 145-2C11 anti-CD3ε mAb for 30 min on ice. Mouse Fas and Fc receptor-positive P815 cells (1 X 10^6) were mock-infected or infected with 1000 PFU per cell of *rec*700 or *dl*7001 and labeled overnight with 100 μCi of $Na_2{}^{51}CrO_4$. These ^{51}Cr-labeled P815 target cells were washed, resuspended in DME, and then incubated with the activated anti-CD3ε-treated CTL using effector lymphocyte:target ratios of 60:1, 20:1 or 6:1. Cell lysis was determined 6 h later from a standard ^{51}Cr release assay and the results are shown in Figs. 16A and 16B. The presence of Fas on the surface of P815 cells infected with *rec*700 or *dl*7000 was also examined by flow cytometry and the results are shown in Fig. 16C.

The perforin (-/-) CTL lysed mock-infected P815 cells efficiently (Fig. 16A). Lysis was inhibited by *rec*700 but not by *dl*7001 (lacks all E3 genes). Since the mice lack perforin, it follows that the CTL were killing the mock- and mutant-infected cells through the Fas pathway and that the E3 region is required to inhibit killing through this pathway. The CTL from perforin (+/+) mice killed mock-, *rec*700-, or *dl*7001-infected P815 cells with similar high efficiency (Fig. 16B). Cell surface Fas was diminished on P815 cells infected with *rec*700 but not with *dl*7000 (lacks all E3 genes except for E3-14.7K) (Fig. 16C). These results indicate that E3 proteins expressed by *rec*700 but not *dl*7000, presumably RID, inhibit CTL killing through the Fas pathway by down-regulating Fas from the cell surface.

A second experiment was conducted to investigate the role of RID in inhibiting killing of Ad-infected cells by NK cells. Human A549 cells were mock-infected or infected with *rec*700 (wild-type Ad) or *dl*764, a virus mutant that lacks only RIDβ and then labeled with 100 μCi of $Na_2{}^{51}CrO_4$. These ^{51}Cr-labeled A549 target cells were washed, resuspended in DME, and then incubated with a semi-permanent line of human NK cells. After 24 h, cell lysis was measured based on release of ^{51}Cr from the cells as described elsewhere (Tollefson et al., Nature 392:726-730 (1998)) and the results are shown in Figure 17.

Mock-infected cells were lysed efficiently at NK:A549 cell ratios of 10:1 and 5:1 (Fig. 17). This lysis was dramatically inhibited by infection with *rec*700, but it was only marginally reduced by infection with *dl*764 (Fig. 17). Since the only protein not expressed by *dl*764 is RIDβ, it is believed that RID is required to inhibit killing of Ad-infected cells by NK cells. Most likely RID inhibits killing by NK cells by blocking the Fas pathway. However, a RID effect on the perforin-granzyme pathway cannot be excluded.

In summary, RID inhibits killing of Ad-infected cells by NK cells and by CTL. Thus, RID should protect infected cells from attack by killer cells that are active in both the early

innate phase and the late immune-specific phase of the anti-viral immune response. Similarly, transplanted cells and tissues are destroyed by NK cells and CTL. Therefore, RID should be useful to inhibit killing of transplanted cells or tissues by NK cells and CTL.

Example 8

This example illustrates that RID is required and probably sufficient to remove the TNFR1 from the cell surface.

Human HeLa cells were mock-infected or infected with 50 PFU/cell of *rec*700 (wild-type) or *dl*712, which is a *rec*700-derived mutant with a deletion in the *adp* gene in the E3 region that results in overexpression of both RID (i.e. RIDα and RIDβ) and E3-14.7K, and only trace amounts of other E3 proteins (Tollefson et al., *J. Virol.* 64,794-801, 1990; Tollefson et al., *Virol.* 175:19-29, 190; Gooding et al., *Cell* 53:341-346, 1988). At 26 h p.i., cells were analyzed by flow cytometry (Tollefson et al., Nature 392:726-730 (1998)) using the B/O:2/18/91 rabbit antiserum against TNFR1 (obtained from Immunex Corp.) and PE-conjugated goat anti-rabbit IgG (Caltag). Fas was detected in the same experiment using supernatants from the M38 anti-Fas hybridoma cell line (obtained from the American Type Culture Collection) and FITC-conjugated goat anti-mouse IgG. The results are shown in Figure 18.

As shown in Fig. 18A, TNFR1 was removed from the surface of most cells infected with *rec*700 (red trace) or *dl*712 (blue trace). The percentage of mock-infected cells that were stained for TNFR1 was 93%, as compared to 16% and 18%, respectively, for *rec*700 and *dl*712. In this same experiment, cell surface Fas was also internalized by *rec*700 and *dl*712 (Fig. 18B). Thus, Ad infection removes TNFR1 from the cell surface, as is the case with Fas.

The mutant used in the above experiment, *dl*712, overexpresses RID and E3-14.7K, and expresses very little of the other E3 proteins. To determine whether RID and/or E314.K is involved in internalization of TNFR1 in Ad-infected HeLa cells, the same experiment was performed using *dl*712 and additional E3 mutants: *dl*309, which lacks RIDα, RIDβ, and E3-14.7K; *dl*753, which lacks RIDα but expresses RIDβ and E3-14.7K; and *dl*764, which lacks RIDβ but expresses RIDα and E3-14.7K. The deletions in these mutants do not affect expression of any other Ad proteins. The results are shown in Figure 19.

With *rec*700 and *dl*712, TNFR1 was removed from the cell surface such that only 29% and 24%, respectively, of cells were stained for TNFR1 as compared to 92% with mock-infected cells (Fig. 19A). With *dl*309, *dl*753, and *dl*764 infected cells, 84%, 85%, and 84%, respectively, were stained for TNFR1, indicating that these mutants did not induce removal of TNFR1 from the cell surface. Cell surface Fas was also examined in this same experiment.

*rec*700 and *dl*712 cleared Fas whereas *dl*309, *dl*753, and *dl*764 did not (Fig. 19B). Thus, RID is required to remove TNFR1 from the surface of Ad-infected cells, as is the case with Fas.

As a means to determine whether RID is sufficient to remove TNFR1 from the cell surface, HeLa cells were infected with the Ad vector named 231-10. This vector will be described in detail in Example 10 below. In brief, 231-10 lacks the E1A, E1B, and E3 transcription units. The deleted E1A plus E1B regions are replaced with an expression cassette wherein all the E3 proteins are expressed from the human cytomegalovirus (CMV) promoter. Because 231-10 lacks E1A, viral genes in the vector backbone are not expressed; only the E3 proteins are expressed from the CMV promoter. Thus, the vector serves as an essentially inert vehicle by which E3 genes can be delivered into cells and the properties of their proteins studied.

HeLa cells were mock-infected or infected with the 231-10 vector, and cell surface TNFR1 was examined by flow cytometry at 24 h and 48 h p.i. as described above. At 24 h p.i., the percentage of cells bearing TNFR1 was reduced from 93% to 35%, and by 48 h the percentage was reduced to 11% (Fig. 20). This time course of TNFR1 down-regulation correlates with expression of the E3 proteins. In a parallel experiment, Fas was nearly completely cleared by 24, 36, and 48 h p.i. (data not shown). Thus, TNFR1 and Fas are removed from the cell surface by the E3 proteins expressed by 231-10. RID is undoubtedly the E3 protein responsible for the removal of these death receptors.

The ability of Ad and the RID protein to remove TNFR1 from the cell surface was examined using the biotin-streptavidin system (Stewart et al., 1995) to detect TNFR1. Multiple dishes of A549 cells were mock-infected or infected with 50 PFU/cell of *rec*700 (wild-type). At 16 h p.i., cell surface proteins in mock- and Ad-infected cells were labeled using biotin. Ad-infected cells in other dishes were also labeled with biotin at 18, 20, 22, 24, and 30 h p.i. Proteins were extracted using buffer containing 0.5% NP-40, and were incubated with protein A-Sepharose CL-4B attached to the B/O:2/18/91 rabbit antiserum against TNFR1. After washing, proteins were solubilized, subjected to SDS-PAGE, and transferred to membranes. Membranes were incubated with peroxidase-conjugated streptavidin (Sigma), and proteins were visualized using ECL (Amersham).

In this assay, if Ad infection has resulted in the removal of TNFR1 from the cell surface, then TNFR1 will not be available for biotinylation and therefore TNFR1 will not be detected. As shown in Fig. 21, similar amounts of TNFR1 were obtained from mock- or *rec*700-infected cells at 16 h p.i. With *rec*700, TNFR1 declined from 18 to 30 h p.i. until only small amounts were detected. Thus, as was the case when TNFR1 was detected by flow cytometry, Ad infection results in markedly decreased amounts of cell surface TNFR1.

The ability of the 231-10 Ad vector to down-regulate cell surface TNFR1 as determined with the biotin-streptavidin assay was also examined. As discussed above, 231-10 expresses only Ad E3 proteins. Cells were mock-infected, infected with 50 PFU/cell of *rec*700 (wild-type), or infected with 250 PFU/cell of 231-10. At different days p.i., cells were biotinylated and TNFR1 detected as described above. As expected, most of the TNFR1 was cleared by *rec*700 at 1 day p.i. (Fig. 22A, compare lanes a and b). With 231-10, reduced amounts of TNFR1 were detected by 1 day p.i., and by 5 days p.i. the TNFR1 levels declined to those of *rec*700. The levels of TNFR1 in mock-infected cells were similar after 5 days to those after 1 day (Fig. 22A, compare lane h with lane a). Therefore, the reduction at 5 days seen with 231-10 is not due to a non-viral event associated with maintaining the cells in dishes for 5 days. These results indicate that the E3 proteins expressed by the 231-10 vector, presumably RID, are sufficient to clear TNFR1 from the cell surface.

The accumulation of RIDβ in these same cell extracts was also examined by standard immunoblot using the rabbit P118-132 antiserum (Stewart et al., 1995). With *rec*700, RIDβ was abundant after 1 day (Fig. 22B, lane b). The multiple bands on RIDβ are species of RIDβ that are differentially O-glycosylated and phosphorylated. With 231-10, RIDβ was detected after 2 days, and it increased dramatically in abundance from days 3-5 (Fig. 22B, lanes c-g). Therefore, as expected, the accumulation of RIDβ in this experiment correlated inversely with the decline in cell-surface TNFR1.

These results obtained using the B/O:2/18/91 antibody in the biotin-streptavidin and flow cytometry assays to detect TNFR1 are consistent. Thus, it is believed that RID is necessary to efficiently down-regulate cell surface TNFR1 in Ad-infected cells. The results with 231-10 indicate that RID is sufficient to down-regulate TNFR1, with the caveat that the E3 14.7K and gp19K proteins, and possibly the E3 12.5K and 6.7K proteins, are expressed by 231-10.

To determine if RID is responsible for clearance of cell-surface TNFR1, the following Ad E3 mutants were used: *dl*748, which overexpresses RIDβ but lacks RIDα; and *dl*798, which overexpresses RIDα but lacks RIDβ. A549 cells were mock-infected or infected with 50 PFU/cell of *rec*700, *dl*748, or *dl*798, or infected with 25 PFU/cell each of *dl*748 and *dl*798. At 26 h p.i. cells were biotinylated and TNFR1 examined as described above. As a positive control, a dish of mock-infected cells was treated with TNF, and the cell extract was examined for TNFR1. As expected, TNF removed most of the TNFR1 from the cell surface (Fig. 23A, lanes a and b).

The results with the viruses are shown in Fig. 23A, lanes c-f. With *rec*700 (wild-type)-infected cells, only small amounts of TNFR1 were detected (lane c). With *dl*748

(RIDα–, RIDβ$^+$) and *dl*798 (RIDα$^+$, RIDβ–), high to intermediate levels of TNFR1 were observed, indicating that RIDα and RIDβ are required for efficient clearance of TNFR1. When cells were co-infected with *dl*748 and *dl*798, TNFR1 was reduced to levels comparable to *rec*700-infected cells (lanes f and c). This result indicates that the mutants complement (*dl*748 provides RIDβ, *dl*798 provides RIDα), and that both RIDα and RIDβ are required for efficient removal of TNFR1 from the cell surface. Figure 23B shows a standard immunoblot for E1B-19K from the same extracts that were analyzed for biotinylated TNFR1. Similar amounts of E1B-19K were detected with all viruses. Therefore, differences in TNFR1 levels seen with these viruses are not due to differences in infection efficiency by the viruses.

The partial clearance of TNFR1 observed with these RIDα$^-$ and RIDβ$^-$ mutants is consistent with the flow cytometry data in Fig. 19. These results suggest that there may be a mechanism in addition to RID that down-regulates cell-surface TNFR1 in Ad-infected cells. However, clearly, most of the down-regulation of TNFR1 requires RID.

In summary, RID is required to remove TNFR1 from the surface of Ad-infected cells. RID is also sufficient for removal of TNFR1 as indicated by the experiment with the 231-10 vector, with the caveat that the 231-10 vector also expresses other E3 proteins. RID expressed by the 231-10 vector is also sufficient to remove Fas from the cell surface, again, with the same caveat. However, the down-regulation of TNFR1 and Fas by 231-10 is almost certainly due to RID, because the mutant mapping data with E3 mutants have provided no indication that other E3 proteins play any role in down-regulating these death receptors.

Example 9

This example demonstrates that the 231-10 vector prevents rejection of human cancer cells transplanted into immunocompetent mice.

Cells or tissues transplanted into immunocompetent recipients are usually destroyed (rejected) by immune killer cells of the recipient. Rejection begins within 1-2 days, and therefore is mediated by the innate immune system including macrophages and NK cells. Specific CTL formed after about 5-7 days also play a major role in transplant rejection. As discussed above in Example 7, RID inhibits NK- and CTL-killing of Ad-infected cells and thus should also be able to inhibit NK- and CTL-mediated rejection of transplanted cells or tissues.

This idea was tested by determining whether the E3 proteins expressed by the 231-10 vector will permit human cancer A549 cells to grow as a tumor in immunocompetent C57BL/6 (H-2^b) mice. Human cancer cells normally will be rejected when transplanted in

C57BL/6 mice. However, RID should inhibit rejection by removing Fas and TNFR1 from the transplanted cells. E3-14.7K may also prevent rejection.

A549 cells mock-infected or infected with 50 PFU/cell of 231-10. After 48 h, 2 x 10^6 cells (in 100 μl) were injected subcutaneously into each hind limb flank of female C57BL/6 mice. At 18 days post-injection, the mice were sacrificed and the site of injection was examined following removal of the skin. With mice that received mock-infected cells, there was a pin-point mass on one flank, and no mass at all on the other flank (data not shown). With the 231-10-infected cells, there were significant tumor masses on both flanks (Fig. 24). The tumors were opaque and ellipsoid in shape. The left-flank tumor was attached to the muscle. The right-flank tumor, which is shown in higher magnification in Fig. 25, was attached to both the muscle and skin. The size of the tumor obtained with 231-10-infected cells was many times larger than what would be observed from the initial bolus of cells injected (2 x 10^6 cells are barely visible to the naked eye). Thus, the cells grew into a tumor.

In the second experiment, mock-infected and 231-10-infected A549 cells (at 2 days p.i. in culture, 50 PFU/cell) were used, both live cells as well as cells that were killed by freezing and thawing. These cells were injected into each hind limb of C57BL/6 and Balb/c mice, 2 x 10^7 cells per injection. As is the case with C57BL/6, the Balb/c mice are fully immunocompetent. There were four mice of each strain. Mouse 1 received killed uninfected A549 cells, mouse 2 received live A549 cells, mouse 3 received killed 231-10-infected cells, and mouse 4 received live 231-10-infected cells. Mice were harvested at 15 days following injection. No tumors were observed in either mouse strain with killed cells. With the C57BL/6 mouse that received uninfected live cells, there was no growth on one flank and a very small mass on the other flank. With the Balb/c mouse that received live uninfected cells, there were small flat masses on each flank. However, with both the C57BL/6 and the Balb/c mouse that received 231-10-infected cells, there were much larger elipsoid masses (tumors) on both hind flanks. These tumors resembled the tumors shown in Figs. 24 and 25. Therefore, as was the case in the first experiment, the 231-10 vector allowed A549 cells to form tumors in immunocompetent mice.

One of the 231-infected cell tumors from the C57BL/6 mouse was examined for expression of the E3 proteins known to be synthesized in cultured cells by 231-10. Proteins were extracted from the tumor, and the RIDβ, 14.7K, and gp19K proteins assayed by immunoblot. As shown in Fig. 26, all three proteins were detected. This result provides very strong evidence that the cells originally infected with 231-10, at the very minimum, persisted in the mouse. It is very likely that these cells grew as well, considering that tumors were formed. It is not likely that the 231-10 vector replicated in these cells, because the vector

lacks the E1A gene. Most likely, as the A549 cells proliferated in the mouse, a portion of the input vector was segregated into the daughter cells.

In summary, the E3 proteins expressed from the 231-10 vector have permitted the growth of human A549 cancer cells to form tumors in C57BL/6 and Balb/c mice. The tumors would not have been able to form unless they were protected from destruction by the immune system. These results argue strongly that the E3 proteins should prevent immune rejection of other types of transplanted cells and tissues. Thus, the 231-10 vector has the potential to be used in tissue or cell transplants to prevent rejection of the tissues or cells.

Example 10

This example illustrates the construction and properties of the 231-10 vector.

Features of 231-10

The 231-10 vector is a human adenovirus serotype 5 (Ad5) vector. It can be viewed as a "transient transfection" system, analogous to that obtained when a plasmid expression vector is transfected into cells. The basic features of the 231-10 vector are outlined in the schematic shown in Fig. 27 and the entire DNA sequence of the genome of 231-10 is given in Fig. 28.

The horizontal bar in Fig. 27 depicts the linear double-stranded DNA genome. The base pairs (nucleotides) are numbered from 1 to 34427 (see Fig. 28), from left to right in Fig. 27. Nucleotides 342-3523 are deleted, removing all the genes in the Ad E1A and E1B transcription units (collectively known as E1). Nucleotides 28133-30818 are also deleted, removing all the genes in the E3 transcription unit. In place of E1, an expression cassette has been inserted, in which the E3 genes are expressed from the human cytomegalovirus immediate early promoter-enhancer (CMV). This E3 expression cassette contains the E3 genes from the virus named *pm*734.1, which is a derivative of the virus named *rec*700 (Tollefson et al., *Virol. 220*:152-162, 1996). *rec*700 is an Ad5-Ad2-Ad recombinant that has the Ad2 version of the E3 genes for the 12.5K, 6.7K, gp19K, and RIDα proteins, and the Ad5 version of the E3 genes for the RIDβ and 14.7K proteins. The E3 cassette in 231-10 contains all the E3 genes from *pm*734.1. Notably, there are two missense mutations in the *adp* gene (which encodes the Adenovirus Death Protein [ADP], previously named E3-11.6K) (Tollefson et al., *supra*). These two mutations eliminate the first two methionine codons in the *adp* gene, thereby precluding synthesis of functional ADP (Tollefson et al., *supra*).

The 231-10 vector was designed to have the following properties. First, since the E1A genes are lacking, the vector should not replicate (efficiently) on most cell lines. Therefore, Ad early and late proteins will not be expressed and Ad DNA will not replicate. (It is known that Ad mutants lacking E1A do replicate their DNA and express late proteins at low levels when high multiplicities of infection are used and the infection is allowed to

proceed for several days. This is also true for 231-10 [not shown].) Second, the E3 proteins should be expressed in an E1A-independent manner from the CMV promoter/enhancer. Thus, 231-10 is an essentially inert vehicle that can deliver the Ad E3 proteins into cells without having other Ad proteins expressed, at least for the first approximately 3 days following infection. Even after 3 days, other Ad proteins should be expressed only in very small amounts, much less than the E3 proteins.

Construction of Ad 231-10

(a) The genes of the E3 transcription unit were excised from *pm*734.1 (pm734.1 is *rec*700 with mutations of the Met1 and Met41 codons in the *adp* gene. *rec*700 is the same as Ad5 but with the Ad2 EcoRI-D fragment substituted for the corresponding Ad5 EcoRI-C fragment). The *pm*734.1 SrfI-NdeI-D fragment (3560 bp) was blunt-end using the Klenow enzyme and cloned into the SmaI site of the pBluescriptSK(+) vector (Stratagene), resulting in plasmid p1721 which has the whole E3 transcription unit of *pm*734.1 (-39 to 3521) flanked by SalI-BstXI-SacII-NotI-XbaI-SpeI-BamHI sites situated upstream from the E3 sequences and PstI-EcoRI-EcoRV-HindIII-ClaI-SalI-XhoI sites situated downstream from the E3 sequences.

(b) The BamHI-SalI-A fragment (3605 bp) of p1721 was subcloned between the BamHI-XhoI sites of plasmid pCDNA3.1zeo(+) (Invitrogen), resulting in plasmid p181 in which E3 genes are under control of the CMV promoter-enhancer.

(c) The MfeI-ClaI fragment of p181 (4328 bp), corresponding to the CMV promoter-E3 genes from the *pm*734.1 expression cassette, was subcloned between the EcoRI-ClaI sites of plasmid pΔE1sp1A (Microbix Biosystems Inc., Toronto), resulting in plasmid p231 which has the CMV-E3 expression cassette flanked by Ad5 genomic sequences (Ad5 map units 0-1 and 9.8-16.1). The orientation of the CMV-E3 expression cassette is right-to-left (opposite to the Ad E1 and major late transcription units).

(d) Plasmid p231 was cotransfected along with plasmid pBHG10 (Microbix Biosystems Inc., Toronto) into 293 cells resulting in plaques of recombinant virus 231-10. The virus has deletions of E1 (Ad5 nt 342-3523) and E3 (Ad5 nt 28133-30818), and has the CMV-E3 expression cassette in place of the E1 deletion.

The 231-10 Vector Expresses the E3 RID, 14.7K, and gp19K proteins.

The E3 proteins are expected to be synthesized from the E3 expression cassette in 231-10. To demonstrate that this is so, separate dishes of A549 cells were infected with 250 PFU/cell of 231-10, then at 0-5 days p.i. protein extracts were examined for the E3 RID, 14.7K, and gp19K proteins using standard immunoblot procedures (Tollefson et al., Nature 392:726-730 (1998)). In one dish, 231-10-infected cells were treated with 1-β-D-

arabinofuransylcytosine (araC) at 2 h p.i., then proteins were extracted at 1 day p.i. RIDβ, 14.7K, and gp19K were readily detected at 2 days p.i., and their abundance increased until the end of the experiment at 5 days p.i. (Fig. 29, lanes d-g). On longer exposures of the gel shown in Fig. 29, a trace of RIDβ, 14.7K, and gp19K can be seen at 1 day p.i. (not shown).

In the experiment shown in Fig. 29, one dish of cells was treated with araC. AraC inhibits Ad DNA replication, and therefore Ad late genes cannot be expressed. As shown in Fig. 29, small amounts of RIDβ and gp19K were detected in the araC-treated cells; 14.7K was also detected in longer exposures of the gel (lane A). Therefore, as expected, E3 proteins are synthesized by 231-10 without replication of the vector Ad DNA.

These results demonstrate that the RIDβ, 14.7K, and gp19K proteins are expressed in 231-10-infected cells. In another experiment, the levels of RIDβ at 4 or 5 days p.i. were roughly similar to those of *rec*700-infected cells at 1 day p.i. (see Fig. 22). Bearing in mind that *rec*700 has replicated by 1 day p.i. and therefore has expressed higher levels of RIDβ from more templates, the quantities of RIDβ, 14.7K, and gp19K observed with 231-10, which does not replicate (or only replicates in small amounts at 4 or 5 days p.i.), are quite high. The synthesis of the E3 12.5K and 6.7K proteins by 231-10 has not been examined. Although not shown directly in Fig. 29, the RIDα polypeptide is also expressed by 231-10. This can be deduced from the observation that 231-10 exhibits the expected functions of RID, namely it clears Fas and TNFR1 from the surface of infected cells (see Example 8.). These functions require both RIDα and RIDβ.

Indirect immunofluorescence was also used to study the expression of the gp19K, RIDβ, and 14.7K proteins in A549 cells infected with 231-10. At 2 days p.i., the gp19K and RIDβ proteins were visualized as described previously (Tollefson et al., *Nature* 392:726-730 (1998); Hermiston et al., *J. Virol. 67:5289-5298 (1993)*) and the 14.7K protein was stained using a rabbit antiserum directed against a TrpE-14.7K fusion protein (Tollefson and Wold, *J. Virol.*62:33-39 (1988)). Strong staining of gp19K was observed in a pattern typical of the endoplasmic reticulum (Fig. 30A), as has been observed with *rec*700 (Hermiston et al., supra). The pattern for RIDβ was also similar to that seen with *rec*700, i.e. staining of the Golgi, other membranes, and the plasma membrane (Fig. 30B; Tollefson et al., *Nature* 392:726-730 (1998)). The 14.7K protein staining was diffuse in the cytoplasm (Fig. 30C), which again is typical of *rec*700 (unpublished results). These results establish that the E3 gp19K, RID, and 14.7K proteins localize to the same or similar intracellular compartments as they do in wild-type Ad-infected cells.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantageous results attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification are hereby incorporated by reference. The discussion of references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.

What is Claimed is:

1. A method for inhibiting apoptosis of a cell comprising treating the cell with an effective amount of a Receptor Internalization and Degradation (RID) complex.

2. The method of claim 1 wherein the treating step comprises administering to the cell a polynucleotide encoding the RID complex and wherein the RID complex is expressed in the cell.

3. The method of claim 2 wherein the polynucleotide comprises a recombinant adenovirus vector.

4. The method of claim 3 wherein the recombinant adenovirus vector is 231-10.

5. The method of claim 3 wherein the cell expresses Fas, TNFR-1, DR3, TRAIL-R1, or TRAIL-R2.

6. The method of claim 5 wherein the cell is a leukocyte.

7. The method of claim 5 wherein the cell comprises a transplant tissue.

8. The method of claim 1 wherein the treating step comprises administering the RID complex to the cell.

9. The method of claim 8 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the cell.

10. A method for decreasing apoptosis of target cells in a patient comprising treating the patient with an effective amount of a Receptor Internalization and Degradation (RID) complex.

11. The method of claim 10 wherein the treating step comprises administering to the patient a polynucleotide encoding the RID complex and wherein the polynucleotide is internalized in the target cells and the RID complex is expressed.

12. The method of claim 11 wherein the polynucleotide comprises a recombinant adenovirus vector.

13. The method of claim 12 wherein the recombinant adenovirus vector is 231-10.

14. The method of claim 10 wherein the patient suffers from a degenerative disease or an immunodeficiency disease.

15. The method of claim 10 wherein the treating step comprises administering the RID complex to the patient.

16. The method of claim 15 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the cells.

17. A method for decreasing leukocyte apoptosis in a patient comprising:

(1) withdrawing leukocytes from the patient,

(2) treating the leukocytes with an effective amount of a RID complex, and

(3) administering the treated leukocytes to the patient.

18. The method of claim 17 wherein the treating step comprises administering to the leukocytes a polynucleotide encoding the RID complex wherein the RID complex is expressed in the leukocytes.

19. The method of claim 18 wherein the polynucleotide comprises a recombinant adenovirus vector.

20. The method of claim 19 wherein the recombinant adenovirus vector is 231-10.

21. The method of claim 17 wherein the treating step comprises administering the RID complex to the leukocytes.

22. The method of claim 21 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the leukocytes.

23. A composition comprising a Receptor Internalization and Degradation (RID) complex and a carrier suitable for facilitating delivery of the RID complex into a cell.

24. A recombinant adenovirus comprising a polynucleotide encoding a Receptor Internalization and Degradation (RID) complex operably linked to a promoter, wherein the adenovirus is replication defective and wherein the polynucleotide is expressed upon infection of a eukaryotic cell with the adenovirus.

25. The recombinant adenovirus vector of claim 24 consisting of 231-10.

ABSTRACT

A method for inhibiting apoptosis of a cell expressing a death receptor of the TNFR family is disclosed. The method involves treating the cell with a Receptor Internalization and Degradation (RID) protein complex containing RIDα (10.4K) and RIDβ (14.5K) proteins encoded by the E3 region of adenovirus. The cell can be treated by administering to the cell a polynucleotide expressing the RID complex or by administering to the cell a composition containing the RID complex. Compositions containing a RID complex are also disclosed. The compositions and method are useful in the treatment of cancer, degenerative and immune disorders, as well as in promoting survival of tissue transplants. An adenovirus vector for delivering the RID complex to cells is also disclosed.


TNFR1 362 VVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQY 401
Fas 236 IAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKV 275
DR3 338 VMDAVPARRWKEEVRTLGLREAEIEAVEVEIGR-FRDQQY 376
TRAIL-R1 348 FANIVPFDSWDQLMRQLDLTKNEIDVVRAGTAG-PGDALY 386
TRAIL-R2 316 FADLVPFDSWEPLMRKLGLMDNEIKVAKAEAAG-HRDTLY 354
TNFR1 402 SMLATWRRRTPRREATLELLGRVLRDMDLLGCLEDIEE 439
Fas 276 QLLRNWHQLHGK-KEAYDTLIKDLKKANLCTLAEKIQT 313
DR3 377 EMLKRWR--QQQ-PAGLGAVYAALERMGLDGCVEDLRS 411
TRAIL-R1 387 AMLMKWVNKTGR-NASIHTLLDALERMEERHAKEKIQD 423
TRAIL-R2 356 TMLIKWVNKTGR-DASVHTLLDALETLGERLAKQKIED 392

Figure 1


TNFR1 (TNF)
TRAIL-R1 (TRAIL)
TRAIL-R2 (TRAIL)
DR3 (?)
Fas
(FasL)
Plasma
Membrane
Death Effector
Domain
Death
Domain
Receptor
TRADD
FADD
Caspase 8
Effector
Caspases
Apoptosis
Caspase 8
FADD
Fas

FIGURE 2

RID COMPLEX



FIGURE 3

RIDα-L (10.4K-L)

```
                    10                  20
M I P R V L I L L T L V A L F C A C S T L A A V A H I E
        signal sequence

 30                 40                  50
V D C I P P F T V Y L L Y G F V T L I L I C S L V T V V
    *                                transmembrane

     60                  70                  80
I A F I Q F I D W V C V R I A Y L R H H P Q Y R D R T I

         90
A D L L R I L
```

Figure 4A

RIDα-S (10.4K-S)

```
                    10                  20
A V A H I E V D C P P F T V Y L L Y G F V T L I L I C
                  *                    transmembrane

 30                 40                  50
S L V T V V I A F Q F I D W V C V R I A Y L R H H P Q

       60
Y R D R T I A D L L R I L
```

Figure 4B

Pre-RIDβ (14.5K)

```
                    10                  20
M K F T V T F L L I I C T L S A F C S P T S K P Q R H I
    signal sequence

 30                  40                  50
S C R F T R I W N I P S C Y N E K S D L S E A W L Y A I

     60                  70                  80
I S V M V F C S T I L A L A I Y P Y L D I G W N A I D A
    Transmembrane

          90                  100                 110
M N H P T F P A P A M L P L Q Q V V A G G F V P A N Q P


               120                 130
R P P S P T P T E I S Y F N L T G G D D
      *             *
```

Figure 4C

Mature-RIDβ (14.5K)

```
                    10                  20
S P T S K P Q R H I S C R F T R I W N I P S C Y N E K S

 30                  40                  50
D L S E A W L Y A I I S V M V F C S T I L A L A I Y P Y
                   Transmembrane

     60                  70                  80
L D I G W N A I D A M N H P T F P A P A M L P L Q Q V V


          90                  100                 110
A G G F V P A N Q P R P P S P T P T E I S Y F N L T G G
                          *             *

D D
```

Figure 4D


Fas
or TNFR1
RID
Plasma
Membrane
LL-
-YXXϕ
Early/Sorting
Endosomes
Recycling
Endosomes
Late Endosomes
Lysosomes
Fas
is degraded

FIGURE 5


Mock
Ad5 (wild-type)
A
B
Cell number
0 60 120 180 240 300
10^0 10^1 10^2 10^3 10^4
Fluoresence intensity (FITC)
rec 700 (wild-type)
dl309 (RIDα⁻, RIDβ⁻, 14.7K⁻)
C
D
dl748 (RIDα⁻, RIDβ⁺, 14.7K⁻)
dl764 (RIDα⁺, RIDβ⁻, 14.7K⁺)
E
F
dl 758 (RIDα⁺, RIDβ⁺, 14.7K⁻)
pm 760 (RIDα ↑, RIDβ ↑, 14.7K ↓)
G
H

FIGURE 7


A
R1
FSC-Height
SSC-Height
Mock
B
Cell number
Fluoresence intensity (FITC)
rec 700 (wild-type)
C
dl 758 (RIDα+, RIDβ+, 14.7K-)
D
dl309 (RIDα-, RIDβ-, 14.7K-)
E
dl764 (RIDα+, RIDβ-, 14.7K+)
F
dl748 (RIDα-, RIDβ+, 14.7K-)
G
pm 760 (↑RIDα, ↑RIDβ, ↓14.7K)
H

FIGURE 8


A.
Mock
Ad5 (WT)
Ad2 (WT)
rec700 (WT)
dl309 (RID⁻, 14.7K⁻)
dl748 (RIDα⁻, 14.7K⁻)
dl758 (RID⁺, 14.7K⁻)
dl764 (RIDβ⁻, 14.7K⁺)
pm760 (RID↑, 14.7K↓)
Fas
-66
-45
-31
B.
TfR
-116
-97
-66
C.
E1A
-66
-45
a b c d e f g h i

FIGURE 10


A rec700 (WT), Baf +
B rec700 (WT), Baf -
C dl309 (RID-), Baf +
D
Mock 700 309
Baf - + - + - +
Fas
ERp72
E1B-19K
a b c d e f

FIGURE 13



FIGURE 13E



FIGURE 14



FIGURE 15


A. CTL From Perforin (-/-) Mice
% Specific Lysis
90
80
70
60
50
40
30
20
10
0
Mock
rec700 (WT)
dl7001 (E3⁻)
B. CTL From Perforin (+/+) Mice
% Specific Lysis
90
80
70
60
50
40
30
20
10
0
Mock
rec700 (WT)
dl7001 (E3⁻)
C. FACS In Infected P815 Cells
Counts
200
160
120
80
40
0
10⁰
10¹
10²
10³
10⁴
FL2-

FIGURE 16


80
60
40
20
0
% Specific Lysis
10:1
5:1
10:1
5:1
10:1
5:1
Mock
Wild-type Adenovirus
RID⁻ Adenovirus

FIGURE 17



Mock - 93%
rec 700 (Wild type) - 16%
*dl*712 (↑ RID) - 18%
Unstained control - 1.5%

Mock - 100%
rec 700 (Wild type) - 11%
*dl*712 (↑ RID) - 14%
Unstained control - 1.5%

FIGURE 18



Mock - 92%
rec 700 (Wild type) - 29%
***dl*753 (RIDα⁻) - 85%**
***dl*764 (RIDβ⁻) - 84%**
***dl*712 (↑RID)- 24%**
***dl*309 (RID⁻) - 84%**
Unstained Control - 2%

Mock - 100%
rec 700 (Wild type) - 4%
***dl*753 (RIDα⁻) - 100%**
***dl*764 (RIDβ⁻) - 100%**
***dl*712 (↑RID) - 2%**
***dl*309 (RID⁻) - 100%**
Unstained Control - 1%

FIGURE 19



Mock - 93%
231-10 ($E3^+$ vector) 24 hr. p.i. - 35%
231-10 ($E3^+$ vector) 48hr. p.i. - 11%

FIGURE 20



FIGURE 21



FIGURE 22

A.
TNFR1
B.
E1B-19K
Mock
Mock+ TNF
rec700
dl748
dl798
dl748 + dl798
a b c d e f

FIGURE 23

FIGURE 26


ClaI
HindIII
EcoRV
EcoRI
PstI
pm734.1 E3 genes
CMV promoter
HindIII
SalI
BglII
deletion of E1 (Ad5 nt 342-3523)
deletion of E3 (Ad5 nt 28133-30818)

FIGURE 27


catcatcaataatataccttattttggattgaagccaatatgataatgaggggtggagt
gtagtagttattatatggaataaaacctaacttcggttatactattactccccacctca
EciI
ttgtgacgtggcgcggggcgtgggaacggggcgggtgacgtagtagtgtggcggaagtgt
aacactgcaccgcgccccgcacccttgccccgcccactgcatcatcacaccgccttcaca
AflIII
BspLU11I
EciI
NspI
gatgttgcaagtgtggcggaacacatgtaagcgacggatgtggcaaaagtgacgtttttg
ctacaacgttcacaccgccttgtgtacattcgctgcctacaccgttttcactgcaaaaac
BsrGI
BsrFI
SgrAI
TatI
EciI
gtgtgcgccggtgtacacaggaagtgacaattttcgcgcggttttaggcggatgttgtag
cacacgcggccacatgtgtccttcactgttaaaagcgcgccaaaatccgcctacaacatc
HaeI
MscI
ApoI
EaeI
taaatttgggcgtaaccgagtaagatttggccattttcgcgggaaaactgaataagagga
atttaaacccgcattggctcattctaaaccggtaaaagcgccttttgacttattctcct
ApoI
HindIII
EcoRI
ClaI
EcoRV
agtgaaatctgaataattttgtgttactcatagcgcgtaatatcgataagcttgatatcg
tcactttagacttattaaaacacaatgagtatcgcgcattatagctattcgaactatagc
BciVI
PstI
SfcI
Eco57I
BssHII
aattcctgcagccctatggatacacggggttgaaggtatcttcagacggtcttgcgcgct
ttaaggacgtcgggatacctatgtgccccaacttccatagaagtctgccagaacgcgcga
TaqII
tcatctgcaacaacatgaagatagtgggtgcggatggacaggaacaggaggaaactgaca
agtagacgttgttgtacttctatcacccacgcctacctgtccttgtcctcctttgactgt
XcmI
AceIII
ttccatttagattgtggagaaagtttgcagccaggaggaagctgcaataccagagctggg
aaggtaaatctaacacctctttcaaacgtcggtcctccttcgacgttatggtctcgaccc
BseRI
BspGI
ApoI
aggagggcaaggaggtgctgctgaataaactggacagaaatttgctaactgattttaagt
tcctcccgttcctccacgacgacttatttgacctgtctttaaacgattgactaaaattca
BsaI
BglII
BstYI
HgiEII
aagtgatgctttattatttttttttattagttaaagggaataagatctttgagaccgcac
ttcactacgaaataataaaaaaaaataatcaatttcccttattctagaaactctggcgtg

FIGURE 28


Eco0109I
Psp5II
Sse8647I
BstYI
BsgI
BsmI
agggtcttaataagggtgcagagatcctcaggtccttgacaaggtgagtgaatgcagcct
661
720
tcccagaattattcccacgtctctaggagtccaggaactgttccactcacttacgtcgga
tcggtttctaccgagtgctgagttatggtaatgggcttttctcccaccatgaccaccaat
721
780
agccaaagatggctcacgactcaataccattacccgaaaagagggtggtactggtggtta
Bpu10I
BsaWI
Pfl1108I
ttctgacgcttggttggcaacttgtagctaaggcggtgtccggtggtattactgtcgtag
781
840
aagactgcgaaccaaccgttgaacatcgattccgccacaggccaccataatgacagcatc
HincII
HpaI
HaeI
gtgactttggcctgctttaccagacaaaagataccccttttgcactggtgcaagttaacc
841
900
cactgaaaccggacgaaatggtctgttttctatggggaaaacgtgaccacgttcaattgg
MspA1I
BsiEI
BanII
BsiHKAI
EaeI
Bsp1286I
EagI
PflMI
SacI
GdiII
atgtcttggagctcttgattcatgcgctgttgctcggccgctgccctgcgtctttctagc
901
960
tacagaacctcgagaactaagtacgcgacaacgagccggcgacgggacgcagaaagatcg
HaeII
AlwNI
BstAPI
BglII
BstYI
XbaI
BseRI
aggcgctgctctgtaataattccgtccatttctagatctagggtgtcagtcatctcctcc
961
1020
tccgcgacgagacattattaaggcaggtaaagatctagatcccacagtcagtagaggagg
tgttagattaaagtagctgatttcagtgggggtgggagaagtggggcgaggctgattggc
1021
1080
acaatctaatttcatcgactaaagtcacccccaccctcttcaccccgctccgactaaccg
BsrFI
NgoAIV
BtsI
TaqII
tgggacaaagccgccggcaacaacttgttgcagtggaagcatagcgggcgcggggaaagt
1081
1140
accctgtttcggcggccgttgttgaacaacgtcaccttcgtatcgcccgcgccccttttca
DrdII
Bsp24I
Bsp24I
tgggtggttcatggcatctattcgtttccagccaatgtcaaggtagggatatatagctag
1141
1200
acccaccaagtaccgtagataagcaaaggtcggttacagttccatccctatatatcgatc
PstI
SfcI
ggctaagatggtactgcagaacaccataacagagatgattgcatataaccaggcttcgga
1201
1260
ccgattctaccatgacgtcttgtggtattgtctctactaacgtatattggtccgaagcct
SspI
aagatcgctttttttcattgtagcaacttggaatattccatatacgagtgaatctgcatga
1261
1320
ttctagcgaaaaaagtaacatcgttgaaccttataaggtatatgctcacttagacgtact
tatatgtctttgaggcttggaggtcggggaacaaaacgcagatagggtgcaaataatcag
1321
1380
atatacagaaactccgaacctccagccccttgttttgcgtctatcccacgtttattagtc
ApoI
EcoRI
ApoI
SfcI
cagaaaagtcacagtaaatttcataattaaagaattctgagaagatcagctatagtcctg
1381
1440
gtcttttcagtgtcatttaaagtattaatttcttaagactcttctagtcgatatcaggac
Bsu36I
BanI
BsrDI
FspI
BmrI
tctctgtattgcggatggtgcctgaggtacgcaatgcgcacacaaacccagtcaatgaac
1441
1500

FIGURE 28


agagacataacgcctaccacggactccatgcgttacgcgtgtgtttgggtcagttacttg
PstI
SfcI
SfcI
BspMI
tgaatgaaggcgatgactacagtgacgaggctgcagatgaggataagggtgacaaatccg
1501
1560
acttacttccgctactgatgtcactgctccgacgtctactcctattcccactgtttaggc
EaeI
GdiII
SacII
MspA1I
BsiEI
BstDSI
taaagcaggtaaactgtgaaaggtgggatgcaatctacttcgatgtgagcgaccgcggcc
1561
1620
atttcgtccatttgacactttccaccctacgttagatgaagctacactcgctggcgccgg
AvaI
SmlI
XhoI
BsiHKAI
Bsp1286I
aatgtagagcacgcacagaaaagcgcaacaagggtcaataatataagaactcgaggaatc
1621
1680
ttacatctcgtgcgtgtcttttcgcgttgttcccagttattatattcttgagctccttag
EarI
ApoI
atgtctcatttaatcatactgtaaaagaagagaacatggtttcagaccgtccaatctatg
1681
1740
tacagagtaaattagtatgacattttcttctcttgtaccaaagtctggcaggttagatac
SfcI
RleAI
XmnI
BsiHKAI
Bsp1286I
HaeI
StuI
HaeIV
Hin4I
aatttttttcattgtgtgggttgagcacaatgataggcctatagatgggggggtctggcgcg
1741
1800
ttaaaaaagtaacacacccaactcgtgttactatccggatatctacccccccagaccgcgc
Bsp24I
HaeII
Tth111II
Eco47III
tctgcgctttaggcaacaaataagccacataataataaggcaaacaaacataagcgctat
1801
1860
agacgcgaaatccgttgtttattcggtgtattattattccgtttgtttgtattcgcgata
Bsp24I
BmrI
Tth111II
ApoI
ggaaaaccaccacaagtccaagctcgcccagtcattgacaaaggcatgaacttggggtaa
1861
1920
ccttttggtggtgttcaggttcgagcgggtcagtaactgtttccgtacttgaaccccatt
RleAI
BsaWI
BtsI
BsbI
atttagggcagatgttagtccggtagcagtggtgttgcgatagtccgttgtgggcgcgat
1921
1980
taaatcccgtctacaatcaggccatcgtcaccacaacgctatcaggcaacacccgcgcta
HincII
Eco57I
BsrFI
BpmI
BclI
ApoI
BtsI
ggttgagccggtcaactctggagcaggcaagctgaagctgggtttgatcaaatttgcagt
1981
2040
ccaactcggccagttgagacctcgtccgttcgacttcgacccaaactagtttaaacgtca
HaeII
AlwNI
HaeII
BsgI
BspGI
RleAI
gcaggcgctggcagaaatcaggcgctaacgtccaggaaagtttgatttgaaggttgtggg
2041
2100
cgtccgcgaccgtctttagtccgcgattgcaggtcctttcaaactaaacttccaacaccc
BspGI
BpmI
RleAI
tataatcttgcccgcctggagcatatcccacatagagtaaattgtccaggggaatacaag
2101
2160
atattagaacgggcggacctcgtatagggtgtatctcatttaacaggtccccttatgttc
Tth111II
caagcggaaaatcaaggcattttcttttcatcaataaaactgcgtctgcttttgtatttg
2161
2220

FIGURE 28


gttcgccttttagttccgtaaaagaaaagtagttattttgacgcagacgaaaacataaac
HaeII
Eco47III
BsrBI
BanI
agataaagtaaggtacataccaaagcaagcgctgtaataagcagagcggtggaacaaaag
2221
2280
tctatttcattccatgtatggtttcgttcgcgacattattcgtctcgccaccttgttttc
MslI
BsrGI
RleAI
MslI
Tth111II
TatI
TatI
gtgccagtgttctctaaacacttttgtgggggccacaacttgtactgtttgctcatgtac
2281
2340
cacggtcacaagagatttgtgaaaacaccccggtgttgaacatgacaaacgagtacatg
ApoI
atggtaatatcgcacatttcataaaatggaaatttatacataaaagttttacgattttca
2341
2400
taccattatagcgtgtaaagtattttacctttaaatatgtattttcaaaatgctaaaagt
StyI
BbsI
DrdI
ccttggaagactgtgacattatagtcgttagtgtcacctggctgccaaatagcatataca
2401
2460
ggaaccttctgacactgtaatatcagcaatcacagtggaccgacggtttatcgtatatgt
HindIII
gcatacttgccaattttgtctttgtggcgaataataagcttttcatgttctgtggtgcat
2461
2520
cgtatgaacggttaaaacagaaacaccgcttattattcgaaaagtacaagacaccacgta
DraI
BsmI
SwaI
BsrDI
DrdII
tttataagagtagtgcattcattagcttctgatttaaatgtaacattgcaagctggttcc
2521
2580
aaatattctcatcacgtaagtaatcgaagactaaatttacattgtaacgttcgaccaagg
HaeII
SfcI
Eco47III
PstI
BglI
ttaaactcaacctttttggcagcgctgcagactgccgcaagggcgagcaagcctaaaatc
2581
2640
aatttgagttggaaaaaccgtcgcgacgtctgacggcgttcccgctcgttcggattttag
DraI
BaeI
atgtacctcatcttggatgttgcccccagcgtttaaaaagctgacaataggtacaaacgt
2641
2700
tacatggagtagaacctacaacgggggtcgcaaatttttcgactgttatccatgtttgca
BsgI
Bsu36I
BaeI
MslI
gcgtgcagcaggcggcaaccctaaggcacagaagtgctagtataagaataaacagaatta
2701
2760
cgcacgtcgtccgccgttgggattccgtgtcttcacgatcatattcttatttgtcttaat
HindIII
caagagtaaggataaccccgaccccaattccagaaaaattagacaagcttgtagagttac
2761
2820
gttctcattcctattggggctggggttaaggtctttttaatctgttcgaacatctcaatg
PacI
ttgaattgctcatatacttaattaaaaaatcccagcaccccgcaaaatgctttttgacc
2821
2880
aacttaacgagtatatgaattaatttttagggtcgtggggcgttttacgaaaaaactgg
BanII
BsiHKAI
Bsp1286I
Hin4I
Hin4I
SacI
BplI
BplI
tgagttccgggagttgagctcacctcctgttttggaaaaatgggagtaatgtctggttac
2881
2940
actcaaggccctcaactcgagtggaggacaaaaccttttaccctcattacagaccaatg
SfcI
BsaWI
RleAI
BsrFI
BspMI
Bpu10I
PinAI
SunI
AarI

FIGURE 28


gctcaggctgtaggtgtgggcgcagcaaccggtgacgcactcgtacgttcccggcaggtg
2941
cgagtccgacatccacacccgcgtcgttggccactgcgtgagcatgcaagggccgtccac
3000
BseRI
aggagggtggtggtggtggttttttcttgacggtgtagttgaagccgagaaggttgtgt
3001
tcctcccaccaccaccaccacaaaaagaactgccacatcaacttcggctcttccaacaca
3060
EarI
SapI
BsmBI
ggcaaacttacttcgtctcgctggaaactgttgtaaattacaaatgaagagccgttaaag
3061
ccgtttgaatgaagcagagcgacctttgacaacatttaatgtttacttctcggcaatttc
3120
HgiEII
SexAI
BsaWI
BsaXI
TaqII
taccaggtaaggtacttattggcccgcttgtgcaaaccggaggtgaggtttgctttggtc
3121
atggtccattccatgaataaccgggcgaacacgtttggcctccactccaaacgaaaccag
3180
BmrI
BanII
BsaXI
Bsp1286I
tgctttgggtgggtaaaaacggtggcgttcacaggatggcgacaggagccccagtagatt
3181
acgaaacccacccatttttgccaccgcaagtgtcctaccgctgtcctcggggtcatctaa
3240
BglII
BstYI
MslI
ctaatttctgtatttattatactcagcacagagatgacaacaaagatcttgatgtaatcc
3241
gattaaagacataaataatatgagtcgtgtctctactgttgtttctagaactacattagg
3300
Eco0109I
Psp5II
BstDSI
SanDI
BsrBI
BsrBI
agggttaggacagttgcaaaccaccgtcagaacacagggaccccgctcccgctccactag
3301
tcccaatcctgtcaacgtttggtgccagtcttgtgtccctggggcgagggcgaggtgatc
3360
BsaAI
HaeII
AflIII
TaqII
caggggcgcttggtaaactcccgaatcaggctacgtgtaagctctacctgggtggtgag
3361
gtcccccgcgaaccatttgagggcttagtccgatgcacattcgagatggacccaccactc
3420
ApaI
BanII
Bsp1286I
BmgI
BseSI
EarI
SapI
BsaHI
Eco0109I
ccggacgccgtgcgccgggccctcgatatgctcttcgggcaattcaaagtaacaaaactc
3421
ggcctgcggcacgcggcccgggagctatacgagaagcccgttaagtttcattgttttgag
3480
SacII
MspA1I
BsaWI
BstDSI
BtsI
accggagccgcgggcaaagcacttgtggcggcggcagtggtcgaggtgtgtcaggcgcag
3481
tggcctcggcgcccgtttcgtgaacaccgccgccgtcaccagctccacacagtccgcgtc
3540
Pfl1108I
EciI
tcgctctgcctctccactggtcattcagtcgtagccgtccgccgagtctttcaccgcgtc
3541
agcgagacggagaggtgaccagtaagtcagcatcggcaggcggctcagaaagtggcgcag
3600
EaeI
GdiII
BspGI
aaagttgggaataaactggtccgggtagtggccgggaggtccagaaaaggggttgaagta
3601
tttcaacccttatttgaccaggcccatcaccggccctccaggtcttttccccaacttcat
3660
BsaWI
BspEI
Hin4I
BseRI

FIGURE 28


aaccgaaggcacgaactcctcaataaattgtagagttccaatgcctccggagcggcggctc
3661
3720
ttggcttccgtgcttgaggagttatttaacatctcaaggttacggaggcctcgcgccgag
PstI
BplI
Tth111I SfcI
Hin4I
EarI
SapI
EaeI
GdiII
BsrBI
cgaggacgaggtctgcagagttaggatcgcctgacggggcgtaaatgaagagcggccagc
3721
3780
gctcctgctccagacgtctcaatcctagcggactgccccgcatttacttctcgccggtcg
BseRI
AceIII
BanII
BsiHKAI
Bsp1286I
Hin4I SacI
BsaI
BsaWI
BspEI
HaeII
gccgccgatctgaaatgtcccgtccggacggagaccaagagaggagctcaccgactcgtc
3781
3840
cggcggctagactttacagggcaggcctgcctctggttctctcctcgagtggctgagcag
SmaI BamHI
AvaI
BstYI
BplI
gttgagctgaatacctcgccctctgattttcaggtgagttataccctgcccgggggGGAT
3841
3900
caactcgacttatggagcgggagactaaaagtccactcaatatgggacgggcccccCCTA
AflII
SmlI
HindIII
BanI
BanII
BsiHKAI
Bsp1286I
Hin4I SacI
KpnI
NheI
Bsp24I
DraI
PmeI
SfcI
BsaI
Bsp24I
CCGAGCTCGGTACCAAGCTTAAGTTTAAACGCTAGCCAGCTTGGGTCTCCCTATAGTGAG
3901
3960
GGCTCGAGCCATGGTTCGAATTCAAATTTGCGATCGGTCGAACCCAGAGGGATATCACTC
BanII
BsiHKAI
Bsp1286I
SacI
VspI
BtsI
TCGTATTAATTTCGATAAGCCAGTAAGCAGTGGGTTCTCTAGTTAGCCAGAGAGCTCTGC
3961
4020
AGCATAATTAAAGCTATTCGGTCATTCGTCACCCAAGAGATCAATCGGTCTCTCGAGACG
EciI
TTATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGT
4021
4080
AATATATCTGGAGGGTGGCATGTGCGGATGGCGGGTAAACGCAGTTACCCCGCCTCAACA
AatII
BsaHI
BanI
TACGACATTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAAACTCCCATTGACGTCAA
4081
4140
ATGCTGTAAAACCTTTCAGGGCAACTAAAACCACGGTTTTGTTTGAGGGTAACTGCAGTT
TatI
TGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACT
4141
4200
ACCCCACCTCTGAACCTTTAGGGGCACTCAGTTTGGCGATAGGTGCGGGTAACTACATGA
BstDSI
NcoI
StyI
MslI
BsaAI
SnaBI
TatI
GCCAAAACCGCATCACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAG
4201
4260
CGGTTTTGGCGTAGTGGTACCATTATCGCTACTGATTATGCATCTACATGACGGTTCATC
BglI
TatI BmrI
Bsp24I
BsaHI
GAAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGA
4261
4320
CTTTCAGGGTATTCCAGTACATGACCCGTATTACGGTCCGCCCGGTAAATGGCAGTAACT
Bsp24I
AatII
NdeI
TatI
BglI

FIGURE 28


CGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTT
4321
4380
GCAGTTATCCCCCGCATGAACCGTATACTATGTGAACTACATGACGGTTCACCCGTCAAA
TaqII
AatII
BsaHI
ACCGTAAATAGTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATGGGAA
4381
4440
TGGCATTTATCAGGTGGGTAACTGCAGTTACCTTTCAGGGATAACCGCAATGATACCCTT
AatII
BsaHI
BglI
CATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCAT
4441
4500
GTATGCAGTAATAACTGCAGTTACCCGCCCCCAGCAACCCGCCAGTCGGTCCGCCCGGTA
TTACCGTAAGTTATGTAACGCGGAACTCCATATATGGGCTATGAACTAATGACCCCGTAA
4501
4560
AATGGCATTCAATACATTGCGCCTTGAGGTATATACCCGATACTTGATTACTGGGGCATT
AflIII
MluI
VspI
SpeI
HincII
TTGATTACTATTAATAACTAGTCAATAATCAATGTCAACGCGTATATCTGGCCCGTACAT
4561
4620
AACTAATGATAATTATTGATCAGTTATTAGTTACAGTTGCGCATATAGACCGGGCATGTA
HincII
Bsp24I
AccI
NruI
Bpu10I
HindIII
SalI
CGCGAAGCAGCGCAAAACGCCTAACCCTAAGCAGATTCTTCATGCAATTcaagcttgtcg
4621
4680
GCGCTTCGTCGCGTTTTGCGGATTGGGATTCGTCTAAGAAGTACGTTAAgttcgaacagc
Bsp24I
BglII
BstYI
AflII
SmlI
acagatcttgggcgtggcttaagggtgggaaagaatatataaggtgggggtcttatgtag
4681
4740
tgtctagaacccgcaccgaattcccacccttttcttatatattccacccccagaatacatc
BsiHKAI
Bsp1286I
ttttgtatctgttttgcagcagccgccgccgccatgagcaccaactcgtttgatggaagc
4741
4800
aaaacatagacaaaacgtcgtcggcggcggcggtactcgtggttgagcaaactaccttcg
BstDSI
NcoI
StyI
BanII
BsiHKAI
Bsp1286I
NspI
SacI
SphI
BpmI
attgtgagctcatatttgacaacgcgcatgccccatgggccggggtgcgtcagaatgtg
4801
4860
taacactcgagtataaactgttgcgcgtacgggggtacccggccccacgcagtcttacac
Pfl1108I
BanII
BsaI
Bsp1286I
Bsp24I
atgggctccagcattgatggtcgccccgtcctgcccgcaaactctactaccttgacctac
4861
4920
tacccgaggtcgtaactaccagcggggcaggacgggcgtttgagatgatggaactggatg
PstI
Tth111I
Eco57I
SfcI
Hin4I
AlwNI
MmeI
Bsp24I
EciI
MspA1I
PstI
gagaccgtgtctggaacgccgttggagactgcagcctccgccgccgcttcagccgctgca
4921
4980
ctctggcacagaccttgcggcaacctctgacgtcggaggcggcggcgaagtcggcgacgt
SacII
BanII
MspA1I
Bsp1286I
BstAPI
BstDSI
Bpu10I
BtsI
gccaccgcccgcgggattgtgactgactttgctttcctgagcccgcttgcaagcagtgca
4981
5040
cggtggcgggcgccctaacactgactgaaacgaaaggactcgggcgaacgttcgtcacgt
BsgI

FIGURE 28


Tth111II
EciI
HincII
MunI
gcttcccgttcatccgcccgcgatgacaagttgacggctcttttggcacaattggattct
5041
5100
cgaagggcaagtaggcgggcgctactgttcaactgccgagaaaaccgtgttaacctaaga
SmaI
AvaI
MmeI
AlwNI
MspA1I
PvuII
BspMI
BstYI
ttgacccgggaacttaatgtcgtttctcagcagctgttggatctgcgccagcaggtttct
5101
5160
aactgggcccttgaattacagcaaagagtcgtcgacaacctagacgcggtcgtccaaaga
BglI
Eco57I
DraI
Tth111II
Bsp24I
XcmI
AlwNI
gccctgaaggcttcctcccctcccaatgcggtttaaaacataaataaaaaaccagactct
5161
5220
cgggacttccgaaggaggggagggttacgccaaattttgtatttatttttttggtctgaga
BsaBI
Bsp24I
Tth111II
BssHII
BssHII
gtttggatttggatcaagcaagtgtcttgctgtctttatttaggggttttgcgcgcgcgg
5221
5280
caaacctaaacctagttcgttcacagaacgacagaaataaatccccaaaacgcgcgcgcc
AhdI
MspA1I
HaeIV
Hin4I
TaqII
SmaI
AvaI
Eco0109I
BsiEI
BsaI
Psp5II
PflMI
taggcccgggaccagcggtctcggtcgttgagggtcctgtgtatttttccaggacgtgg
5281
5340
atccgggccctggtcgccagagccagcaactcccaggacacataaaaaaggtcctgcacc
BsmBI
taaaggtgactctggatgttcagatacatgggcataagcccgtctctggggtggaggtag
5341
5400
atttccactgagacctacaagtctatgtacccgtattcgggcagagaccccacctccatc
PstI
BtsI
SfcI
BsbI
Pfl1108I
caccactgcagagcttcatgctgcggggtggtgttgtagatgatccagtcgtagcaggag
5401
5460
gtggtgacgtctcgaagtacgacgccccaccacaacatctactaggtcagcatcgtcctc
HaeII
Eco47III
BanI
StyI
Eco0109I
cgctgggcgtggtgcctaaaaatgtctttcagtagcaagctgattgccaggggcaggccc
5461
5520
gcgacccgcaccacggatttttacagaaagtcatcgttcgactaacggtccccgtccggg
TaqII
BsaAI
ttggtgtaagtgtttacaaagcggttaagctgggatgggtgcatacgtggggatatgaga
5521
5580
aaccacattcacaaatgtttcgccaattcgaccctacccacgtatgcacccctatactct
NsiI
tgcatcttggactgtatttttaggttggctatgttcccagccatatccctccggggattc
5581
5640
acgtagaacctgacataaaaatccaaccgatacaagggtcggtatagggaggcccctaag
BciVI
BsiHKAI
Bsp1286I
BseSI
ApaLI
BsaWI
DrdII
BsgI
ApoI
atgttgtgcagaaccaccagcacagtgtatccggtgcacttgggaaatttgtcatgtagc
5641
5700
tacaacacgtcttggtggtcgtgtcacataggccacgtgaacccttaaacagtacatcg
BsmBI
BsaHI
BsmI
ttagaaggaaatgcgtggaagaacttggagacgcccttgtgacctccaagattttccatg
5701
5760
aatcttcctttacgcaccttcttgaacctctgcgggaacactggaggttctaaaaggtac

FIGURE 28


ApaI
BanII
Bsp1286I
BstDSI
BmgI
BstXI
BseSI
NsiI
MslI
BsrDI
5761 cattcgtccataatgatggcaatgggcccacgggcggcggcctgggcgaagatatttctg
5820 gtaagcaggtattactaccgttacccgggtgcccgccgccggacccgcttctataaagac
MslI
HaeI
5821 ggatcactaacgtcatagttgtgttccaggatgagatcgtcataggccatttttacaaag
5880 cctagtgattgcagtatcaacacaaggtcctactctagcagtatccggtaaaaatgtttc
EciI
BanI
DrdII
5881 cgcgggcggagggtgccagactgcggtataatggttccatccggcccaggggcgtagtta
5940 gcgcccgcctcccacggtctgacgccatattaccaaggtaggccgggtccccgcatcaat
AccI
5941 ccctcacagatttgcatttcccacgctttgagttcagatgggggggatcatgtctacctgc
6000 gggagtgtctaaacgtaaagggtgcgaaactcaagtctacccccctagtacagatggacg
BspMI
BspMI
MspA1I
PvuII
6001 ggggcgatgaagaaaacggtttccgggggtaggggagatcagctgggaagaaagcaggttc
6060 ccccgctacttcttttgccaaaggccccatcccctctagtcgacccttctttcgtccaag
ApaI
BanII
Bsp1286I
MspA1I
BsrFI
BmgI
Bpu10I
PvuII
HgiEII
BseSI
6061 ctgagcagctgcgacttaccgcagccggtgggcccgtaaatcacacctattaccgggtgc
6120 gactcgtcgacgctgaatggcgtcggccacccgggcatttagtgtggataatggcccacg
MspA1I
PvuII
PstI
AceIII
SfcI
Bpu10I
6121 aactggtagttaagagagctgcagctgccgtcatccctgagcaggggggccacttcgtta
6180 ttgaccatcaattctctcgacgtcgacggcagtagggactcgtccccccggtgaagcaat
NspI
NspI
EciI
HaeII
6181 agcatgtccctgactcgcatgttttccctgaccaaatccgccagaaggcgctcgccgccc
6240 tcgtacagggactgagcgtacaaaagggactggtttaggcggtcttccgcgagcggcggg
BstAPI
BsaI
EciI
6241 agcgatagcagttcttgcaaggaagcaaagtttttcaacggtttgagaccgtccgccgta
6300 tcgctatcgtcaagaacgttccttcgtttcaaaaagttgccaaactctggcaggcggcat
RleAI
NspI
SphI
TaqII
Tth111II
AceIII
BstEII
AarI
6301 ggcatgcttttgagcgtttgaccaagcagttccaggcggtcccacagctcggtcacctgc
6360 ccgtacgaaaactcgcaaactggttcgtcaaggtccgccagggtgtcgagccagtggacg
BspMI
BseRI
6361 tctacggcatctcgatccagcatatctcctcgtttcgcgggttggggcggctttcgctgt
6420 agatgccgtagagctaggtcgtatagaggagcaaagcgcccaaccccgccgaaagcgaca
BspGI
BsiHKAI
Bsp1286I
BstDSI
BcgI
Eco0109I
Psp5II
6421 acggcagtagtcggtgctcgtccagacgggccagggtcatgtctttccacgggcgcaggg
6480

FIGURE 28


tgccgtcatcagccacgagcaggtctgcccggtcccagtacagaaaggtgcccgcgtccc
HaeI
MscI
BcgI
BssHII
EaeI
tcctcgtcagcgtagtctgggtcacggtgaaggggtgcgctccgggctgcgcgctggcca
6481
6540
aggagcagtcgcatcagacccagtgccacttccccacgcgaggcccgacgcgcgaccggt
BsrFI
HaeII
BbsI
Eco47III
SmlI
Bce83I
Eco57I
gggtgcgcttgaggctggtcctgctggtgctgaagcgctgccggtcttcgccctgcgcgt
6541
6600
cccacgcgaactccgaccaggacgaccacgacttcgcgacggccagaagcgggacgcgca
DrdI
BstDSI
NcoI
StyI
EaeI
GdiII
BspGI
SacII
MspA1I
BstDSI
BssHII
StyI
cggccaggtagcatttgaccatggtgtcatagtccagcccctccgcggcgtggcccttgg
6601
6660
gccggtccatcgtaaactggtaccacagtatcaggtcggggaggcgccgcaccgggaacc
BseRI
BssSI
HaeII
BsaHI
NarI
StyI
BanI
BtsI
cgcgcagcttgcccttggaggaggcgccgcacgaggggcagtgcagacttttgagggcgt
6661
6720
gcgcgtcgaacgggaacctcctccgcggcgtgctccccgtcacgtctgaaaactcccgca
BsgI
Hin4I
Eco0109I
agagcttgggcgcgagaaataccgattccggggagtaggcatccgcgccgcaggccccgc
6721
6780
tctcgaacccgcgctctttatggctaaggcccctcatccgtaggcgcggcgtccggggcg
EaeI
GdiII
BanII
BsiHKAI
Bsp1286I
SacI
BsaI
BsmI
BssSI
XcmI
SexAI
agacggtctcgcattccacgagccaggtgagctctggccgttcggggtcaaaaaccaggt
6781
6840
tctgccagagcgtaaggtgctcggtccactcgagaccggcaagccccagttttggtcca
Hin4I
BsrFI
ttcccccatgcttttgatgcgtttcttacctctggtttccatgagccggtgtccacgct
6841
6900
aaggggggtacgaaaaactacgcaaagaatggagaccaaaggtactcggccacaggtgcga
Bce83I
BsrBI
AvaI
BstZ17I
AccI
SmlI
HaeI
StuI
SmlI
XhoI
cggtgacgaaaaggctgtccgtgtccccgtatacagacttgagaggcctgtcctcgagcg
6901
6960
gccactgcttttccgacaggcacaggggcatatgtctgaactctccggacaggagctcgc
SacII
MspA1I
BstDSI
BseRI
Hin4I
BspGI
gtgttccgcggtcctcctcgtatagaaactcggaccactctgagacaaaggctcgcgtcc
6961
7020
cacaaggcgccaggaggagcatatctttgagcctggtgagactctgtttccgagcgcagg
HaeI
BsaXI
BsiEI
BpmI
aggccagcacgaaggaggctaagtgggaggggtagcggtcgttgtccactagggggtcca
7021
7080
tccggtcgtgcttcctccgattcaccctccccatcgccagcaacaggtgatcccccaggt

FIGURE 28


NspI
BbsI
PshAI
AflIII
BspLU11I
EarI
ctcgctccagggtgtgaagacacatgtcgccctcttcggcatcaaggaaggtgattggtt
7081
gagcgaggtcccacacttctgtgtacagcgggagaagccgtagttccttccactaaccaa
7140
BsaAI
PmlI
HaeI
Eco57I
tgtaggtgtaggccacgtgaccgggtgttcctgaaggggggctataaaaggggtggggg
7141
acatccacatccggtgcactggcccacaaggacttccccccgatattttcccccacccc
7200
PflMI
MspA1I
ScaI
PvuII
TatI
EarI
cgcgttcgtcctcactctcttccgcatcgctgtctgcgagggccagctgttggggtgagt
7201
gcgcaagcaggagtgagagaaggcgtagcgacagacgctcccggtcgacaaccccactca
7260
actccctctgaaaagcgggcatgacttctgcgctaagattgtcagtttccaaaaacgagg
7261
tgagggagacttttcgcccgtactgaagacgcgattctaacagtcaaaggtttttgctcc
7320
SacII
MspA1I
BseRI
BstDSI
EaeI
GdiII
aggatttgatattcacctggcccgcggtgatgcctttgagggtggccgcatccatctggt
7321
tcctaaactataagtggaccgggcgccactacggaaactcccaccggcgtaggtagacca
7380
HindIII
MmeI
cagaaaagacaatctttttgttgtcaagcttggtggcaaacgacccgtagagggcgttgg
7381
gtcttttctgttagaaaaacaacagttcgaaccaccgtttgctgggcatctcccgcaacc
7440
BssHII
BsgI
BsiEI
EaeI
PvuI
GdiII
NruI
StyI
acagcaacttggcgatggagcgcagggtttggtttttgtcgcgatcggcgcgctccttgg
7441
tgtcgttgaaccgctacctcgcgtcccaaaccaaaaaacagcgctagccgcgcgaggaacc
7500
BsaAI
BssHII
ccgcgatgtttagctgcacgtattcgcgcgcaacgcaccgccattcgggaaagacggtgg
7501
ggcgctacaaatcgacgtgcataagcgcgcgttgcgtggcggtaagccctttctgccacc
7560
BsiHKAI
Bsp1286I
BseSI
ApaLI
BstAPI
DraIII
Bsp1286I
SexAI
BmgI
BseSI
BanI
SacII
MspA1I
BstDSI
HincII
Tth111I
tgcgctcgtcgggcaccaggtgcacgccccaaccgcggttgtgcagggtgacaaggtcaa
7561
acgcgagcagcccgtggtccacgtgcgcggttggcgccaacacgtcccactgttccagtt
7620
BsiEI
EaeI
EagI
GdiII
NotI
BsgI
HaeII
BspGI
cgctggtggctacctctccgcgtaggcgctcgttggtccagcagaggcggccgcccttgc
7621
gcgaccaccgatggagaggcgcatccgcgagcaaccaggtcgtctccgccggcgggaacg
7680
BsmBI
BstDSI
gcgagcagaatggcggtaggggtctagctgcgtctcgtccgggggtctgcgtccacgg
7681
cgctcgtcttaccgccatcccccagatcgacgcagagcaggccccccagacgcaggtgcc
7740

FIGURE 28


SmaI
AvaI
BssHII
taaagaccccgggcagcaggcgcgcgtcgaagtagtctatcttgcatccttgcaagtcta
7741
7800
atttctggggcccgtcgtccgcgcgcagcttcatcagatagaacgtaggaacgttcagat
BstDSI
Eco0109I
BssHII
Psp5II
NcoI
HaeII
BssHII
SanDI
StyI
gcgcctgctgccatgcgcgggcggcaagcgcgcgctcgtatgggttgagtgggggacccc
7801
7860
cgcggacgacggtacgcgcccgccgttcgcgcgcgagcatacccaactcacccccctgggg
PflMI
TaqII
NspI
Hin4I
atggcatggggtgggtgagcgcggaggcgtacatgccgcaaatgtcgtaaacgtagaggg
7861
7920
taccgtaccccacccactcgcgcctccgcatgtacggcgtttacagcatttgcatctccc
SacII
MspA1I
BanII
Bsp1286I
BplI
BstDSI
BssHII
gctctctgagtattccaagatatgtagggtagcatcttcaccgcggatgctggcgcgca
7921
7980
cgagagactcataaggttctatacatcccatcgtagaaggtggcgcctacgaccgcgcgt
BsaAI
BseRI
TaqII
cgtaatcgtatagttcgtgcgagggagcgaggaggtcgggaccgaggttgctacgggcgg
7981
8040
gcattagcatatcaagcacgctccctcgctcctccagccctggctccaacgatgcccgcc
MmeI
NspI
BbsI
MmeI
Eco57I
gctgctctgctcggaagactatctgcctgaagatggcatgtgagttggatgatatggttg
8041
8100
cgacgagacgagccttctgatagacggacttctaccgtacactcaacctactataccaac
BsaI
BbsI
BsaHI
gacgctggaagacgttgaagctggcgtctgtgagacctaccgcgtcacgcacgaaggagg
8101
8160
ctgcgaccttctgcaacttcgaccgcagacactctggatggcgcagtgcgtgcttcctcc
BsgI
AceIII
BspMI
HincII
BstEII
DrdI
cgtaggagtcgcgcagcttgttgaccagctcggcggtgacctgcacgtctagggcgcagt
8161
8220
gcatcctcagcgcgtcgaacaactggtcgagccgccactggacgtgcagatcccgcgtca
BspGI
agtccagggtttccttgatgatgtcatacttatcctgtccctttttttttccacagctcgc
8221
8280
tcaggtcccaaaggaactactacagtacgaataggacagggaaaaaaaaggtgtcgagcg
ScaI
AceIII
EarI
TatI
ggttgaggacaaactcttcgcggtctttccagtactcttggatcggaaacccgtcggcct
8281
8340
ccaactcctgtttgagaagcgccagaaaggtcatgagaacctagcctttgggcagccgga
NspI
HincII
BglI
ccgaacggtaagagcctagcatgtagaactggttgacggcctggtaggcgcagcatccct
8341
8400
ggcttgccattctcggatcgtacatcttgaccaactgccggaccatccgcgtcgtaggga
TaqII
RleAI
BsaWI
BglI
BspEI
tttctacgggtagcgcgtatgcctgcgcggccttccggagcgaggtgtgggtgagcgcaa
8401
8460
aaagatgcccatcgcgcatacggacgcgccggaaggcctcgctccacacccactcgcgtt
EciI
aggtgtccctgaccatgactttgaggtactggtatttgaagtcagtgtcgtcgcatccgc

FIGURE 28


8461
tccacagggactggtactgaaactccatgaccataaacttcagtcacagcagcgtaggcg
cctgctcccagagcaaaaagtccgtgcgctttttggaacgcggatttggcagggcgaagg
8521
ggacgagggtctcgtttttcaggcacgcgaaaaaccttgcgcctaaaccgtcccgcttcc
8580
Eco0109I
Psp5II
SanDI
EarI
tgacatcgttgaagagtatctttcccgcgcgaggcataaagttgcgtgtgatgcggaagg
8581
actgtagcaacttctcatagaaagggcgcgctccgtatttcaacgcacactacgccttcc
8640
BsiHKAI
Bsp1286I
BanI
gtcccggcacctcggaacggttgttaattacctgggcggcgagcacgatctcgtcaaagc
8641
cagggccgtggagccttgccaacaattaatggacccgccgctcgtgctagagcagtttcg
8700
RleAI
cgttgatgttgtggcccacaatgtaaagttccaagaagcgcgggatgcccttgatggaag
8701
gcaactacaacaccgggtgttacatttcaaggttcttcgcgccctacgggaactaccttc
8760
BsiHKAI
Bsp1286I
BanII
BsiHKAI
Bsp1286I
BanII
Bsp1286I
Bpu1102I
Pfl1108I
SacI
EarI
Eco57I
AceIII
SapI
gcaatttttaagttcctcgtaggtgagctcttcaggggagctgagcccgtgctctgaaa
8761
cgttaaaaaattcaaggagcatccactcgagaagtcccctcgactcgggcacgagacttt
8820
BmrI
ApaI
BanII
Bsp1286I
MmeI
BmgI
BseSI
Eco0109I
BanII
BsiHKAI
Bsp1286I
SacI
gggcccagtctgcaagatgagggttggaagcgacgaatgagctccacaggtcacgggcca
8821
cccgggtcagacgttctactcccaaccttcgctgcttactcgaggtgtccagtgcccggt
8880
Eco0109I
Psp5II
Sse8647I
HaeI
MscI
BspMI
AarI
NruI
EaeI
ttagcatttgcaggtggtcgcgaaaggtcctaaactggcgacctatggccatttttctg
8881
aatcgtaaacgtccaccagcgctttccaggatttgaccgctggataccggtaaaaaagac
8940
MspA1I
StyI
gggtgatgcagtagaaggtaagcgggtcttgttcccagcggtcccatccaaggttcgcgg
8941
cccactacgtcatcttccattcgcccagaacaagggtcgccagggtaggttccaagcgcc
9000
BsaI
EciI
RcaI
AceIII
ctaggtctcgcgcggcagtcactagaggctcatctccgccgaacttcatgaccagcatga
9001
gatccagagcgcgccgtcagtgatctccgagtagaggcggcttgaagtactggtcgtact
9060
BstAPI
Bsp1286I
BssSI
BmgI
BseSI
Eco0109I
Pfl1108I
BsaI
BsmBI
agggcacgagctgcttcccaaaggcccccatccaagtataggtctctacatcgtaggtga
9061
tcccgtgctcgacgaagggtttccgggggtaggttcatatccagagatgtagcatccact
9120
BsaXI
AloI
BsiEI
PvuI
BstYI
UbaLI
MunI
caaagagacgctcggtgcgaggatgcgagccgatcgggaagaactggatctcccgccacc

FIGURE 28


9121
9180
gtttctctgcgagccacgctcctacgctcggctagccctttcttgacctagagggcggtgg
PflMI
BseRI
BssSI
aattggaggagtggctattgatgtggtgaaagtagaagtccctgcgacgggccgaacact
9181
9240
ttaacctcctcaccgataactacaccactttcatcttcagggacgctgcccggcttgtga
BsiHKAI
Bsp1286I
BsgI
ScaI
BseSI
TatI
ApaLI
BsrGI
FspI
MspA1I
TatI
cgtgctggcttttgtaaaaacgtgcgcagtactggcagcggtgcacgggctgtacatcct
9241
9300
gcacgaccgaaaacatttttgcacgcgtcatgaccgtcgccacgtgcccgacatgtagga
BssSI
EcoNI
HincII
BsiEI
ApoI
BanII
Bsp1286I
gcacgaggttgacctgacgaccgcgcacaaggaagcagagtgggaatttgagcccctcgc
9301
9360
cgtgctccaactggactgctggcgcgtgttccttcgtctcacccttaaactcggggagcg
AvaI
SmlI
XhoI
BbsI
Tth111II
ctggcgggtttggctggtggtcttctacttcggctgcttgtccttgaccgtctggctgct
9361
9420
gaccgcccaaaccgaccaccagaagatgaagccgacgaacaggaactggcagaccgacga
BanII
MmeI
BsaXI
Bsp1286I
BspGI
BssHII
cgaggggagttacggtggatcggaccaccacgccgcgcgagcccaaagtccagatgtccg
9421
9480
gctcccctcaatgccacctagcctggtggtgcggcgcgctcgggtttcaggtctacaggc
BstDSI
NcoI
BsiEI
AceIII
StyI
PflMI
cgcgcggcggtcggagcttgatgacaacatcgcgcagatgggagctgtccatggtctgga
9481
9540
gcgcgccgccagcctcgaactactgttgtagcgcgtctaccctcgacaggtaccagacct
BsaHI
SacII
MspA1I
BstDSI
SfcI
BanII
BanII
BsiHKAI
BsiHKAI
Bsp1286I
PstI
Bsp1286I
SacI
BpmI
BspMI
SacI
SbfI
gctcccgcggcgtcaggtcaggcgggagctcctgcaggtttacctcgcatagacgggtca
9541
9600
cgagggcgccgcagtccagtccgccctcgaggacgtccaaatggagcgtatctgcccagt
XcmI
AlwNI
BstYI
PflMI
BsaHI
gggcgcgggctagatccaggtgatacctaatttccaggggctggttggtggcggcgtcga
9601
9660
cccgcgcccgatctaggtccactatggattaaaggtccccgaccaaccaccgccgcagct
SacII
MspA1I
BstDSI
KpnI
Hin4I
BaeI
BanI
BaeI
tggcttgcaagaggccgcatccccgcggcgcgactacggtaccgcgcggcgggcggtggg
9661
9720
accgaacgttctccggcgtaggggcgccgcgctgatgccatggcgcgccgcccgccaccc
SacII
NsiI
MspA1I
HaeIV
BanII
BstDSI
StyI
Hin4I
Bsp1286I
ccgcgggggtgtccttggatgatgcatctaaaagcggtgacgcgggcgagcccccggagg
9721
9780
ggcgcccccacaggaacctactacgtagattttcgccactgcgcccgctcgggggcctcc
AceIII
BssHII

FIGURE 28


BanII
BsaWI
Bsp1286I
BspEI
HaeII
Bsp1286I
BmgI
BseSI
BsaHI
NarI
BanI
9781
9840
AlwNI
BssHII
9841
9900
ApaI
BanII
Bsp1286I
BmgI
BseSI
HaeII
BsaHI
NarI
BanI
BbsI
SmlI
9901
9960
Bce83I
HincII
BsgI
9961
10020
HaeIV
Hin4I
EaeI
GdiII
BsmBI
EarI
BglII
BstYI
10021
10080
BstDSI
BpmI
MmeI
AceIII
10081
10140
HaeI
StuI
AccI
SfcI
10141
10200
BsaAI
PmlI
BanII
BsiHKAI
Bsp1286I
BssHII
AarI
BspMI
SacI
10201
10260
HaeII
AlwNI
BbsI
10261
10320
SmlI
EcoRV
HaeI
Bce83I
StyI
StuI
TatI
10321
10380
BstDSI
NcoI
StyI
Pfl1108I
HaeII
HaeI
BstDSI
BmrI
BssHII
10381
10440
HincII
HpaI
BanII

FIGURE 28


BseRI
BpmI
BseRI
BsaXI
BsiHKAI
Bsp1286I
BbsI
SacI
Tth111I
cacggttaactcctcctccagaagacggatgagctcggcgacagtgtcgcgcacctcgcg
10441
10500
gtgccaattgaggaggaggtcttctgcctactcgagccgctgtcacagcgcgtggagcgc
Eco0109I
SfcI
BseRI
EarI
Eco0109I
EarI
ctcaaaggctacaggggcctcttcttcttcttcaatctcctcttccataagggcctcccc
10501
10560
gagtttccgatgtccccggagaagaagaagaagttagaggagaaggtattcccggagggg
ttcttcttcttctggcggcggtgggggaggggggacacggcggcgacgacggcgcaccgg
10561
10620
aagaagaagaagaccgccgccacccctccccccctgtgccgccgctgctgccgcgtggcc
HincII
AccI
BsiEI
SalI
HaeII
Eco47III
SacII
MspA1I
BstDSI
Bsp24I
BsaI
gaggcggtcgacaaagcgctcgatcatctccccgcggcgacggcgcatggtctcggtgac
10621
10680
ctccgccagctgtttcgcgagctagtagaggggcgccgctgccgcgtaccagagccactg
BsiEI
MmeI
EaeI
EagI
GdiII
Bsp24I
BbsI
BsaHI
ggcgcggccgttctcgcgggggcgcagttggaagacgccgcccgtcatgtcccggttatg
10681
10740
ccgcgccggcaagagcgcccccgcgtcaaccttctgcggcgggcagtacagggccaatac
BciVI
HaeII
NsiI
MunI
ggttggcgggggctgccatgcggcagggatacggcgctaacgatgcatctcaacaattg
10741
10800
ccaaccgccccccgacggtacgccgtccctatgccgcgattgctacgtagagttgttaac
Bpu10I
Eco0109I
EciI
Psp5II
BsiEI
Hin4I
BsaWI
ttgtgtaggtactccgccgccgaggggacctgagcgagtccgcatcgaccggatcggaaaa
10801
10860
aacacatccatgaggcggcggctccctggactcgctcaggcgtagctggcctagcctttt
BstDSI
BsiHKAI
Bsp1286I
AvaI
SmlI
XhoI
BsaHI
Bsp24I
Bsp24I
Bpu1102I
cctctcgagaaaggcgtctaaccagtcacagtcgcaaggtaggctgagcaccgtggcggg
10861
10920
ggagagctctttccgcagattggtcagtgtcagcgttccatccgactcgtggcaccgccc
MspA1I
BsiEI
EciI
cggcagcgggcggcggtcggggttgtttctggcggaggtgctgctgatgatgtaattaaa
10921
10980
gccgtcgcccgccgccagccccaacaaagaccgcctccacgacgactactacattaattt
Bce83I
SmlI
HincII
AccI
SalI
BsmBI
Bsp24I
EciI
Bsp24I
BstXI
StyI
gtaggcggtcttgagacggcggatggtcgacagaagcaccatgtccttgggtccggcctg
10981
11040
catccgccagaactctgccgcctaccagctgtcttcgtggtacaggaacccaggccggac
EaeI
BsmI
FspI
GdiII
BsiEI
BspMI
ctgaatgcgcaggcggtcggccatgccccaggcttcgttttgacatcggcgcaggtcttt
11041
11100
gacttacgcgtccgccagccggtacggggtccgaagcaaaactgtagccgcgtccagaaa
BsrFI
gtagtagtcttgcatgagcctttctaccggcacttcttcttctccttcctcttgtcctgc
11101
11160

FIGURE 28


catcatcagaacgtactcggaaagatggccgtgaagaagaagaggaaggagaacaggacg
HaeII
BsaHI
NarI
EaeI
EciI
GdiII
BanI
BstAPI
EarI
atctcttgcatctatcgctgcggcggcggcggagtttggccgtaggtggcgccctcttcc
11161
11220
tagagaacgtagatagcgacgccgccgccgcctcaaaccggcatccaccgcgggagaagg
MslI
Eco57I
tcccatgcgtgtgaccccgaagcccctcatcggctgaagcagggctaggtcggcgacaac
11221
11280
agggtacgcacactggggcttcggggagtagccgacttcgtcccgatccagccgctgttg
BspMI
EcoNI
AhdI
MslI
HaeIV
BsgI
HaeI
AarI
AccI
Hin4I
gcgctcggctaatatggcctgctgcacctgcgtgagggtagactggaagtcatccatgtc
11281
11340
cgcgagccgattataccggacgacgtggacgcactcccatctgaccttcagtaggtacag
HaeI
MscI
BsbI
EaeI
BsgI
cacaaagcggtggtatgcgcccgtgttgatggtgtaagtgcagttggccataacggacca
11341
11400
gtgtttcgccaccatacgcgggcacaactaccacattcacgtcaaccggtattgcctggt
BsmBI
BanII
BsiHKAI
Bsp1286I
SacI
AvaI
SmlI
XhoI
HincII
HpaI
BstEII
gttaacggtctggtgacccggctgcgagagctcggtgtacctgagacgcgagtaagccct
11401
11460
caattgccagaccactgggccgacgctctcgagccacatggactctgcgctcattcggga
BsaAI
SnaBI
AlwNI
SexAI
PflMI
BciVI
cgagtcaaatacgtagtcgttgcaagtccgcaccaggtactggtatcccaccaaaaagtg
11461
11520
gctcagtttatgcatcagcaacgttcaggcgtggtccatgaccatagggtggttttcac
EaeI
BanII
BglII
GdiII
Bsp1286I
BstYI
cggcggcggctggcggtagaggggccagcgtagggtggccggggctccgggggcgagatc
11521
11580
gccgccgccgaccgccatctccccggtcgcatcccaccggccccgaggcccccgctctag
BsrFI
EcoRV
MmeI
BspGI
MslI
NgoAIV
ttccaacataaggcgatgatatccgtagatgtacctggacatccaggtgatgccggcggc
11581
11640
aaggttgtattccgctactataggcatctacatggacctgtaggtccactacggccgccg
MspA1I
FspI
BssHII
BstAPI
ggtggtggaggcgcgcggaaagtcgcggacgcggttccagatgttgcgcagcggcaaaaa
11641
11700
ccaccacctccgcgcgcctttcagcgcctgcgccaaggtctacaacgcgtcgccgttttt
BstDSI
NcoI
StyI
BsrFI
BssHII
BsiHKAI
EaeI
BssHII
Bsp1286I
GdiII
BglI
HincII
XbaI
gtgctccatggtcgggacgctctggccggtcaggcgcgcgcaatcgttgacgctctagac
11701
11760
cacgaggtaccagccctgcgagaccggccagtccgcgcgcgttagcaactgcgagatctg
Bsp1286I
BmgI
EarI
BsaXI
BseSI
BstDSI
ApoI
cgtgcaaaaggagagcctgtaagcgggcactcttccgtggtctggtggataaattcgcaa
11761
11820
gcacgttttcctctcggacattcgcccgtgagaaggcaccagaccacctatttaagcgtt

FIGURE 28


EciI
BciVI
BsiEI
EaeI
EagI
BanII
Bsp1286I
GdiII
EciI
BsiEI
gggtatcatggcggacgaccggggttcgagccccgtatccggccgtccgccgtgatccat
11821
11880
cccatagtaccgcctgctggccccaagctcggggcataggccggcaggcggcactaggta
AatII
BsaHI
BsiHKAI
Bsp1286I
BstEII
gcggttaccgcccgcgtgtcgaacccaggtgtgcgacgtcagacaacgggggagtgctcc
11881
11940
cgccaatggcgggcgcacagcttgggtccacacgctgcagtctgttgccccctcacgagg
HaeI
BssHII
MscI
EaeI
NheI
EaeI
GdiII
ttttggcttccttccaggcgcggcggctgctgcgctagctttttggccactggccgcgc
11941
12000
aaaaccgaaggaaggtccgcgccgccgacgacgcgatcgaaaaaaccggtgaccggcgcg
SfcI
gcagcgtaagcggttaggctggaaagcgaaagcattaagtggctcgctccctgtagccgg
12001
12060
cgtcgcattcgccaatccgacctttcgctttcgtaattcaccgagcgagggacatcggcc
BsiEI
EaeI
EagI
Eco0109I
GdiII
Psp5II
BsrFI
StyI
SanDI
AloI
RsrII
agggttattttccaagggttgagtcgcgggacccccggttcgagtctcggaccggccgga
12061
12120
tcccaataaaaggttcccaactcagcgccctgggggccaagctcagagcctggccggcct
BsaWI
ApoI
BspEI
ctgcggcgaacgggggtttgcctccccgtcatgcaagaccccgcttgcaaattcctccgg
12121
12180
gacgccgcttgcccccaaacggaggggcagtacgttctggggcgaacgtttaaggaggcc
BstAPI
BanII
BsaWI
Bsp1286I
NsiI
BseRI
aaacagggacgagccccttttttgctttttcccagatgcatccggtgctgcggcagatgcg
12181
12240
tttgtccctgctcggggaaaaaacgaaaagggtctacgtaggccacgacgccgtctacgc
Bsp1286I
BseRI
BmgI
BseSI
BanI
BbvCI
Bpu10I
MspA1I
MspA1I
NspI
ccccccctcctcagcagcggcaagagcaagagcagcggcagacatgcagggcaccctcccc
12241
12300
gggggggaggagtcgtcgccgttctcgttctcgtcgccgtctgtacgtcccgtgggagggg
HincII
SacII
MspA1I
BstDSI
tcctcctaccgcgtcaggaggggcgacatccgcggttgacgcggcagcagatggtgatta
12301
12360
aggaggatggcgcagtcctccccgctgtaggcgccaactgcgccgtcgtctaccactaat
ApaI
BanII
Bsp1286I
BmgI
BseSI
HaeII
BsaHI
NarI
BanI
SacII
MspA1I
BstDSI
BseRI
BspGI
Eco0109I

FIGURE 28


cgaacccccgcggcgccgggcccggcactacctggacttggaggagggcgagggcctggc
12361
gcttgggggcgccgcggcccgggccgtgatggacctgaacctcctcccgctcccggaccg
BanI
BsrBI
StyI
MspA1I
AflIII
BsgI
HaeII
Bpu10I
KpnI
PvuII
MluI
gcggctaggagcgccctctcctgagcggtacccaagggtgcagctgaagcgtgatacgcg
12421
cgccgatcctcgcgggagaggactcgccatgggttcccacgtcgacttcgcactatgcgc
SacII
MspA1I
BstDSI
BsaAI
SunI
Eco57I
BsiEI
AlwNI
NruI
BanII
Bsp1286I
AvaI
tgaggcgtacgtgccgcggcagaaccgtttcgcgaccgcgagggagaggagcccgagga
12481
actccgcatgcacggcgccgtcttggacaaagcgctggcgctccctctcctcgggctcct
HaeIV
Hin4I
AloI
BseRI
BseRI
AceIII
HaeI
NruI
BsrBI
gatgcgggatcgaaagttccacgcagggcgcgagctgcggcatggcctgaatcgcgagcg
12541
ctacgccctagctttcaaggtgcgtcccgcgctcgacgccgtaccggacttagcgctcgc
BanII
Bsp1286I
BseRI
BssHII
BssHII
gttgctgcgcgaggaggactttgagcccgacgcgcgaaccgggattagtcccgcgcgcgc
12601
caacgacgcgctcctcctgaaactcgggctgcgcgcttggccctaatcagggcgcgcgcg
BsiEI
EaeI
EagI
GdiII
BsaAI
PmlI
BstEII
AflIII
NotI
SexAI
DrdII
acacgtggcggccgccgacctggtaaccgcatacgagcagacggtgaaccaggagattaa
12661
tgtgcaccgccggcggctggaccattggcgtatgctcgtctgccacttggtcctctaatt
SunI
BsaAI
PmlI
HindIII
BssHII
SfcI
ctttcaaaaaagctttaacaaccaccgtgcgtacgcttgtggcgcgcgaggaggtggctat
12721
gaaagtttttttcgaaattgttggtgcacgcatgcgaacaccgcgcgctcctccaccgata
RleAI
BseRI
NsiI
BssHII
BpmI
aggactgatgcatctgtgggactttgtaagcgcgctggagcaaaacccaaatagcaagcc
12781
tcctgactacgtagacaccctgaaacattcgcgcgacctcgttttgggtttatcgttcgg
MspA1I
BsrBI
PvuII
BsmI
BsgI
gctcatggcgcagctgttccttatagtgcagcacagcagggacaacgaggcattcaggga
12841
cgagtaccgcgtcgacaaggaatatcacgtcgtgtcgtccctgttgctccgtaagtccct
BanII
Bsp1286I
AvaI
MspA1I
BsaBI
SfcI
tgcgctgctaaacatagtagagcccgagggccgctggctgctcgatttgataaacatcct
12901
acgcgacgatttgtatcatctcgggctcccggcgaccgacgagctaaactatttgtagga
Bce83I
EaeI
GdiII
PstI
MslI
SmlI
BsgI
gcagagcatagtggtgcaggagcgcagcttgagcctggctgacaaggtggccgccatcaa
12961
cgtctcgtatcaccacgtcctcgcgtcgaactcggaccgactgttccaccggcggtagtt
13020

FIGURE 28


XcmI
Bpu1102I
ctattccatgcttagcctgggcaagttttacgcccgcaagatataccatacccttacgt
13021
13080
gataaggtacgaatcggacccgttcaaaatgcgggcgttctatatggtatggggaatgca
FspI
MslI
NspI
HaeII
tcccatagacaaggaggtaaagatcgaggggttctacatgcgcatggcgctgaaggtgct
13081
13140
agggtatctgttcctccatttctagctccccaagatgtacgcgtaccgcgacttccacga
SmlI
Eco57I
Bce83I
taccttgagcgacgacctgggcgtttatcgcaacgagcgcatccacaaggccgtgagcgt
13141
13200
atggaactcgctgctggacccgcaaatagcgttgctcgcgtaggtgttccggcactcgca
ApaI
BanII
Bsp1286I
BmgI
BseSI
EcoO109I
EcoO109I
BanII
BsiHKAI
Bsp1286I
SacI
BsrFI
NgoAIV
AceIII
Bpu1102I
BsiEI
BstAPI
gagccggcggcgcgagctcagcgaccgcgagctgatgcacagcctgcaaagggccctggc
13201
13260
ctcggccgccgcgctcgagtcgctggcgctcgactacgtgtcggacgtttcccgggaccg
MspA1I
Hin4I
Bsp24I
HaeII
tggcacgggcagcggcgatagagaggccgagtcctactttgacgcgggcgctgacctgcg
13261
13320
accgtgcccgtcgccgctatctctccggctcaggatgaaactgcgcccgcgactggacgc
ApaI
BanII
Bsp1286I
Bsp24I
BmgI
BseSI
EcoO109I
BspMI
Bsp24I
Bsp24I
Bsp24I
MspA1I
BglI
PvuII
BpmI
BanI
ctgggccccaagccgacgcgccctggaggcagctggggccggacctgggctggcggtggc
13321
13380
gacccggggttcggctgcgcgggacctccgtcgaccccggcctggacccgaccgccaccg
BssHII
Bsp24I
BssHII
acccgcgcgcgctggcaacgtcggcggcgtggaggaatatgacgaggacgatgagtacga
13381
13440
tgggcgcgcgcgaccgttgcagccgccgcacctccttatactgctcctgctactcatgct
ScaI
TatI
BclI
gccagaggacggcgagtactaagcggtgatgtttctgatcagatgatgcaagacgcaacg
13441
13500
cggtctcctgccgctcatgattcgccactacaaagactagtctactacgttctgcgttgc
PstI
HaeII
SfcI
BstDSI
gacccggcggtgcgggcggcgctgcagagccagccgtccggccttaactccacggacgac
13501
13560
ctgggccgccacgcccgccgcgacgctctcggtcggcaggccggaattgaggtgcctgctg
HaeII
BsaHI
NarI
BanI
PflMI
BssHII
AflIII
MluI
tggcgccaggtcatggaccgcatcatgtcgctgactgcgcgcaatcctgacgcgttccgg
13561
13620
accgcggtccagtacctggcgtagtacagcgactgacgcgcgttaggactgcgcaaggcc
BsaXI
BsrFI
HaeI
BssHII
BssHII
cagcagccgcaggccaaccggctctccgcaattctggaagcggtggtcccggcgcgcgca

FIGURE 28


13621
gtcgtcggcgtccggttggccgagaggcgttaagaccttcgccaccagggccgcgcgcgt
BssSI
BsiEI
PvuI
EaeI
GdiII
aaccccacgcacgagaaggtgctggcgatcgtaaacgcgctggccgaaaacagggccatc
13681
ttggggtgcgtgctcttccacgaccgctagcatttgcgcgaccggcttttgtcccggtag
13740
Pfl1108I
AccI
Eco57I
FseI
BsrFI
NgoAIV
cggcccgacgaggccggcctggtctacgacgcgctgcttcagcgcgtggctcgttacaac
13741
gccgggctgctccggccggaccagatgctgcgcgacgaagtcgcgcaccgagcaatgttg
13800
BsrFI
BspGI
BsgI
MspA1I
BstDSI
agcggcaacgtgcagaccaacctggaccggctggtgggggatgtgcgcgaggccgtggcg
13801
tcgccgttgcacgtctggttggacctggccgaccacccccctacacgcgctccggcaccgc
13860
BstDSI
NcoI
StyI
BanII
Bsp1286I
BsaXI
BssHII
BssHII
cagcgtgagcgcgcgcagcagcagggcaacctgggctccatggttgcactaaacgccttc
13861
gtcgcactcgcgcgcgtcgtcgtcccgttggacccgaggtaccaacgtgatttgcggaag
13920
SacII
MspA1I
BstDSI
TatI
ctgagtacacagcccgccaacgtgccgcggggacaggaggactacaccaactttgtgagc
13921
gactcatgtgtcgggcggttgcacggcgcccctgtcctcctgatgtggttgaaacactcg
13980
BtsI
gcactgcggctaatggtgactgagacaccgcaaagtgaggtgtaccagtctgggccagac
13981
cgtgacgccgattaccactgactctgtggcgtttcactccacatggtcagacccggtctg
14040
SfcI
HaeI
AccI
StuI
PstI
EcoNI
Bpu10I
tatttttccagaccagtagacaaggcctgcagaccgtaaacctgagccaggctttcaaa
14041
ataaaaaaggtctggtcatctgttccggacgtctggcatttggactcggtccgaaagttt
14100
Tth111I
BsiEI
BanII
Bsp1286I
RleAI
AlwNI
BsiEI
RleAI
aacttgcaggggctgtgggggtgcgggctcccacaggcgaccgcgcgaccgtgtctagc
14101
ttgaacgtccccgacacccccacgcccgagggtgtccgctggcgcgctggcacagatcg
14160
BsaHI
HaeII
ttgctgacgcccaactcgcgcctgttgctgctgctaatagcgcccttcacggacagtggc
14161
aacgactgcgggttgagcgcggacaacgacgacgattatcgcgggaagtgcctgtcaccg
14220
SmaI
AvaI
AvrII
StyI
HaeI
agcgtgtcccgggacacatacctaggtcacttgctgacactgtaccgcgaggccataggt
14221
tcgcacagggccctgtgtatggatccagtgaacgactgtgacatggcgctccggtatcca
14280
NspI
BssHII
caggcgcatgtggacgagcatactttccaggagattacaagtgtcagccgcgcgctgggg
14281
gtccgcgtacacctgctcgtatgaaaggtcctctaatgttcacagtcggcgcgcgacccc
14340
BsrFI
BpmI
BspMI

FIGURE 28


caggaggacacgggcagcctggaggcaaccctaaactacctgctgaccaaccggcggcag
14341
14400
gtcctcctgtgcccgtcggacctccgttgggatttgatggacgactggttggccgccgtc
DraI
PmeI
BseRI
BseRI
BsaAI
BstYI
aagatcccctcgttgcacagtttaaacagcgaggaggagcgcattttgcgctacgtgcag
14401
14460
ttctaggggagcaacgtgtcaaatttgtcgctcctcctcgcgtaaaacgcgatgcacgtc
BspGI
HaeII
BsgI
XcmI
cagagcgtgagccttaacctgatgcgcgacggggtaacgcccagcgtggcgctggacatg
14461
14520
gtctcgcactcggaattggactacgcgctgccccattgcgggtcgcaccgcgacctgtac
BsiEI
EaeI
EagI
GdiII
BssHII
NspI
BsrFI
accgcgcgcaacatggaaccgggcatgtatgcctcaaaccggccgtttatcaaccgccta
14521
14580
tggcgcgcgttgtaccttggcccgtacatacggagtttggccggcaaatagttggcggat
BsiEI
EaeI
EagI
GdiII
NotI
AvaI
atggactacttgcatcgcgcggccgccgtgaaccccgagtatttcaccaatgccatcttg
14581
14640
tacctgatgaacgtagcgcgccggcggcacttggggctcataaagtggttacggtagaac
Bsp1286I
AvaI
BmgI
BseSI
BanI
aacccgcactggctaccgccccctggtttctacaccgggggattcgaggtgcccgagggt
14641
14700
ttgggcgtgaccgatggcgggggaccaaagatgtggccccctaagctccacgggctccca
AlwNI
BstAPI
aacgatggattcctctgggacgacatagacgacagcgtgttttccccgcaaccgcagacc
14701
14760
ttgctacctaaggagaccctgctgtatctgctgtcgcacaaaaggggcgttggcgtctgg
HaeII
HindIII
ctgctagagttgcaacagcgcgagcaggcagaggcggcgctgcgaaaggaaagcttccgc
14761
14820
gacgatctcaacgttgtcgcgctcgtccgtctccgccgcgacgctttcctttcgaaggcg
SacII
MspA1I
HaeI
Tth111II
HaeII
BstDSI
aggccaagcagcttgtccgatctaggcgctgcggccccgcggtcagatgctagtagccca
14821
14880
tccggttcgtcgaacaggctagatccgcgacgccggggcgccagtctacgatcatcgggt
HindIII
Hin4I
BsaI
BglI
tttccaagcttgatagggtctcttaccagcactcgcaccacccgcccgcgcctgctgggc
14881
14940
aaaggttcgaactatcccagagaatggtcgtgagcgtggtgggcgggcgcggacgacccg
BseRI
BseRI
PstI
SfcI
BspMI
gaggaggagtacctaaacaactcgctgctgcagccgcagcgcgaaaaaaacctgcctccg
14941
15000
ctcctcctcatggatttgttgagcgacgacgtcggcgtcgcgctttttttggacggaggc
BbsI
SunI
gcatttcccaacaacgggatagagagcctagtggacaagatgagtagatggaagacgtac
15001
15060
cgtaaagggttgttgccctatctctcggatcacctgttctactcatctaccttctgcatg

FIGURE 28


BsiHKAI
Bsp1286I
Bsp24I
BsiEI
gcgcaggagcacagggacgtgccaggcccgcgcccgcccacccgtcgtcaaaggcacgac
15061
cgcgtcctcgtgtccctgcacggtccgggcgcgggcgggtgggcagcagtttccgtgctg
15120
RleAI
MspA1I
Bsp24I
Hin4I
DrdI
cgtcagcggggtctggtgtgggaggacgatgactcggcagacgacagcagcgtcctggat
15121
gcagtcgccccagaccacaccctcctgctactgagccgtctgctgtcgtcgcaggaccta
15180
FspI
DraI
ttgggagggagtggcaacccgtttgcgcaccttcgccccaggctggggagaatgttttaa
15181
aaccctccctcaccgttgggcaaacgcgtggaagcggggtccgacccctcttacaaaatt
15240
BanI
BstXI
BstDSI
NcoI
StyI
StyI HaeI
aaaaaaaaaagcatgatgcaaaataaaaaactcaccaaggccatggcaccgagcgttggt
15241
ttttttttttcgtactacgttttatttttgagtggttccggtaccgtggctcgcaacca
15300
Eco0109I
Psp5II
Sse8647I
BssHII
BseRI
tttcttgtattccccttagtatgcggcgcgcggcgatgtatgaggaaggtcctcctccct
15301
aaagaacataaggggaatcatacgccgcgcgccgctacatactccttccaggaggaggga
15360
HaeII
BsaHI
NarI
Pfl1108I
BanI
HaeII
cctacgagagtgtggtgagcgcggcgccagtggcggcggcgctgggttctcccttcgatg
15361
ggatgctctcacaccactcgcgccgcggtcaccgccgccgcgacccaagagggaagctac
15420
BanI
SacII
MspA1I
BspGI
BstDSI
KpnI
BspMI
ctcccctggacccgccgtttgtgcctccgcggtacctgcggcctaccgggggggagaaaca
15421
gaggggacctgggcggcaaacacggaggcgccatggacgccggatggccccccctctttgt
15480
BanI
MslI
SexAI
gcatccgttactctgagttggcacccctattcgacaccacccgtgtgtacctggtggaca
15481
cgtaggcaatgagactcaaccgtggggataagctgtggtgggcacacatggaccacctgt
15540
HincII
AhdI
HaeIV
Hin4I
HaeIV
Hin4I
PshAI
BstDSI
acaagtcaacggatgtggcatccctgaactaccagaacgaccacagcaactttctgacca
15541
tgttcagttgcctacaccgtagggacttgatggtcttgctggtgtcgttgaaagactggt
15600
Tth111II
HaeIV
Hin4I
SmaI
SfcI
AvaI
cggtcattcaaaacaatgactacagcccgggggaggcaagcacacagaccatcaatcttg
15601
gccagtaagttttgttactgatgtcgggccccctccgttcgtgtgtctggtagttagaac
15660
BsiEI
AhdI
BsiEI
BsaWI
BsrFI
HaeIV
Hin4I

FIGURE 28


PinAI
BmrI
NspI
15661
15720
XmnI
15721
15780
AceIII
TaqII
AvaI
15781
15840
BsiEI
BsiHKAI
PvuI
Bsp1286I
BsaI
15841
15900
Eco57I
15901
15960
BmrI
Tth111I
15961
16020
16021
16080
RleAI
TaqII
Bpu10I
16081
16140
Pfl1108I
MmeI
BpmI
BsaHI
BglI
16141
16200
BtsI
16201
16260
SacII
BsrFI
EarI
MspA1I
BstDSI
BsrDI
MmeI
16261
16320
BcgI
BseRI
BbvCI
Bpu10I
BglI
BssHII
16321
16380
BsiEI
EaeI
EagI
GdiII
MspA1I
FspI
AvaI
16381
16440
BsaWI
BsrFI

FIGURE 28


PinAI BclI
EcoNI
agaagaaaccggtgatcaaaccccctgacagaggacagcaagaaacgcagttacaacctaa
16441
16500
tcttctttggccactagtttggggactgtctcctgtcgttctttgcgtcaatgttggatt
BanI
TaqII
MspA1I
PvuII
BsrDI
BmrI
HgiEII
KpnI
taagcaatgacagcaccttcacccagtaccgcagctggtaccttgcatacaactacggcg
16501
16560
attcgttactgtcgtggaagtgggtcatggcgtcgaccatggaacgtatgttgatgccgc
BspMI
BspMI
BsaWI
BsrBI
accctcagaccggaatccgctcatggaccctgctttgcactcctgacgtaacctgcggct
16561
16620
tgggagtctggccttaggcgagtacctgggacgaaacgtgaggactgcattggacgccga
AccI
BsrBI
cggagcaggtctactggtcgttgccagacatgatgcaagaccccgtgaccttccgctcca
16621
16680
gcctcgtccagatgaccagcaacggtctgtactacgttctggggcactggaaggcgaggt
HaeII
BsiHKAI
BsaHI
Bsp1286I
AceIII
NarI
BseSI
BsaWI
BanI
ApaLI
cgcgccagatcagcaactttccggtggtgggcgccgagctgttgcccgtgcactccaaga
16681
16740
gcgcggtctagtcgttgaaaggccaccacccgcggctcgacaacgggcacgtgaggttct
AccI
DrdI
EciI
gcttctacaacgaccaggccgtctactcccaactcatccgccagtttacctctctgaccc
16741
16800
cgaagatgttgctggtccggcagatgagggttgagtaggcggtcaaatggagagactggg
BsaAI
PmlI
AscI
BssHII
AflIII
AvaI
DrdII
PflMI
acgtgttcaatcgctttcccgagaaccagattttggcgcgcccgccagcccccaccatca
16801
16860
tgcacaagttagcgaaagggctcttggtctaaaaccgcgcgggcggtcgggggtggtagt
AclI
XmnI
MspA1I
BcgI
FspI
ccaccgtcagtgaaaacgttcctgctctcacagatcacgggacgctaccgctgcgcaaca
16861
16920
ggtggcagtcacttttgcaaggacgagagtgtctagtgccctgcgatggcgacgcgttgt
BseRI
BcgI
BspGI
BsaHI
BsaHI
AarI
BspMI
gcatcggaggagtccagcgagtgaccattactgacgccagacgccgcacctgcccctacg
16921
16980
cgtagcctcctcaggtcgctcactggtaatgactgcggtctgcggcgtggacggggatgc
Eco0109I
tttacaaggccctgggcatagtctcgccgcgcgtcctatcgagccgcacttttgagcaa
16981
17040
aaatgttccgggacccgtatcagagcggcgcgcaggatagctcggcgtgaaaaactcgtt
NspI Tth111II
Eco0109I
Tth111II
gcatgtccatccttatatcgcccagcaataacacaggctggggcctgcgcttcccaagca
17041
17100
cgtacaggtaggaatatagcgggtcgttattgtgtccgaccccggacgcgaagggttcgt
Bsp1286I
BmgI
BseSI
HaeII
DraIII
MmeI
Tth111II
Eco47III
BsbI
BmrI
TaqII
agatgtttggcggggccaagaagcgctccgaccaacacccagtgcgcgtgcgcgggcact
17101
17160
tctacaaaccgccccggttcttcgcgaggctggttgtgggtcacgcgcacgcgcccgtga

FIGURE 28


BcgI
BsiEI
EaeI
EagI
GdiII
BssHII
BssHII
NotI
BmrI
BsaHI
accgcgcgccctggggcgcgcacaaacgcggccgcactgggcgcaccaccgtcgatgacg
17161
17220
tggcgcgcgggaccccgcgcgtgtttgcgccggcgtgacccgcgtggtggcagctactgc
XcmI
BcgI
BssHII
BseRI
ccatcgacgcggtggtggaggaggcgcgcaactacacgcccacgccgccaccagtgtcca
17221
17280
ggtagctgcgccaccacctcctccgcgcgttgatgtgcgggtgcggcggtggtcacaggt
EaeI
GdiII
BstDSI
XcmI
BanII
Bsp1286I
HaeII
BsmBI
EarI
cagtggacgcggccattcagaccgtggtgcgcggagcccggcgctatgctaaaatgaaga
17281
17340
gtcacctgcgccggtaagtctggcaccacgcgcctcgggccgcgatacgattttacttct
EciI
BglI
BtsI
gacggcggaggcgcgtagcacgtcgccaccgccgccgacccggcactgccgcccaacgcg
17341
17400
ctgccgcctccgcgcatcgtgcagcggtggcggcggctgggccgtgacggcgggttgcgc
BsiEI
EaeI
EagI
GdiII
EaeI
BglI
BsrFI
GdiII
SfiI
BsrBI
cggcggcggccctgcttaaccgcgcacgtcgcaccggccgacgggcggccatgcgggccg
17401
17460
gccgccgccgggacgaattggcgcgtgcagcgtggccggctgcccgccggtacgcccggc
BsiEI
SacII
EaeI
MspA1I
EagI
BstDSI
Esp1286I
GdiII
EaeI
BmgI
NotI
GdiII
BseSI
BspGI
BsrBI
ctcgaaggctggccgcgggtattgtcactgtgccccccaggtccaggcgacgagcggccg
17461
17520
gagcttccgaccggcgcccataacagtgacacgggggggtccaggtccgctgctcgccggc
EaeI
GdiII
SacII
AhdI
MspA1I
HaeIV
AflIII
BstDSI
Hin4I
TaqII
ccgcagcagccgcggccattagtgctatgactcagggtcgcaggggcaacgtgtattggg
17521
17580
ggcgtcgtcggcgccggtaatcacgatactgagtcccagcgtccccgttgcacataaccc
Bsp1286I
BmgI
BseSI
FspI
tgcgcgactcggttagcggcctgcgcgtgcccgtgcgcacccgccccccgcgcaactaga
17581
17640
acgcgctgagccaatcgccggacgcgcacgggcacgcgtgggcgggggggcgcgttgatct
BssHII
BciVI
MspA1I
ttgcaagaaaaaactacttagactcgtactgttgtatgtatccagcggcggcggcgcgca
17641
17700
aacgttcttttttgatgaatctgagcatgacaacatacataggtcgccgccgccgcgcgt
EarI
BpmI
BglII
BstYI
acgaagctatgtccaagcgcaaaatcaaagaagagatgctccaggtcatcgcgccggaga
17701
17760
tgcttcgatacaggttcgcgttttagtttcttctctacgaggtccagtagcgcggcctct
EarI
SapI
tctatggcccccgaagaaggaagagcaggattacaagccccgaaagctaaagcgggtca
17761
17820

FIGURE 28


agataccgggggcttcttccttctcgtcctaatgttcggggctttcgatttcgcccagt
BsgI
aaaagaaaaagaaagatgatgatgatgaacttgacgacgaggtggaactgctgcacgcta
17821
17880
ttttcttttttctttctactactactacttgaactgctgctccaccttgacgacgtgcgat
AflIII
MluI
HincII
AccI
SalI
AflIII
BanI
ccgcgcccaggcgacgggtacagtggaaaggtcgacgcgtaaaacgtgttttgcgacccg
17881
17940
ggcgcgggtccgctgcccatgtcacctttccagctgcgcattttgcacaaaacgctgggc
HaeII
Eco47III
gcaccaccgtagtctttacgcccggtgagcgctccacccgcacctacaagcgcgtgtatg
17941
18000
cgtggtggcatcagaaatgcgggccactcgcgaggtgggcgtggatgttcgcgcacatac
EcoO109I
Psp5II
Sse8647I
Tth111II
BspMI
SmlI
HaeI
AvaI
Bce83I
HaeII
atgaggtgtacggcgacgaggacctgcttgagcaggccaacgagcgcctcggggagtttg
18001
18060
tactccacatgccgctgctcctggacgaactcgtccggttgctcgcggagcccctcaaac
BspGI
NspI
MspA1I
BsbI
cctacggaaagcggcataaggacatgctggcgttgccgctggacgagggcaacccaacac
18061
18120
ggatgcctttcgccgtattcctgtacgaccgcaacggcgacctgctcccgttgggttgtg
AlwNI
BstAPI
BtsI
AarI
SfcI
BstAPI
BspMI
PstI
ctagcctaaagcccgtaacactgcagcaggtgctgcccgcgcttgcaccgtccgaagaaa
18121
18180
gatcggatttcgggcattgtgacgtcgtccacgacgggcgcgaacgtggcaggcttctttt
BanI
TaqII
MspA1I
PvuII
BanI
KpnI
agcgcggcctaaagcgcgagtctggtgacttggcacccaccgtgcagctgatggtaccca
18181
18240
tcgcgccggatttcgcgctcagaccactgaaccgtgggtggcacgtcgactaccatgggt
BanII
Bsp1286I
AvaI
HaeII
AlwNI
BsgI
PflMI
BstDSI
agcgccagcgactggaagatgtcttggaaaaaatgaccgtggaacctgggctggagcccg
18241
18300
tcgcggtcgctgaccttctacagaacctttttttactggcaccttggacccgacctcgggc
Tth111II
HaeII
BspMI
BsaHI
BpmI
NarI
EaeI
BanI
GdiII
AarI
BmrI
BstDSI
aggtccgcgtgcggccaatcaagcaggtggcgccgggactgggcgtgcagaccgtggacg
18301
18360
tccaggcgcacgccggttagttcgtccaccgcggccctgacccgcacgtctggcacctgc
BsgI
XcmI
ttcagatacccactaccagtagcaccagtattgccaccgccacagagggcatggagacac
18361
18420
aagtctatgggtgatggtcatcgtggtcataacggtggcggtgtctcccgtacctctgtg
BsgI
BsiEI
SacII
EaeI
MspA1I
MspA1I
EagI
BbvCI
BstDSI
GdiII

FIGURE 28


DrdI
Bpu10I
EciI
BsiEI
NotI
aaacgtccccggttgcctcagcggtggcggatgccgcggtgcaggcggtcgctgcggccg
18421
18480
tttgcaggggccaacggagtcgccaccgcctacggcgccacgtccgccagcgacgccggc
BstDSI
cgtccaagacctctacggaggtgcaaacggacccgtggatgtttcgcgtttcagcccccc
18481
18540
gcaggttctggagatgcctccacgtttgcctgggcacctacaaagcgcaaagtcgggggg
HaeII
BsaHI
NarI
BanI
HaeII
BsaHI
NarI
BanI
BssHII
ggcgcccgcgcggttcgaggaagtacggcgccgccagcgcgctactgcccgaatatgccc
18541
18600
ccgcgggcgcgccaagctccttcatgccgcggcggtcgcgcgatgacgggcttatacggg
BsrDI
tacatccttccattgcgcctacccccggctatcgtggctacacctaccgccccagaagac
18601
18660
atgtaggaaggtaacgcggatgggggccgatagcaccgatgtggatggcggggtcttctg
BbsI
BsaHI
DrdII
gagcaactacccgacgccgaaccaccactggaacccgccgccgccgtcgccgtcgccagc
18661
18720
ctcgttgatgggctgcggcttggtggtgaccttgggcggcggcggcagcggcagcggtcg
NruI
BcgI
Eco0109I
BcgI
FspI
Psp5II
ccgtgctggccccgatttccgtgcgcagggtggctcgcgaaggaggcaggaccctggtgc
18721
18780
ggcacgaccggggctaaaggcacgcgtcccaccgagcgcttcctccgtcctgggaccacg
BsrFI
BssHII
DraI
DrdII
tgccaacagcgcgctaccaccccagcatcgtttaaaagccggtctttgtggttcttgcag
18781
18840
acggttgtcgcgcgatggtggggtccgtagcaaattttcggccagaaacaccaagaacgtc
AarI
BspMI
BanI
BsmI
atatggccctcacctgccgcctccgtttcccggtgccgggattccgaggaagaatgcacc
18841
18900
tataccgggagtggacggcggaggcaaagggccacggccctaaggctccttcttacgtgg
BstDSI
FseI
EaeI
GdiII
BsrFI
NgoAIV
EaeI
GdiII
NspI
SphI
BglI
FspI
BsrFI
SgrAI
gtaggaggggcatggccggccacggcctgacgggcggcatgcgtcgtgcgcaccaccggc
18901
18960
catcctccccgtaccggccggtgccggactgcccgccgtacgcagcacgcgtggtggccg
NspI
SphI
BssHII
BciVI
ggcggcgcgcgtcgcaccgtcgcatgcgcggcggtatcctgcccctccttattccactga
18961
19020
ccgccgcgcgcagcgtggcagcgtacgcgccgccataggacggggaggaataaggtgact
Bsp1286I
BmgI
BseSI
HaeII
SacII
BsaHI
MspAlI
NarI
BstDSI
BanI
BstDSI
HaeI
BglI
tcgccgcggcgattggcgccgtgcccggaattgcatccgtggccttgcaggcgcagagac
19021
19080
agcggcgccgctaaccgcggcacgggccttaacgtaggcaccggaacgtccgcgtctctg
NspI
BspGI
actgattaaaaacaagttgcatgtggaaaaatcaaaataaaaagtctggactctcacgct
19081
19140
tgactaatttttgttcaacgtacacctttttagttttatttttcagacctgagagtgcga

FIGURE 28


BbsI
BsmBI
cgcttggtcctgtaactattttgtagaatggaagacatcaactttgcgtctctggccccg
19141
19200
gcgaaccaggacattgataaaacatcttaccttctgtagttgaaacgcagagaccggggc
BanI
BsrBI
EcoRV
Eco57I
cgacacggctcgcgcccgttcatgggaaactggcaagatatcggcaccagcaatatgagc
19201
19260
gctgtgccgagcgcgggcaagtacccttgaccgttctatagccgtggtcgttatactcg
HaeII
BanII
BsaHI
Bsp1286I
NarI
MspA1I
BanI
PvuII
BsrBI
ApoI
ggtggcgccttcagctggggctcgctgtggagcggcattaaaaatttcggttccaccgtt
19261
19320
ccaccgcggaagtcgaccccgagcgacacctcgccgtaatttttaaagccaaggtggcaa
BbvCI
Bpu10I
HaeI
StuI
HaeI
AlwNI
aagaactatggcagcaaggcctggaacagcagcacaggccagatgctgagggataagttg
19321
19380
ttcttgataccgtcgttccggaccttgtcgtcgtgtccggtctacgactccctattcaac
HaeI
MmeI
ApoI
HaeI
aaagagcaaaatttccaacaaaaggtggtagatggcctggcctctggcattagcggggtg
19381
19440
tttctcgttttaaaggttgttttccaccatctaccggaccggagaccgtaatcgccccac
HaeI
MscI
EaeI
BglI
BtsI
HindIII
gtggacctggccaaccaggcagtgcaaaataagattaacagtaagcttgatccccgccct
19441
19500
cacctggaccggttggtccgtcacgttttattctaattgtcattcgaactaggggcggga
BpmI
BsiEI
BstDSI
BseRI
BsaXI
EaeI
Hin4I
EagI
Tth111I
GdiII
BsaXI
BsrFI
Hin4I
cccgtagaggagcctccaccggccgtggagacagtgtctccagaggggcgtggcgaaaag
19501
19560
gggcatctcctcggaggtggccggcacctctgtcacagaggtctccccgcaccgcttttc
Hin4I
SunI
cgtccgcgccccgacagggaagaaactctggtgacgcaaatagacgagcctccctcgtac
19561
19620
gcaggcgcggggctgtcccttctttgagaccactgcgtttatctgctcggagggagcatg
BstAPI
HaeI
StuI
Bsp24I
Bsp24I
BstDSI
NcoI
StyI
BplI
BseRI
XcmI
BsaWI
gaggaggcactaaagcaaggcctgcccaccacccgtcccatcgcgcccatggctaccgga
19621
19680
ctcctccgtgatttcgttccggacgggtggtgggcagggtagcgcgggtaccgatggcct
BspGI
BspMI
gtgctgggccagcacacacccgtaacgctggacctgcctccccccgccgacacccagcag
19681
19740
cacgacccggtcgtgtgtgggcattgcgacctggacggagggggcggctgtgggtcgtc
TaqII
BsiEI
aaacctgtgctgccaggcccgaccgccgttgttgtaacccgtcctagccgcgcgtccctg
19741
19800
tttggacacgacggtccgggctggcggcaacaacattgggcaggatcggcgcgcagggac
RsrII
BsiEI
MspA1I
PvuI

FIGURE 28


cgccgcgccgccagcggtccgcgatcgttgcggcccgtagccagtggcaactggcaaagc
19801
gcggcgcggcggtcgccaggcgctagcaacgccgggcatcggtcaccgttgaccgtttcg
19860
HaeII
Eco57I
acactgaacagcatcgtgggtctgggggtgcaatccctgaagcgccgacgatgcttctga
19861
tgtgacttgtcgtagcacccagacccccacgttagggacttcgcggctgctacgaagact
19920
AflIII
AceIII
Bpu1102I
atagctaacgtgtcgtatgtgtgtcatgtatgcgtccatgtcgccgccagaggagctgct
19921
tatcgattgcacagcatacacacagtacatacgcaggtacagcggcggtctcctcgacga
19980
BssHII
BseRI
BtsI
gagccgccgcgcgcccgctttccaagatggctacccttcgatgatgccgcagtggtctt
19981
ctcggcggcgcgcgggcgaaaggttcctaccgatggggaagctactacggcgtcaccagaa
20040
SmaI
AvaI
BanII
Bsp1286I
NspI
AvaI
BsaHI
Bpu10I
acatgcacatctcgggccaggacgcctcggagtacctgagccccgggctggtgcagtttg
20041
tgtacgtgtagagcccggtcctgcggagcctcatggactcggggcccgaccacgtcaaac
20100
HaeII
BsaHI
NarI
BsmBI
Eco57I
BsgI
BstDSI
BanI
cccgcgccaccgagacgtacttcagcctgaataacaagtttagaaaccccacggtggcgc
20101
gggcgcggtggctctgcatgaagtccgacttattgttcaaatctttggggtgccaccgcg
20160
BsaWI
BsrFI
PinAI
DraIII
MslI
ctacgcacgacgtgaccacagaccggtcccagcgtttgacgctgcggttcatccctgtgg
20161
gatgcgtgctgcactggtgtctggccagggtcgcaaactgcgacgccaagtagggacacc
20220
TaqII
RleAI
BciVI
accgtgaggatactgcgtactcgtacaaggcgcggttcaccctagctgtgggtgataacc
20221
tggcactcctatgacgcatgagcatgttccgcgccaagtgggatcgacacccactattgg
20280
ApaI
BanII
Bsp1286I
BmgI
BseSI
Eco0109I
Eco0109I
SacII
MspA1I
BstDSI
BspGI
BspGI
BsaAI
gtgtgctggacatggcttccacgtactttgacatccgcggcgtgctggacaggggccctа
20281
cacacgacctgtaccgaaggtgcatgaaactgtaggcgccgcacgacctgtccccgggat
20340
Bsp1286I
BmgI
BseSI
BtsI
StyI
BanI
cttttaagccctactctggcactgcctacaacgccctggctcccaagggtgccccaaatc
20341
gaaaattcgggatgagaccgtgacggatgttgcgggaccgagggttcccacggggtttag
20400
EarI
cttgcgaatgggatgaagctgctactgctcttgaaataaacctagaagaagaggacgatg
20401
gaacgcttaccctacttcgacgatgacgagaactttatttggatcttcttctcctgctac
20460
BsaHI
NarI
BanI
AccI
BbsI
Bpu1102I
BsaAI

FIGURE 28


acaacgaagacgaagtagacgagcaagctgagcagcaaaaaactcacgtatttgggcagg
20461
tgttgcttctgcttcatctgctcgttcgactcgtcgtttttgagtgcataaacccgtcc
20520
HaeII
SspI
cgccttattctggtataaatattacaaaggagggtattcaaataggtgtcgaaggtcaaa
20521
gcggaataagaccatatttataatgtttcctcccataagtttatccacagcttccagttt
20580
Tth111II
EcoNI
cacctaaatatgccgataaaacatttcaacctgaacctcaaataggagaatctcagtggt
20581
gtggatttatacggctattttgtaaagttggacttggagtttatcctcttagagtcacca
20640
MspA1I
VspI
PvuII
acgaaactgaaattaatcatgcagctgggagagtccttaaaaagactaccccaatgaaac
20641
tgctttgactttaattagtacgtcgaccctctcaggaatttttctgatggggttactttg
20700
NdeI
RleAI
BsmI
catgttacggttcatatgcaaaacccacaaatgaaaatggagggcaaggcattcttgtaa
20701
gtacaatgccaagtatacgttttgggtgtttacttttacctcccgttccgtaagaacatt
20760
agcaacaaaatggaaagctagaaagtcaagtggaaatgcaatttttctcaactactgagg
20761
tcgttgttttacctttcgatctttcagttcacctttacgttaaaaagagttgatgactcc
20820
BsrGI
BsiEI
BsrDI
TatI
cgaccgcaggcaatggtgataacttgactcctaaagtggtattgtacagtgaagatgtag
20821
gctggcgtccgttaccactattgaactgaggatttcaccataacatgtcacttctacatc
20880
NspI
BssSI
atatagaaaccccagacactcatatttcttacatgcccactattaaggaaggtaactcac
20881
tatatctttggggtctgtgagtataaagaatgtacgggtgataattccttccattgagtg
20940
HaeI
StuI
BglI
BsrDI
gagaactaatgggccaacaatctatgcccaacaggcctaattacattgcttttagggaca
20941
ctcttgattacccggttgttagatacgggttgtccggattaatgtaacgaaaatccctgt
21000
TaqII
attttattggtctaatgtattacaacagcacgggtaatatgggtgttctggcgggccaag
21001
taaaataaccagattacataatgttgtcgtgcccattatacccacaagaccgcccggttc
21060
BsmI
Tth111II
Tth111II
catcgcagttgaatgctgttgtagatttgcaagacagaaacacagagctttcataccagc
21061
gtagcgtcaacttacgacaacatctaaacgttctgtctttgtgtctcgaaagtatggtcg
21120
DrdII
SexAI
HincII
ttttgcttgattccattggtgatacaaccaggtacttttctatgtggaatcaggctgttg
21121
aaaacgaactaaggtaaccactatcttggtccatgaaaagatacaccttagtccgacaac
21180
acagctatgatccagatgttagaattattgaaaatcatggaactgaagatgaacttccaa
21181
tgtcgatactaggtctacaatcttaataacttttagtaccttgacttctacttgaaggtt
21240
Eco57I
BmrI
VspI
StyI
attactgctttccactgggaggtgtgattaatacagagactcttaccaaggtaaaaccta
21241
taatgacgaaaggtgaccctccacactaattatgtctctgagaatggttccattttggat
21300
EcoNI
SfcI
ApoI
MmeI
aaacaggtcaggaaaatggatgggaaaaagatgctacagaattttcagataaaaatgaaa
21301
tttgtccagtccttttacctacccttttttctacgatgtcttaaaagtctatttttacttt
21360

FIGURE 28


BstDSI
NcoI
StyI
PflMI
ApoI
taagagttggaaataattttgccatggaaatcaatctaaatgccaacctgtggagaaatt
21361
attctcaacctttattaaaacggtacctttagttagatttacggttggacacctctttaa
21420
HaeII
TatI
Eco47III
MmeI
TatI
tcctgtactccaacatagcgctgtatttgcccgacaagctaaagtacagtccttccaacg
21421
aggacatgaggttgtatcgcgacataaacgggctgttcgatttcatgtcaggaaggttgc
21480
Tth111II
SmaI
ApoI
MmeI
Pfl1108I
AvaI
taaaaatttctgataacccaaacacctacgactacatgaacaagcgagtggtggctcccg
21481
atttttaaagactattgggtttgtggatgctgatgtacttgttcgctcaccaccgagggc
21540
BsiHKAI
StyI
Bsp1286I
Tth111I
ggttagtggactgctacattaaccttggagcacgctggtcccttgactatatggacaacg
21541
ccaatcacctgacgatgtaattggaacctcgtgcgaccagggaactgatatacctgttgc
21600
XcmI
HaeI
HincII
MslI
BsrDI
BsrBI
tcaacccatttaaccaccaccgcaatgctggcctgcgctaccgctcaatgttgctgggca
21601
agttgggtaaattggtggtggcgttacgaccggacgcgatggcgagttacaacgacccgt
21660
Bsp1286I
BmgI
BanI
BsrDI
BseSI
MslI
atggtcgctatgtgcccttccacatccaggtgcctcagaagttctttgccattaaaaacc
21661
taccagcgatacacgggaaggtgtaggtccacggagtcttcaagaaacggtaatttttgg
21720
Pfl1108I
Eco57I
BanII
HincII
Bsp1286I
HpaI
DrdII
tccttctcctgccgggctcatacacctacgagtggaacttcaggaaggatgttaacatgg
21721
aggaagaggacggcccgagtatgtggatgctcaccttgaagtccttcctacaattgtacc
21780
AvrII
StyI
BanII
BsiHKAI
Bsp1286I
PstI
SfcI
SacI
Bsu36I
HincII
ttctgcagagctccctaggaaatgacctaagggttgacggagccagcattaagtttgata
21781
aagacgtctcgagggatcctttactggattcccaactgcctcggtcgtaattcaaactat
21840
BstDSI
NcoI
StyI
BsaXI
BsbI
SmlI
RleAI
HaeI
gcatttgcctttacgccaccttcttccccatggcccacaacaccgcctccacgcttgagg
21841
cgtaaacggaaatgcggtggaagaaggggtaccgggtgttgtggcggaggtgcgaactcc
21900
BsaXI
Bce83I
Hin4I
EciI
ccatgcttagaaacgacaccaacgaccagtcctttaacgactatctctccgccgccaaca
21901
ggtacgaatctttgctgtggttgctggtcaggaaattgctgatagagaggcggcggttgt
21960
Bsp1286I
BmgI
NspI
BseSI
BmrI
tgctctaccctatacccgccaacgctaccaacgtgcccatatccatcccctcccgcaact
21961
acgagatgggatatgggcggttgcgatggttgcacgggtataggtaggggagggcgttga
22020
SacII
MspA1I
AflII

FIGURE 28


BstDSI
SmlI
BmrI
gggcggctttccgcggctgggccttcacgcgccttaagactaaggaaaccccatcactgg
22021
22080
cccgccgaaaggcgccgacccggaagtgcgcggaattctgattcctttggggtagtgacc
Pfl1108I
BanII
Bsp1286I
AvaI
gctcgggctacgacccttattacacctactctggctctataccctacctagatggaacct
22081
22140
cgagcccgatgctgggaataatgtggatgagaccgagatatgggatggatctaccttgga
HaeI
MscI
EaeI
MspA1I
EarI
DrdI
PvuII
HaeI
tttacctcaaccacacctttaagaaggtggccattacctttgactcttctgtcagctggc
22141
22200
aaatggagttggtgtggaaattcttccaccggtaatggaaactgagaagacagtcgaccg
HaeII
BsrDI
Eco47III
HincII
ctggcaatgaccgcctgcttacccccaacgagtttgaaattaagcgctcagttgacgggg
22201
22260
gaccgttactggcggacgaatgggggttgctcaaactttaattcgcgagtcaactgcccc
DrdII
AclI
BmrI
PflMI
NheI
agggttacaacgttgcccagtgtaacatgaccaaagactggttcctggtacaaatgctag
22261
22320
tcccaatgttgcaacgggtcacattgtactggtttctgaccaaggaccatgtttacgatc
NspI
TatI
ctaactacaacattggctaccagggcttctatatcccagagagctacaaggaccgcatgt
22321
22380
gattgatgttgtaaccgatggtcccgaagatatagggtctctcgatgttcctggcgtaca
Bsp24I
Bsp24I
actccttctttagaaacttccagcccatgagccgtcaggtggtggatgatactaaataca
22381
22440
tgaggaagaaatctttgaaggtcgggtactcggcagtccaccacctactatgatttatgt
PflMI
BsbI
aggactaccaacaggtgggcatcctacaccaacacaacaactctggatttgttggctacc
22441
22500
tcctgatggttgtccacccgtaggatgtggttgtgttgttgagacctaaacaaccgatgg
HaeI
StuI
ttgcccccaccatgcgcgaaggacaggcctaccctgctaacttcccctatccgcttatag
22501
22560
aacgggggtggtacgcgcttcctgtccggatgggacgattgaaggggataggcgaatatc
BsiEI
PvuI
SgfI
HincII
BpmI
gcaagaccgcagttgacagcattacccagaaaaagtttctttgcgatcgcacccttttggc
22561
22620
cgttctggcgtcaactgtcgtaatgggtctttttcaaagaaacgctagcgtgggaaaccg
BstDSI
NcoI
StyI
gcatcccattctccagtaactttatgtccatgggcgcactcacagacctgggccaaaacc
22621
22680
cgtagggtaagaggtcattgaaatacaggtacccgcgtgagtgtctggacccggttttgg
BstDSI
BamHI
NcoI
BsaXI
EciI
BstYI
StyI
ttctctacgccaactccgcccacgccctagacatgacttttgaggtggatcccatggacg
22681
22740
aagagatgcggttgaggcgggtgcgcgatctgtactgaaaactccacctagggtacctgc
BsiEI
EaeI
EagI

FIGURE 28


GdiII
BsiHKAI
Bsp1286I
BsrFI
BseSI
Tth111II
BanII
Bsp1286I
Tth111I
ApaLI
agcccacccttctttatgttttgtttgaagtctttgacgtggtccgtgtgcaccggccgc
22741
22800
tcgggtgggaagaaatacaaaacaaacttcagaaactgcaccaggcacacgtggccggcg
BsiEI
BsrFI
NgoAIV
BsaHI
SacII
EaeI
MspA1I
BspMI
EagI
BstDSI
FspI
GdiII
accgcggcgtcatcgaaaccgtgtacctgcgcacgcccttctcggccggcaacgccacaa
22801
22860
tggcgccgcagtagctttggcacatggacgcgtgcgggaagagccggccgttgcggtgtt
BanII
MspA1I
Bsp1286I
PvuII
BstDSI
BpmI
NcoI
Tth111II
StyI
AlwNI
cataaagaagcaagcaacatcaacaacagctgccgccatgggctccagtgagcaggaact
22861
22920
gtatttcttcgttcgttgtagttgttgtcgacggcggtacccgaggtcactcgtccttga
Bsp1286I
BglII
BmgI
BstYI
BseSI
RleAI
BanI
Eco47III
gaaagccattgtcaaagatcttggttgtgggccatatttttgggcacctatgacaagcg
22921
22980
ctttcggtaacagtttctagaaccaacacccggtataaaaaaacccgtggatactgttcgc
NruI
BsiEI
BsiEI
BsrFI
EaeI
EagI
HaeII
GdiII
ctttccaggctttgtttctccacacaagctcgcctgcgccatagtcaatacggccggtcg
22981
23040
gaaaggtccgaaacaaagaggtgtgttcgagcggacgcggtatcagttatgccggccagc
BmrI
HaeI
UbaLI
NspI
cgagactgggggcgtacactggatggcctttgcctggaacccgcactcaaaaacatgcta
23041
23100
gctctgaccccgcatgtgacctaccggaaacggaccttgggcgtgagtttttgtacgat
BanII
SmlI
Bsp1286I
Bce83I
BspMI
Tth111II
Hin4I
cctctttgagccctttggcttttctgaccagcgactcaagcaggtttaccagtttgagta
23101
23160
ggagaaactcgggaaaccgaaaagactggtcgctgagttcgtccaaatggtcaaactcat
BsrDI
MspA1I
HaeII
BsiEI
cgagtcactcctgcgccgtagcgccattgcttcttcccccgaccgctgtataacgctgga
23161
23220
gctcagtgaggacgcggcatcgcggtaacgaagaaggggctggcgacatattgcgacct
ApaI
BanII
Bsp1286I
BmgI
BsiEI
BseSI
EaeI
Eco0109I
EagI
TaqII
GdiII
aaagtccacccaaagcgtacaggggcccaactcggccgcctgtggactattctgctgcat
23221
23280
tttcaggtgggtttcgcatgtccccgggttgagccggcggacacctgataagacgacgta
BstDSI
NcoI
NspI
StyI
BaeI
gtttctccacgcctttgccaactggccccaaactcccatggatcacaaccccaccatgaa

FIGURE 28


23281
caaagaggtgcggaaacggttgaccggggtttgagggtacctagtgttggggtggtactt
KpnI
BanI
BaeI
Bsp24I
ccttattaccggggtacccaactccatgctcaacagtccccaggtacagcccaccctgcg
23341
23400
ggaataatggccccatgggttgaggtacgagttgtcaggggtccatgtcgggtgggacgc
SfcI
HaeII
Bsp24I
AceIII
Hin4I
BpmI
BplI
tcgcaaccaggaacagctctacagcttcctggagcgccactcgccctacttccgcagcca
23401
23460
agcgttggtccttgtcgagatgtcgaaggacctcgcggtgagcgggatgaaggcgtcggt
NspI
AflIII
FspI
HaeII
BspLU11I
TatI
cagtgcgcagattaggagcgccacttctttttgtcacttgaaaaacatgtaaaaataatg
23461
23520
gtcacgcgtctaatcctcgcggtgaagaaaaacagtgaacttttgtacatttttattac
BsrGI
TatI
AvaI
tactagagacactttcaataaaggcaaatgcttttatttgtacactctcgggtgattatt
23521
23580
atgatctctgtgaaagttatttccgtttacgaaaataaacatgtgagagcccactaataa
DraI
MslI
tacccccacccttgccgtctgcgccgtttaaaaatcaaaggggttctgccgcgcatcgct
23581
23640
atgggggtgggaacggcagacgcggcaaatttttagtttccccaagacggcgcgtagcga
BaeI
AflIII
BsiHKAI
Bsp1286I
BaeI
atgcgccactggcagggacacgttgcgatactggtgtttagtgctccacttaaactcagg
23641
23700
tacgcggtgaccgtccctgtgcaacgctatgaccacaaatcacgaggtgaatttgagtcc
SacII
MspA1I
BstDSI
AceIII
FspI
AflIII
BspMI
MluI
cacaaccatccgcggcagctcggtgaagttttcactccacaggctgcgcaccatcaccaa
23701
23760
gtgttggtaggcgccgtcgagccacttcaaaagtgaggtgtccgacgcgtggtagtggtt
EcoRV
HaeII
BsaHI
NarI
BanI
BssHII
BssHII
Eco0109I
EciI
cgcgtttagcaggtcgggcgccgatatcttgaagtcgcagttggggcctccgccctgcgc
23761
23820
gcgcaaatcgtccagcccgcggctatagaacttcagcgtcaaccccggaggcgggacgcg
MmeI
BsiHKAI
Bsp1286I
BseSI
HaeII
ApaLI
gcgcgagttgcgatacacagggttgcagcactggaacactatcagcgccgggtggtgcac
23821
23880
cgcgctcaacgctatgtgtcccaacgtcgtgaccttgtgatagtcgcggcccaccacgtg
Eco0109I
Psp5II
HaeI
MscI
BstYI
Sse8647I
EaeI
Hin4I
BspGI
Bpu10I
gctggccagcacgctcttgtcggagatcagatccgcgtccaggtcctccgcgttgctcag
23881
23940
cgaccggtcgtgcgagaacagcctctagtctaggcgcaggtccaggaggcgcaacgagtc
Bsp1286I
BmgI
BseSI
HincII
ggcgaacggagtcaactttggtagctgccttcccaaaaagggcgcgtgcccaggctttga
23941
24000
ccgcttgcctcagttgaaaccatcgacggaagggtttttcccgcgcacgggtccgaaact

FIGURE 28


Bsp1286I
BmgI
BseSI
Hin4I
MslI
BplI
BstEII
HgiEII
BciVI
gttgcactcgcaccgtagtggcatcaaaaggtgaccgtgcccggtctgggcgttaggata
24001
caacgtgagcgtggcatcaccgtagttttccactggcacgggccagacccgcaatcctat
24060
AlwNI
HaeII
Bpu10I
Eco57I
cagcgcctgcataaaagccttgatctgcttaaaagccacctgagcctttgcgccttcaga
24061
gtcgcggacgtattttcggaactagacgaattttcggtggactcggaaacgcggaagtct
24120
MmeI
BsiHKAI
Bsp1286I
BseSI
EaeI
GdiII
BglI
SfiI
ApaLI
NspI
BstAPI
gaagaacatgccgcaagacttgccggaaaactgattggccggacaggccgcgtcgtgcac
24121
cttcttgtacggcgttctgaacggccttttgactaaccggcctgtccggcgcagcacgtg
24180
BglII
BstYI
BsaWI
BsrFI
PinAI
BsgI
BsbI
gcagcaccttgcgtcggtgttggagatctgcaccacatttcggccccaccggttcttcac
24181
cgtcgtggaacgcagccacaacctctagacgtggtgtaaagccggggtggccaagaagtg
24240
Eco57I
HaeI
BssHII
BssHII
gatcttggccttgctagactgctccttcagcgcgcgctgcccgttttcgctcgtcacatc
24241
ctagaaccggaacgatctgacgaggaagtcgcgcgcgacgggcaaaagcgagcagtgtag
24300
BsiHKAI
Bsp1286I
BsaAI
PmlI
AflII
AccI
SmlI
catttcaatcacgtgctccttatttatcataatgcttccgtgtagacacttaagctcgcc
24301
gtaaagttagtgcacgaggaataaatagtatta cgaaggcacatctgtgaattcgagcgg
24360
BanII
Bsp1286I
BssSI
Tth111II
BsgI
MspA1I
BstDSI
ttcgatctcagcgcagcggtgcagccacaacgcgcagcccgtgggctcgtgatgcttgta
24361
aagctagagtcgcgtcgccacgtcggtgttgcgcgtcgggcacccgagcactacgaacat
24420
PstI
SbfI
PstI
BstEII
BspMI
SfcI
SfcI
ggtcacctctgcaaacgactgcaggtacgcctgcaggaatcgccccatcatcgtcacaaa
24421
ccagtggagacgtttgctgacgtccatgcggacgtccttagcggggtagtagcagtgttt
24480
BsiHKAI
Bsp1286I
SacII
MspA1I
MspA1I
BstDSI
PvuII
BseRI
ggtcttgttgctggtgaaggtcagctgcaacccgcggtgctcctcgttcagccaggtctt
24481
ccagaacaacgaccacttccagtcgacgttgggcgccacgaggagcaagtcggtccagaa
24540
BsiEI
EaeI
EagI
GdiII
gcatacggccgccagagcttccactggtcaggcagtagtttgaagttcgcctttagatc
24541
cgtatgccggcggtctcgaaggtgaaccagtccgtcatcaaacttcaagcggaaatctag
24600
BssHII

FIGURE 28


BsaAI
BsaBI PmlI
BssHII
BssHII
gttatccacgtggtacttgtccatcagcgcgcgcgcagcctccatgcccttctcccacgc
24601
24660
caataggtgcaccatgaacaggtagtcgcgcgcgcgtcggaggtacgggaagagggtgcg
BsiEI
PvuI
MspA1I
agacacgatcggcacactcagcgggttcatcaccgtaatttcactttccgcttcgctggg
24661
24720
tctgtgctagccgtgtgagtcgcccaagtagtggcattaaagtgaaaggcgaagcgaccc
BanII EarI
Bsp1286I SapI EarI
BmrI
BbsI
ctcttcctcttcctcttgcgtccgcataccacgcgccactgggtcgtcttcattcagccg
24721
24780
gagaaggagaaggagaacgcaggcgtatggtgcgcggtgacccagcagaagtaagtcggc
BsaWI
BsrFI
PinAI
SgrAI
Tth111II
ccgcactgtgcgcttacctcctttgccatgcttgattagcaccggtgggttgctgaaacc
24781
24840
ggcgtgacacgcgaatggaggaaacggtacgaactaatcgtggccacccaacgactttgg
HaeII
caccatttgtagcgccacatcttctcttcttcctcgctgtccacgattacctctggtga
24841
24900
gtggtaaacatcgcggtgtagaagagaaagaaggagcgacaggtgctaatggagaccact
BsrDI
HaeI
MscI
AvaI
HaeII
HaeII
EaeI
tggcgggcgctcgggcttgggagaagggcgcttcttttttcttcttgggcgcaatggccaa
24901
24960
accgcccgcgagcccgaaccctcttcccgcgaagaaaaagaagaacccgcgttaccggtt
SacII
MspA1I
BstDSI
TaqII
EaeI
EciI
GdiII
BanI
BbsI
atccgccgccgaggtcgatggccgcgggctgggtgtgcgcggcaccagcgcgtcttgtga
24961
25020
taggcggcggctccagctaccggcgcccgacccacacgcgccgtggtcgcgcagaacact
SmaI
AvaI
HaeII
BsaHI
NarI
BanI
Hin4I
BplI
tgagtcttcctcgtcctcggactcgatacgccgcctcatccgctttttgggggcgcccg
25021
25080
actcagaaggagcaggagcctgagctatgcggcggagtaggcgaaaaaacccccgcgggc
BstDSI
BsaXI
Hin4I
AhdI
AflIII
HaeIV
Hin4I
NcoI
StyI
AatII
BsaHI
gggaggcggcggcgacggggacgggcacgacacgtcctccatggttgggggacgtcgcgc
25081
25140
ccctccgccgccgctgcccctgcccctgctgtgcaggaggtaccaacccccctgcagcgcg
HaeI
MscI
AvaI
BseRI
EarI
EaeI
cgcaccgcgtccgcgctcgggggtggtttcgcgctgctcctcttcccgactggccatttc
25141
25200
gcgtggcgcaggcgcgagcccccaccaaagcgcgacgaggagaagggctgaccggtaaag
SfcI
cttctcctataggcagaaaaagatcatggagtcagtcgagaagaaggacagcctaaccgc

FIGURE 28


25201
gaagaggatatccgtctttttctagtacctcagtcagctcttcttcctgtcggattggcg
ccccctctgagttcgccaccaccgcctccaccgatgccgccaacgcgcctaccaccttccc
25261
ggggagactcaagcggtggtggcggaggtggctacggcggttgcgcggatggtggaaggg
EcoO109I
Bce83I
BseRI
BanI
SmlI
BseRI
Psp5II
cgtcgaggcacccccgcttgaggaggaggaagtgattatcgagcaggacccaggttttgt
25321
gcagctccgtgggggcgaactcctcctccttcactaatagctcgtcctgggtccaaaaca
25380
BsrBI
BbsI
Hin4I
BplI
aagcgaagacgacgaggaccgctcagtaccaacagaggataaaaagcaagaccaggacaa
25381
ttcgcttctgctgctcctggcgagtcatggttgtctcctatttttcgttctggtcctgtt
25440
RleAI
BsmBI
cgcagaggcaaacgaggaacaagtcgggcgggggacgaaaggcatggcgactacctaga
25441
gcgtctccgtttgctccttgttcagcccgccccctgctttccgtaccgctgatggatct
25500
HaeII
PstI
BsaXI
SfcI
AflIII
MluI
tgtgggagacgacgtgctgttgaagcatctgcagcgccagtgcgccattatctgcgacgc
25501
acaccctctgctgcacgacaacttcgtagacgtcgcggtcacgcggtaatagacgctgcg
25560
Bsp1286I
BmgI
BseSI
Pfl1108I
gttgcaagagcgcagcgatgtgcccctcgccatagcggatgtcagccttgcctacgaacg
25561
caacgttctcgcgtcgctacacggggagcggtatcgcctacagtcggaacggatgcttgc
25620
BanII
Bsp1286I
NspI
ccacctattctcaccgcgcgtacccccaaacgccaagaaaacggcacatgcgagcccaa
25621
ggtggataagagtggcgcgcatgggggtttgcggttcttttgccgtgtacgctcgggtt
25680
Tth111II
cccgcgcctcaacttctaccccgtatttgccgtgccagaggtgcttgccacctatcacat
25681
gggcgcggagttgaagatggggcataaacggcacggtctccacgaacggtggatagtgta
25740
BsrBI
ctttttccaaaactgcaagataccctatcctgccgtgccaaccgcagccgagcggacaa
25741
gaaaaaggttttgacgttctatggggataggacggcacggttggcgtcggctcgcctgtt
25800
Tth111II
HaeI
MspA1I
PvuII
HaeII
Hin4I
EcoRV
gcagctggccttgcggcagggcgctgtcatacctgatatcgcctcgctcaacgaagtgcc
25801
cgtcgaccggaacgccgtcccgcgacagtatggactatagcggagcgagttgcttcacgg
25860
BssHII
aaaaatctttgagggtcttggacgccacgagaagcgcgcggcaaacgctctgcaacagga
25861
tttttagaaactcccagaacctgcgctgctcttcgcgcgccgtttgcgagacgttgtcct
25920
BpmI
AvaI
BsaXI
SmlI
BsbI
XhoI
BssHII
aaacagcgaaaatgaaagtcactctggagtgttggtggaactcgagggtgacaacgcgcg
25921
tttgtcgcttttactttcagtgagacctcacaaccaccttgagctcccactgttgcgcgc
25980
BglI

FIGURE 28


BstEII
TaqII
cctagccgtactaaaacgcagcatcgaggtcacccactttgcctacccggcacttaaccc
25981
26040
ggatcggcatgattttgcgtcgtagctccagtgggtgaaacggatgggccgtgaattgga
RcaI
MslI
AceIII
BsiHKAI
HgiEII
Bsp1286I
StyI
RcaI
FspI
AlwNI
acccccccaaggtcatgagcacagtcatgagtgagctgatcgtgcgccgtgcgcagccccc
26041
26100
tgggggggttccagtactcgtgtcagtactcactcgactagcacgcggcacgcgtcgggga
Tth111II
ApoI
BpmI
Eco0109I
BseRI
ggagagggatgcaaatttgcaagaacaaacagaggagggcctacccgcagttggcgacga
26101
26160
cctctccctacgtttaaacgttcttgtttgtctcctcccggatgggcgtcaaccgctgct
BssHII
NheI
BseRI
gcagctagcgcgctggcttcaaacgcgcgagcctgccgacttggaggagcgacgcaaact
26161
26220
cgtcgatcgcgcgaccgaagtttgcgcgctcggacggctgaacctcctcgctgcgtttga
BsiHKAI
MspA1I
EaeI
Bsp1286I
BsaXI
NspI
GdiII
BtsI
BstDSI
SmlI
SphI
Bce83I
aatgatggccgcagtgctcgttaccgtggagcttgagtgcatgcagcggttctttgctga
26221
26280
ttactaccggcgtcacgagcaatggcacctcgaactcacgtacgtcgccaagaaacgact
BsaAI
SnaBI
BsrDI
SunI
cccggagatgcagcgcaagctagaggaaacattgcactacacctttcgacagggctacgt
26281
26340
gggcctctacgtcgcgttcgatctcctttgtaacgtgatgtggaaagctgtcccgatgca
BanII
BsiHKAI
MmeI
HaeI
BglII
Bsp1286I
BsaXI
StyI
StuI
BstYI
SacI
SexAI
BsaI
ApoI
acgccaggcctgcaagatctccaacgtggagctctgcaacctggtctcctaccttggaat
26341
26400
tgcggtccggacgttctagaggttgcacctcgagacgttggaccagaggatggaacctta
Bce83I
AscI
StyI
BstAPI
SmlI
BssHII
tttgcacgaaaaccgccttgggcaaaacgtgcttcattccacgctcaagggcgaggcgcg
26401
26460
aaacgtgcttttggcggaacccgttttgcacgaagtaaggtgcgagttcccgctccgcgc
BstDSI
NcoI
StyI
EaeI
Tth111I
GdiII
ccgcgactacgtccgcgactgcgtttacttatttctatgctacacctggcagacggccat
26461
26520
ggcgctgatgcaggcgctgacgcaaatgaataaagatacgatgtggaccgtctgccggta
AlwNI
BstAPI
Bce83I
BseRI
PstI
Tth111II
BtsI
AceIII
SmlI
SfcI
gggcgtttggcagcagtgcttggaggagtgcaacctcaaggagctgcagaaactgctaaa
26521
26580
cccgcaaaccgtcgtcacgaacctcctcacgttggagttcctcgacgtctttgacgattt
EaeI
GdiII
BstDSI
Eco0109I
HaeII
Psp5II
Eco47III
Sse8647I
BsaXI
EciI
gcaaaacttgaaggacctatggacggccttcaacgagcgctccgtggccgcgcacctggc

FIGURE 28


26581
cgttttgaacttcctggatacctgccggaagttgctcgcgaggcaccggcgcgtggaccg
EcoNI
AlwNI
ggacatcattttccccgaacgcctgcttaaaaccctgcaacagggtctgccagacttcac
26641
26700
cctgtagtaaaaggggcttgcggacgaattttgggacgttgtcccagacggtctgaagtg
Bpu10I
HaeII
NspI
Eco47III
cagtcaaagcatgttgcagaactttaggaactttatcctagagcgctcaggaatcttgcc
26701
26760
gtcagtttcgtacaacgtcttgaaatccttgaaataggatctcgcgagtccttagaacgg
BsiHKAI
Bsp1286I
BseSI
BspMI
Bsp1286I
BmgI
BseSI
EciI
BsmI
AarI
ApaLI
cgccacctgctgtgcacttcctagcgactttgtgcccattaagtaccgcgaatgccctcc
26761
26820
gcggtggacgacacgtgaaggatcgctgaaacacgggtaattcatggcgcttacgggagg
NheI
PstI
BtsI
SfcI
gccgctttggggccactgctaccttctgcagctagccaactaccttgcctaccactctga
26821
26880
cggcgaaaccccggtgacgatggaagacgtcgatcggttgatggaacggatggtgagact
BsrBI
BbsI
AccI
BstAPI
BpmI
cataatggaagacgtgagcggtgacggtctactggagtgtcactgtcgctgcaacctatg
26881
26940
gtattaccttctgcactcgccactgccagatgacctcacagtgacagcgacgttggatac
MspA1I
PvuII
BsrBI
BanI
AceIII
caccccgcaccgctccctggtttgcaattcgcagctgcttaacgaaagtcaaattatcgg
26941
27000
gtggggcgtggcgagggaccaaacgttaagcgtcgacgaattgctttcagtttaatagcc
SacII
MspA1I
EcoO109I
Psp5II
SanDI
PstI
BstDSI
AhdI
HaeIV
Hin4I
KpnI
SfcI
tacctttgagctgcagggtccctcgcctgacgaaaagtccgcggctccggggttgaaact
27001
27060
atggaaactcgacgtcccagggagcggactgcttttcaggcgccgaggccccaactttga
AatII
BsaHI
ApoI
Bsu36I
cactccggggctgtggacgtcggctaccttcgcaaatttgtacctgaggactaccacgc
27061
27120
gtgaggccccgacacctgcagccgaatggaagcgtttaaacatggactcctgatggtgcg
Pfl1108I
BssSI
UbaLI
BbsI
ccacgagattaggttctacgaagaccaatcccgcccgccaaatgcggagcttaccgcctg
27121
27180
ggtgctctaatccaagatgcttctggttagggcgggcggtttacgcctcgaatggcggac
MunI
HaeI
MscI
EaeI
BstXI
cgtcattacccagggccacattcttggccaattgcaagccatcaacaaagcccgccaaga
27181
27240
gcagtaatgggtcccggtgtaagaaccggttaacgttcggtagttgtttcgggcggttct
BmrI
AhdI
HaeIV
Hin4I
BanII
BsiHKAI
Bsp1286I
SacI
Pfl1108I
gtttctgctacgaaagggacgggggttacttggacccccagtccggcgaggagctcaa

FIGURE 28


27241
caaagacgatgctttccctgccccccaaatgaacctgggggtcaggccgctcctcgagtt
27300
ApaI
BanII
Bsp1286I
BmgI
BseSI
Eco0109I
SacII
MspA1I
BstDSI
BseRI
cccaatccccccgccgccgcagccctatcagcagcagccgcgggccccttgcttcccagga
27301
27360
gggttaggggggcggcggcgtcgggatagtcgtcgtcggcgcccgggaacgaagggtcct
MspA1I
PvuII
PstI
TaqII
SfcI
BanI
BstDSI
TaqII
BseRI
BmrI
tggcacccaaaaagaagctgcagctgccgccgccacccacggacgaggaggaatactggg
27361
27420
accgtgggtttttcttcgacgtcgacggcggcggtgggtgcctgctcctccttatgaccc
BseRI
BseRI
BseRI
BbsI
BmrI
acagtcaggcagaggaggttttggacgaggaggaggaggacatgatggaagactgggaga
27421
27480
tgtcagtccgtctcctccaaaacctgctcctcctcctcctgtactaccttctgaccctct
HindIII
EcoNI
EarI
TaqII
BcgI
gcctagacgaggaagcttccgaggtcgaagaggtgtcagacgaaacaccgtcaccctcgg
27481
27540
cggatctgctccttcgaaggctccagcttctccacagtctgctttgtggcagtgggagcc
HaeII
BsaHI
NarI
BanI
BsrFI
NgoAIV
SgrAI
BsmI
BsiEI
BcgI
BsaWI
BsrFI
PinAI
BseRI
tcgcattcccctcgccggcgccccagaaatcggcaaccggttccagcatggctacaacct
27541
27600
agcgtaaggggagcggccgcggggtctttagccgttggccaaggtcgtaccgatgttgga
BsrFI
NgoAIV
HaeII
BsaHI
Bsu36I
NarI
BanI
BsrBI
BsaXI
BtsI
ccgctcctcaggcgccgccggcactgcccgttcgccgacccaaccgtagatgggacacca
27601
27660
ggcgaggagtccgcggcggccgtgacgggcaagcggctgggttggcatctaccctgtggt
BsrFI
HgiEII
DrdII
Tth111II
ctggaaccagggccggtaagtccaagcagccgccgccgttagcccaagagcaacaacagc
27661
27720
gaccttggtcccggccattcaggttcgtcggcggcggcaatcgggttctcgttgttgtcg
Tth111II
Tth111II
Bsp1286I
BmgI
BseSI
HaeII
StyI
BsrBI
RleAI
gccaaggctaccgctcatggcgcgggcacaagaacgccatagttgcttgcttgcaagact
27721
27780
cggttccgatggcgagtaccgcgcccgtgttcttgcggtatcaacgaacgaacgttctga
HaeI
DraIII
gtgggggcaacatctccttcgcccgccgctttcttctctaccatcacggcgtggccttcc
27781
27840
caccccgttgtagaggaagcgggcggcgaaagaagagatggtagtgccgcaccggaagg

FIGURE 28


SfcI
BsgI
BsrFI
SgrAI
MspA1I
cccgtaacatcctgcattactaccgtcatctctacagcccatactgcaccggcggcagcg
27841
27900
gggcattgtaggacgtaatgatggcagtagagatgtcgggtatgacgtggccgccgtcgc
EaeI
GdiII
MspA1I
BsiEI
BsaWI
MspA1I
gcagcggcagcaacagcagcggccacacagaagcaaaggcgaccggatagcaagactctg
27901
27960
cgtcgccgtcgttgtcgtcgccggtgcgtcttcgtttccgctggcctatcgttctgagac
BsaHI
NarI
BanI
BseRI
BseRI
HaeII
MspA1I
Eco47III
acaaagcccaagaaatccacagcggcggcagcagcaggaggaggagcgctgcgtctggcg
27961
28020
tgtttcgggttctttaggtgtcgccgccgtcgtcgtcctcctcctcgcgacgcagaccgc
HaeII
cccaacgaacccgtatcgacccgcgagcttagaaacaggatttttcccactctgtatgct
28021
28080
gggttgcttgggcatagctgggcgctcgaatctttgtcctaaaaagggtgagacatacga
AceIII
BsaI
atatttcaacagagcaggggccaagaacaagagctgaaaatataaaaaacaggtctctgcga
28081
28140
tataaagttgtctcgtccccggttcttgttctcgacttttatttttgtccagagacgct
MspA1I
PvuII
Eco57I
tccctcacccgcagctgcctgtatcacaaaagcgaagatcagcttcggcgcacgctggaa
28141
28200
agggagtgggcgtcgacggacatagtgttttcgcttctagtcgaagccgcgtgcgacctt
AflII
BbsI
EarI
BssHII
SmlI
SpeI
gacgcggaggctctcttcagtaaatactgcgcgctgactcttaaggactagtttcgcgcc
28201
28260
ctgcgcctccgagagaagtcatttatgacgcgcgactgagaattcctgatcaaagcgcgg
HaeII
BsaHI
NarI
EaeI
GdiII
BanI
ApoI
BpmI
BsaXI
MspA1I
Bsp24I
ctttctcaaatttaagcgcgaaaactacgtcatctccagcggccacacccggcgccagca
28261
28320
gaaagagtttaaattcgcgcttttgatgcagtagaggtcgccggtgtgggccgcggtcgt
NspI
Bsp24I
AflIII
AlwNI
HaeII
ApoI
BspLU11I
cctgtcgtcagcgccattatgagcaaggaaattcccacgccctacatgtggagttaccag
28321
28380
ggacagcagtcgcggtaatactcgttcctttaagggtgcgggatgtacacctcaatggtc
AceIII
BpmI
ccacaaatgggacttgcggctggagctgcccaagactactcaacccgaataaactacatg
28381
28440
ggtgtttaccctgaacgccgacctcgacgggttctgatgagttgggcttatttgatgtac
HincII
RleAI
Eco0109I
SmaI
Psp5II
AvaI
ApoI
SanDI
EcoRV
EcoRI
agcgcgggaccccacatgatatcccgggtcaacggaatccgcgcccaccgaaaccgaatt
28441
28500
tcgcgccctggggtgtactatagggcccagttgccttaggcgcgggtggctttggcttaa
ctcttggaacaggcggctattaccacacacctcgtaataaccttaatccccgtagttgg
28501
28560

FIGURE 28


gagaaccttgtccgccgataatggtggtgtggagcattattggaattaggggcatcaacc
BstXI
MspA1I
BsrBI
MslI
BsmBI
BsaHI
cccgctgccctggtgtaccaggaaagtcccgctcccaccactgtggtacttcccagagac
28561
28620
gggcgacgggaccacatggtcctttcagggcgagggtggtgacaccatgaagggtctctg
gcccaggccgaagttcagatgactaactcaggggcgcagcttgcgggcggctttcgtcac
28621
28680
cgggtccggcttcaagtctactgattgagtccccgcgtcgaacgcccgccgaaagcagtg
SmaI
SrfI
AvaI
DraIII
BsiEI
agggtgcggtcgcccgggcagggtataactcacctgacaatcagagggcgaggtattcag
28681
28740
tcccacgccagcgggcccgtcccatattgagtggactgttagtctcccgctccataagtc
BanII
BsiHKAI
BsaWI
BseRI
Bsp1286I
BspEI
AceIII
SacI
BsaI
ctcaacgacgagtcggtgagctcctcgcttggtctccgtccggacgggacatttcagatc
28741
28800
gagttgctgctcagccactcgaggagcgaaccagaggcaggcctgccctgtaaagtctag
BsiEI
EaeI
EagI
GdiII
HaeII
BsrFI
NgoAIV
BsaHI
NarI
BanI
Tth111I
PstI
SfcI
ggcggcgccggccgtccttcattcacgcctcgtcaggcaatcctaactctgcagacctcg
28801
28860
ccgccgcggccggcaggaagtaagtgcggagcagtccgttaggattgagacgtctggagc
Hin4I
BplI
BpmI
TaqII
tcctctgagccgcgctctggaggcattggaactctgcaatttattgaggagtttgtgcca
28861
28920
aggagactcggcgcgagacctccgtaaccttgagacgttaaataactcctcaaacacggt
Eco0109I
AccI
Psp5II
EaeI
BsaWI
BseRI
AvaI
GdiII
BspEI
tcggtctactttaacccctctcgggacctcccggccactatccggatcaatttattcct
28921
28980
agccagatgaaattggggaagagccctggagggccggtgataggcctagttaaataagga
EciI
Pfl1108I
aactttgacgcggtaaaggactcggcggacggctacgactgaatgttaagtggagaggca
28981
29040
ttgaaactgcgccatttcctgagccgcctgccgatgctgacttacaattcacctctccgt
SexAI
gagcaactgcgcctgaaacacctggtccactgtcgccgccacaagtgctttgcccgcgac
29041
29100
ctcgttgacgcggactttgtggaccaggtgacagcggcggtgttcacgaaacgggcgctg
ApaI
BanII
Bsp1286I
BmgI
BseSI
BsaWI
AvaI
Eco0109I
BsaHI
tccggtgagttttgctactttgaattgcccgaggatcatatcgagggcccggcgcacggc
29101
29160
aggccactcaaaacgatgaaacttaacgggctcctagtatagctcccgggccgcgtgccg
HaeII
gtccggcttaccgcccagggagagcttgcccgtagcctgattcgggagtttacccagcgc
29161
29220
caggccgaatggcgggtccctctcgaacgggcatcggactaagccctcaaatgggtcgcg
Eco0109I

FIGURE 28


Psp5II
BsrBI SanDI AloI
cccctgctagttgagcgggacaggggaccctgtgttctcactgtgatttgcaactgtcct
29221 29280
ggggacgatcaactcgccctgtcccctgggacacaagagtgacactaaacgttgacagga
BglII
BglII BstYI
StyI BstYI PacI
aaccttggattacatcaagatcTTAATTAAgatcttattccctttaactaataaaaaaaa
29281 29340
ttggaacctaatgtagttctagAATTAATTctagaataagggaaattgattatttttttt
ApoI BspGI
ataataaagcatcacttacttaaaatcagttagcaaatttctgtccagtttattcagcag
29341 29400
tattatttcgtagtgaatgaatttagtcaatcgtttaaagacaggtcaaataagtcgtc
BseRI AceIII
cacctccttgccctcctcccagctctggtattgcagcttcctcctggctgcaaactttct
29401 29460
gtggaggaacgggaggagggtcgagaccataacgtcgaaggaggaccgacgtttgaaaga
XcmI
ccacaatctaaatggaatgtcagtttcctcctgttcctgtccatccgcacccactatctt
29461 29520
ggtgttagatttaccttacagtcaaaggaggacaaggacaggtaggcgtgggtgatagaa
TaqII BssHII Eco57I
catgttgttgcagatgaagcgcgcaagaccgtctgaagataccttcaaccccgtgtatcc
29521 29580
gtacaacaacgtctacttcgcgcgttctggcagacttctatggaagttggggcacatagg
BsaXI
BsaWI
BciVI BsrFI
NdeI PinAI BseRI MmeI
atatgacacggaaaccggtcctccaactgtgccttttcttactcctccctttgtatcccc
29581 29640
tatactgtgcctttggccaggaggttgacacggaaaagaatgaggagggaaacatagggg
BciVI
caatgggtttcaagagagtccccctggggtactctctttgcgcctatccgaacctctagt
29641 29700
gttacccaaagttctctcaggggacccccatgagagaaacgcggataggcttggagatca
NspI BsrFI
Tth111II SphI BspGI NgoAIV
tacctccaatggcatgcttgcgctcaaaatgggcaacggcctctctctggacgaggccgg
29701 29760
atggaggttaccgtacgaacgcgagttttacccgttgccggagagagacctgctccggcc
BanII
Bsp1286I
BsaXI Hin4I BplI
caaccttacctcccaaaatgtaaccactgtgagcccacctctcaaaaaaaccaagtcaaa
29761 29820
gttggaatggagggttttacattggtgacactcgggtggagagttttttggttcagttt
BsgI Tth111II
cataaacctggaaatatctgcacccctcacagttacctcagaagccctaactgtggctgc
29821 29880
gtatttggacctttatagacgtgggagtgtcaatggagtcttcgggattgacaccgacg
HgiEII BsbI Eco0109I
cgccgcacctctaatggtcgcgggcaacacactcaccatgcaatcacaggccccgctaac
29881 29940
gcggcgtggagattaccagcgcccgttgtgtgagtggtacgttagtgtccggggcgattg
BsiHKAI
Bsp1286I Eco0109I
BseSI Psp5II
ApaLI BsrDI StyI TaqII
cgtgcacgactccaaacttagcattgccacccaaggacccctcacagtgtcagaaggaaa
29941 30000
gcacgtgctgaggtttgaatcgtaacggtgggttcctggggagtgtcacagtcttccttt

FIGURE 28


NheI
EcoO109I
Tth111II
BtsI
gctagccctgcaaacatcaggcccccccaccaccaccgatagcagtacccttactatcac
30001
cgatcgggacgtttgtagtccgggggagtggtggtggctatcgtcatgggaatgatagtg
30060
XcmI
BanII
Bsp1286I
tgcctcacccccctctaactactgccactggtagcttgggcattgacttgaaagagcccat
30061
acggagtgggggagattgatgacggtgaccatcgaacccgtaactgaactttctcgggta
30120
BanII
Bsp1286I
NspI
ttatacacaaaatggaaaactaggactaaagtacggggctcctttgcatgtaacagacga
30121
aatatgtgttttacctttgatcctgatttcatgccccgaggaaacgtacattgtctgct
30180
BspGI
VspI
cctaaacactttgaccgtagcaactggtccaggtgtgactattaataatacttccttgca
30181
ggatttgtgaaactggcatcgttgaccaggtccacactgataattattatgaaggaacgt
30240
StyI
BpmI
aactaaagttactggagccttgggttttgattcacaaggcaatatgcaacttaatgtagc
30241
ttgatttcaatgacctcggaacccaaaactaagtgttccgttatacgttgaattacatcg
30300
Hin4I
BsaHI
aggaggactaaggattgattctcaaaacagacgccttatacttgatgttagttatccgtt
30301
tcctcctgattcctaactaagagttttgtctgcggaatatgaactacaatcaataggcaa
30360
ApaI
BanII
Bsp1286I
BmgI
BseSI
EcoO109I
EcoO109II
tgatgctcaaaaccaactaaatctaagactaggacagggccctctttttataaactcagc
30361
actacgagttttggttgatttagattctgatcctgtcccgggagaaaaatatttgagtcg
30420
HaeI
StuI
PflMI
RleAI
ccacaacttggatattaactacaacaaaggcctttacttgtttacagcttcaaacaattc
30421
ggtgttgaacctataattgatgttgtttccggaaatgaacaaatgtcgaagtttgttaag
30480
Tth111II
StyI
SmlI
Bpu10I
Tth111II
HincII
Bce83I
HindIII
HpaI
BtsI
SfcI
caaaaagcttgaggttaacctaagcactgccaaggggttgatgtttgacgctacagccat
30481
gtttttcgaactccaattggattcgtgacggttccccaactacaaactgcgatgtcggta
30540
VspI
ApoI
DrdII
agccattaatgcaggagatgggcttgaatttggttcacctaatgcaccaaacacaaatcc
30541
tcggtaattacgtcctctacccgaacttaaaccaagtggattacgtggtttgtgtttagg
30600
BstDSI
NcoI
StyI
HaeI
MscI
Tth111II
EaeI
HaeI
ApoI
Tth111II
DrdII
EcoNI
cctcaaaacaaaaattggccatggcctagaatttgattcaaacaaggctatggttcctaa
30601
ggagttttgtttttaaccggtaccggatcttaaactaagtttgttccgataccaaggatt
30660
HaeI
BanI
actaggaactggccttagttttgacagcacaggtgccattacagtaggaaacaaaaataa
30661
tgatccttgaccggaatcaaaactgtcgtgtccacggtaatgtcatcctttgttttatt
30720

FIGURE 28


AccI
SfcI
BsaXI
AceIII
tgataagctaactttgtggaccacaccagctccatctcctaactgtagactaaatgcaga
30721
30780
actattcgattgaaacacctggtgtggtcgaggtagaggattgacatctgatttacgtct
SfcI
gaaagatgctaaactcactttggtcttaacaaaatgtggcagtcaaatacttgctacagt
30781
30840
ctttctacgatttgagtgaaaccagaattgttttacaccgtcagtttatgaacgatgtca
BsiHKAI
PflMI
Bsp1286I
ttcagttttggctgttaaaggcagtttggctccaatatctggaacagttcaaagtgctca
30841
30900
aagtcaaaaccgacaatttccgtcaaaccgaggttatagaccttgtcaagtttcacgagt
BspGI
tcttattataagatttgacgaaaatggagtgctactaaacaattccttcctggacccaga
30901
30960
agaataatattctaaactgcttttacctcacgatgatttgttaaggaaggacctgggtct
BstXI
SspI
BglII
BstYI
MmeI
Eco57I
atattggaactttagaaatggagatcttactgaaggcacagcctatacaaacgctgttgg
30961
31020
tataaccttgaaatctttacctctagaatgacttccgtgtcggatatgtttgcgacaacc
atttatgcctaacctatcagcttatccaaaatctcacggtaaaactgccaaaagtaacat
31021
31080
taaatacggattggatagtcgaataggttttagagtgccattttgacggttttcattgta
tgtcagtcaagtttacttaaacggagacaaaactaaacctgtaacactaaccattacact
31081
31140
acagtcagttcaaatgaatttgcctctgttttgatttggacattgtgattggtaatgtga
MslI
aaacggtacacaggaaacaggagacacaactccaagtgcatactctatgtcattttcatg
31141
31200
tttgccatgtgtcctttgtcctctgtgttgaggttcacgtatgagatacagtaaaagtac
HaeI
MscI
EaeI
VspI
SspI
ggactggtctggccacaactacattaatgaaatatttgccacatcctcttacacttttc
31201
31260
cctgaccagaccggtgttgatgtaattactttataaacggtgtaggagaatgtgaaaaag
BsrDI
AflIII
MunI
atacattgcccaagaataaagaatcgtttgtgttatgtttcaacgtgtttatttttcaat
31261
31320
tatgtaacgggttcttatttcttagcaaacacaatacaaagttgcacaaataaaaagtta
ApoI
tgcagaaaatttcaagtcatttttcattcagtagtatagccccaccaccacatagcttat
31321
31380
acgtcttttaaagttcagtaaaaagtaagtcatcatatcggggtggtggtgtatcgaata
BspMI
acagatcaccgtaccttaatcaaactcacagaaccctagtattcaacctgccacctccct
31381
31440
tgtctagtggcatggaattagtttgagtgtcttgggatcataagttggacggtggaggga
BsbI
TatI
HaeI
cccaacacacagagtacacagtcctttctccccggctggccttaaaaagcatcatatcat
31441
31500
gggttgtgtgtctcatgtgtcaggaaagaggggccgaccggaatttttcgtagtatagta
gggtaacagacatattcttaggtgttatattccacacggtttcctgtcgagccaaacgct
31501
31560
cccattgtctgtataagaatccacaatataaggtgtgccaaaggacagctcggtttgcga
AceIII
MspA1I
SmaI
AflII
PvuII
VspI
AvaI
SmlI
BspGI
catcagtgatattaataaactccccgggcagctcacttaagttcatgtcgctgtccagct
31561
31620

FIGURE 28


gtagtcactataattatttgaggggcccgtcgagtgaattcaagtacagcgacaggtcga
Bpu1102I
AlwNI
MmeI
gctgagccacaggctgctgtccaacttgcggttgcttaacgggcggcgaaggagaagtcc
31621
31680
cgactcggtgtccgacgacaggttgaacgccaacgaattgcccgccgcttcctcttcagg
MslI
Hin4I
PstI
BcgI
SfcI
acgcctacatgggggtagagtcataatcgtgcatcaggatagggcggtggtgctgcagca
31681
31740
tgcggatgtacccccatctcagtattagcacgtagtcctatcccgccaccacgacgtcgt
BssHII
BcgI
BsrBI
SfcI
PstI
SbfI
BtsI
MslI
BseRI
gcgcgcgaataaactgctgccgccgccgctccgtcctgcaggaatacaacatggcagtgg
31741
31800
cgcgcgcttatttgacgacggcggcggcgaggcaggacgtccttatgttgtaccgtcacc
BbvCI
Bpu10I
BsaI
HaeII
BsaHI
NarI
BanI
Bsp1286I
BmgI
BseSI
tctcctcagcgatgattcgcaccgcccgcagcataaggcgccttgtcctccgggcacagc
31801
31860
agaggagtcgctactaagcgtggcgggcgtcgtattccgcggaacaggaggcccgtgtcg
SfcI
AlwNI
PstI
SspI
agcgcaccctgatctcacttaaatcagcacagtaactgcagcacagcaccacaatattgt
31861
31920
tcgcgtgggactagagtgaatttagtcgtgtcattgacgtcgtgtcgtggtgttataaca
RleAI
HaeII
BciVI
tcaaaatcccacagtgcaaggcgctgtatccaaagctcatggcggggaccacagaaccca
31921
31980
agttttagggtgtcacgttccgcgacataggtttcgagtaccgcccctggtgtcttgggt
HaeI
MscI
EaeI
BsaAI
PmlI
BspMI
BspGI
cgtggccatcataccacaagcgcaggtagattaagtggcgacccctcataaaacacgctgg
31981
32040
gcaccggtagtatggtgttcgcgtccatctaattcaccgctggggagtatttgtgcgacc
KpnI
NspI
BanI
acataaacattacctcttttggcatgttgtaattcaccacctcccggtaccatataaacc
32041
32100
tgtatttgtaatggagaaaaccgtacaacattaagtggtggagggccatggtatatttgg
HaeII
BsaHI
NarI
BanI
HaeI
MscI
EaeI
MspA1I
PvuII
BspMI
BsrFI
NgoAIV
tctgattaaacatggcgccatccaccaccatcctaaaccagctggccaaaacctgcccgc
32101
32160
agactaatttgtaccgcggtaggtggtggtaggatttggtcgaccggttttggacgggcg
PstI
BtsI
SfcI
BanII
Bsp1286I
cggctatacactgcagggaaccgggactggaacaatgacagtggagagcccaggactcgt
32161
32220
gccgatatgtgacgtcccttggccctgaccttgttactgtcacctctcgggtcctgagca
BstDSI
NcoI
StyI
RcaI
EcoRV
BsaAI
PmlI
BsbI
AflIII
aaccatggatcatcatgctcgtcatgatatcaatgttggcacaacacaggcacacgtgca
32221
32280
ttggtacctagtagtacgagcagtactatagttacaaccgtgttgtgtccgtgtgcacgt

FIGURE 28


BseRI
Bsu36I
DrdII
tacacttcctcaggattacaagctcctcccgcgttagaaccatatcccagggaacaaccc
32281
32340
atgtgaaggagtcctaatgttcgaggagggcgcaatcttggtatagggtcccttgttggg
PstI
BtsI
SfcI
BbsI
RleAI
BsaAI
DraIII
attcctgaatcagcgtaaatcccacactgcagggaagacctcgcacgtaactcacgttgt
32341
32400
taaggacttagtcgcatttagggtgtgacgtcccttctggagcgtgcattgagtgcaaca
MspA1I
BpmI
gcattgtcaaagtgttacattcgggcagcagcggatgatcctccagtatggtagcgcggg
32401
32460
cgtaacagtttcacaatgtaagcccgtcgtcgcctactaggaggtcataccatcgcgccc
AccI
tttctgtctcaaaaggaggtagacgatccctactgtacggagtgcgccgagacaaccgag
32461
32520
aaagacagagttttcctccatctgctagggatgacatgcctcacgcggctctgttggctc
Pfl1108I
BsbI
Tth111I
atcgtgttggtcgtagtgtcatgccaaatggaacgccggacgtagtcatatttcctgaag
32521
32580
tagcacaaccagcatcacagtacggtttaccttgcggcctgcatcagtataaaggacttc
BsmBI
BglII
BsaWI
SexAI
Eco57I
BstYI
Tth111II
BsaI
caaaaccaggtgcgggcgtgacaaacagatctgcgtctccggtctcgccgcttagatcgc
32581
32640
gttttggtccacgcccgcactgtttgtctagacgcagaggccagagcggcgaatctagcg
HaeII
XcmI
BsaHI
NarI
BanI
tctgtgtagtagttgtagtatatccactctctcaaagcatccaggcgccccctggcttcg
32641
32700
agacacatcatcaacatcatataggtgagagagtttcgtaggtccgcgggggaccgaagc
MspA1I
ggttctatgtaaactccttcatgcgccgctgccctgataacatccaccaccgcagaataa
32701
32760
ccaagatacatttgaggaagtacgcggcgacgggactattgtaggtggtggcgtcttatt
BsrBI
EarI
SapI
TaqII
AceIII
gccacacccagccaacctacacattcgttctgcgagtcacacacgggaggagcgggaaga
32761
32820
cggtgtgggtcggttggatgtgtaagcaagacgctcagtgtgtgccctcctcgcccttct
BglII
BstYI
BseRI
DrdII
gctggaagaaccatgttttttttttattccaaaagattatccaaaacctcaaaatgaag
32821
32880
cgaccttcttggtacaaaaaaaaaaaataaggttttctaataggttttggagttttacttc
BsaWI
SfcI
atctattaagtgaacgcgctcccctccggtggcgtggtcaaactctacagccaaagaaca
32881
32940
tagataattcacttgcgcgaggggaggccaccgcaccagtttgagatgtcggtttcttgt
gataatggcatttgtaagatgttgcacaatggcttccaaaaggcaaacggccctcacgtc
32941
33000
ctattaccgtaaacattctacaacgtgttaccgaaggttttccgtttgccgggagtgcag
BseRI
Eco57I
HgiEII
caagtggacgtaaaggctaaacccttcagggtgaatctcctctataaacattccagcacc

FIGURE 28


33001
gttcacctgcatttccgatttgggaagtcccacttagaggagatatttgtaaggtcgtgg
ttcaaccatgcccaaataattctcatctcgccaccttctcaatatatctctaagcaaatc
33061
aagttggtacgggtttattaagagtagagcggtggaagagttatatagagattcgtttag
BpmI
EaeI
SspI
GdiII
Bce83I
Eco57I
HaeII
SmlI
ccgaatattaagtccggccattgtaaaaatctgctccagagcgccctccaccttcagcct
33121
ggcttataattcaggccggtaacatttttagacgaggtctcgcgggaggtggaagtcgga
Tth111II
RcaI
ApoI
caagcagcgaatcatgattgcaaaaattcaggttcctcacagacctgtataagattcaaa
33181
gttcgtcgcttagtactaacgtttttaagtccaaggagtgtctggacatattctaagttt
Eco0109I
Psp5II
MspA1I
PvuII
BsgI
BspMI
agcggaacattaacaaaaataccgcgatcccgtaggtcccttcgcagggccagctgaaca
33241
tcgccttgtaattgtttttatggcgctagggcatccagggaagcgtcccggtcgacttgt
EaeI
GdiII
MslI
BsgI
taatcgtgcaggtctgcacggaccagcgcggccacttccccgccaggaaccttgacaaaa
33301
attagcacgtccagacgtgcctggtcgcgccggtgaaggggcggtccttggaactgtttt
RleAI
gaacccacactgattatgacacgcatactcggagctatgctaaccagcgtagccccgatg
33361
cttgggtgtgactaatactgtgcgtatgagcctcgatacgattggtcgcatcggggctac
HindIII
taagctttgttgcatgggcggcgatataaaatgcaaggtgctgctcaaaaaatcaggcaa
33421
attcgaaacaacgtacccgccgctatattttacgttccacgacgagttttttagtccgtt
Pfl1108I
MslI
BspMI
agcctcgcgcaaaaaagaaagcacatcgtagtcatgctcatgcagataaaggcaggtaag
33481
tcggagcgcgtttttttctttcgtgtagcatcagtacgagtacgtctatttccgtccattc
NspI
BsaWI
BspEI
DrdII
AflIII
BspLU11I
Tth111II
ctccggaaccaccacagaaaaagacaccatttttctctcaaacatgtctgcgggtttctg
33541
gaggccttggtggtgtctttttctgtggtaaaaagagagtttgtacagacgcccaaagac
DraI
cataaacacaaaataaaataacaaaaaaacatttaaacattagaagcctgtcttacaaca
33601
gtatttgtgttttatttattgtttttttgtaaatttgtaatcttcggacagaatgttgt
BglI
EaeI
BsrFI
GdiII
NgoAIV
ggaaaaacaacccttataagcataagacggactacggccatgccggcgtgaccgtaaaaa
33661
ccttttgttgggaatattcgtatctgcctgatgccggtacggccgcactggcattttt
BsaWI
BspEI
TaqII
BstEII
BseRI
Hin4I
AceIII
aactggtcaccgtgattaaaaagcaccaccgacagctcctcggtcatgtccggagtcata
33721
ttgaccagtggcactaatttttcgtggtggctgtcgaggagccagtacaggcctcagtat
TaqII
BsiEI
atgtaagactcggtaaacacatcaggttgattcatcggtcagtgctaaaaagcgaccgaa
33781
tacattctgagccatttgtgtagtccaactaagtagccagtcacgatttttcgctggctt

FIGURE 28



Enzymes that do cut:

AarI	AatII	AccI	AceIII	AclI	AflII	AflIII	AhdI
AloI	AlwNI	ApaI	ApaLI	ApoI	AscI	AvaI	AvrII
BaeI	BamHI	BanI	BanII	BbsI	BbvCI	Bce83I	BcgI
BciVI	BclI	BglI	BglII	BmgI	BmrI	BplI	BpmI
Bpu10I	Bpu1102I	BsaI	BsaAI	BsaBI	BsaHI	BsaWI	BsaXI
BsbI	BseRI	BseSI	BsgI	BsiEI	BsiHKAI	BsmI	BsmBI
Bsp24I	Bsp1286I	BspEI	BspGI	BspLU11I	BspMI	BsrBI	BsrDI
BsrFI	BsrGI	BssHII	BssSI	BstAPI	BstDSI	BstEII	BstXI
BstYI	BstZ17I	Bsu36I	BtsI	ClaI	DraI	DraIII	DrdI
DrdII	EaeI	EagI	EarI	EciI	Eco47III	Eco57I	EcoNI
Eco0109I	EcoRI	EcoRV	FseI	FspI	GdiII	HaeI	HaeII
HaeIV	HgiEII	Hin4I	HincII	HindIII	HpaI	KpnI	MluI
MmeI	MscI	MslI	MspA1I	MunI	NarI	NcoI	NdeI
NgoAIV	NheI	NotI	NruI	NsiI	NspI	PacI	Pfl1108I
PflMI	PinAI	PmeI	PmlI	PshAI	Psp5II	PstI	PvuI
PvuII	RcaI	RleAI	RsrII	SacI	SacII	SalI	SanDI
SapI	SbfI	ScaI	SexAI	SfcI	SfiI	SgfI	SgrAI
SmaI	SmlI	SnaBI	SpeI	SphI	SrfI	Sse8647I	SspI
StuI	StyI	SunI	SwaI	TaqII	TatI	Tth111I	Tth111II
UbaLI	VspI	XbaI	XcmI	XhoI	XmnI		

Enzymes that do not cut:

NspV

FIGURE 28



FIGURE 29

gp19K



FIGURE 30A

RIDβ



FIGURE 30B

14.7K



FIGURE 30C

Practitioner's Docket No. 16153-5587 **PATENT**

COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL, CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is of the following type:

(check one applicable item below)

☒ original.

☐ design.

☐ supplemental.

NOTE: If the declaration is for an International Application being filed as a divisional, continuation or continuation-in-part application, do not check next item; check appropriate one of last three items.

☐ national stage of PCT.

NOTE: If one of the following 3 items apply, then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR C-I-P.

NOTE: See 37 C.F.R. § 1.63(d) (continued prosecution application) for use of a prior nonprovisional application declaration in the continuation or divisional application being filed on behalf of the same or fewer of the inventors named in the prior application.

☐ divisional.

☐ continuation.

NOTE: Where an application discloses and claims subject matter not disclosed in the prior application, or a continuation or divisional application names an inventor not named in the prior application, a continuation-in-part application must be filed under 37 C.F.R. § 1.53(b) (application filing requirements — nonprovisional application).

☐ continuation-in-part (C-I-P).

INVENTORSHIP IDENTIFICATION

WARNING: *If the inventors are each not the inventors of all the claims, an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.*

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am the original, first and sole inventor *(if only one name is listed below)* or an original, first and joint inventor *(if plural names are listed below)* of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

INHIBITING APOPTOSIS WITH ADENOVIRUS RID PROTEIN

SPECIFICATION IDENTIFICATION

the specification of which:

(complete (a), (b), or (c))

(a) ☒ is attached hereto.

NOTE: "The following combinations of information supplied in an oath or declaration filed on the application filing date with a specification are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 CFR 1.63:

"(1) name of inventor(s), and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration on filing;

"(2) name of inventor(s), and attorney docket number which was on the specification as filed; or

"(3) name of inventor(s), and title which was on the specification as filed."

Notice of July 13, 1995 (1177 O.G. 60).

(b) ☐ was filed on _____, as ☐ Serial No. 0 /_____ or ☐ _____ and was amended on _____ *(if applicable).*

NOTE: Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67.

NOTE: "The following combinations of information supplied in an oath or declaration filed after the filing date are acceptable as minimums for identifying a specification and compliance with any one of the items below will be accepted as complying with the identification requirement of 37 CFR 1.63:

"(1) name of inventor(s), and application number (consisting of the series code and the serial number; e.g.,08/123,456);

"(2) name of inventor(s), serial number and filing date;

"(3) name of inventor(s) and attorney docket number which was on the specification as filed;

"(4) name of inventor(s), title which was on the specification as filed and filing date;

"(5) name of inventor(s), title which was on the specification as filed and reference to an attached specification which is both attached to the oath or declaration at the time of execution and submitted with the oath or declaration; or

"(6) name of inventor(s), title which was on the specification as filed and accompanied by a cover letter accurately identifying the application for which it was intended by either the application number (consisting of the series code and the serial number; e.g.,08/123,456), or serial number and filing date. Absent any statement(s) to the contrary, it will be presumed that the application filed in the PTO is the application which the inventor(s) executed by signing the oath or declaration."

Notice of July 13, 1995 (1177 O.G. 60).

(c) ☐ was described and claimed in PCT International Application No. _____, filed on _____ and as amended under PCT Article 19 on _____ *(if any).*

SUPPLEMENTAL DECLARATION (37 C.F.R. § 1.67(b))

(complete the following where a supplemental declaration is being submitted)

☐ I hereby declare that the subject matter of the

☐ attached amendment

☐ amendment filed on _____

was part of my/our invention and was invented before the filing date of the original application, above-identified, for such invention.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, § 1.56,

(also check the following items, if desired)

☐ and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and

☐ in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.

PRIORITY CLAIM (35 U.S.C. §§ 119(a)–(d))

NOTE: *"The claim to priority need be in no special form and may be made by the attorney or agent if the foreign application is referred to in the oath or declaration as required by § 1.63. The claim for priority and the certified copy of the foreign application specified in 35 U.S.C. 119(b) must be filed in the case of an interference (§ 1.630), when necessary to overcome the date of a reference relied upon by the examiner, when specifically required by the examiner, and in all other situations, before the patent is granted. If the claim for priority or the certified copy of the foreign application is filed after the date the issue fee is paid, it must be accompanied by a petition requesting entry and by the fee set forth in § 1.17(i). If the certified copy is not in the English language, a translation need not be filed except in the case of interference; or when necessary to overcome the date of a reference relied upon by the examiner; or when specifically required by the examiner, in which event an English language translation must be filed together with a statement that the translation of the certified copy is accurate." 37 C.F.R. § 1.55(a).*

I hereby claim foreign priority benefits under Title 35, United States Code, §§ 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

(d) ☒ no such applications have been filed.

(e) ☐ such applications have been filed as follows.

NOTE: *Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.*

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
			☐ YES NO ☐
			☐ YES NO ☐
			☐ YES NO ☐
			☐ YES NO ☐
			☐ YES NO ☐

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)

(34 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
60 / 088,993	7/9/97
/	
/	

CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

☐ The claim for the benefit of any such applications are set forth in the attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN PART (C-I-P) APPLICATION.

ALL FOREIGN APPLICATION(S), *IF ANY*, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

_____

_____

_____

NOTE: If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-in-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120.

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

John M. Howell (25,261); Richard E. Haferkamp (29,072); Kenneth Solomon (31,427); Joseph M. Rolnicki (32,653); Joseph E. Walsh, Jr. (36,959); Alan H. Norman (32,285); Donald R. Holland (35,197); Bryan K. Wheelock (31,441); Charles E. Dunlap (35,124); Anthony G. Simon (40,813); Alan L. Cassel (35,842); Michael J. Thomas (39,857); Thomas A. Polcyn (41,256); Melodie W. Henderson (37,848); and Michael E. Kondoudis (P42,758)

(check the following item, if applicable)

☐ I hereby appoint the practitioner(s) associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

☐ Attached, as part of this declaration and power of attorney, is the authorization of the above-named practitioner(s) to accept and follow instructions from my representative(s).

SEND CORRESPONDENCE TO

☒ Address

Donald R. Holland
HOWELL & HAFERKAMP, L.C.
7733 Forsyth, Suite 1400
St. Louis, Missouri 63105

☐ Customer Number _____

DIRECT TELEPHONE CALLS TO:
(Name and telephone number)

Donald R. Holland
(314) 727-5188

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

Full name of sole or first inventor

William (*GIVEN NAME*) S. M. (*MIDDLE INITIAL OR NAME*) Wold (*FAMILY OR LAST NAME*)

Inventor's signature William S M Wold July 8, 1998

Date July 8, 1998 **Country of Citizenship** Canada

Residence 1609 Adgers Wharf, Chesterfield, Missouri 63017

Post Office Address 1609 Adgers Wharf, Chesterfield, Missouri 63017

Full name of second joint inventor, if any

(*GIVEN NAME*) (*MIDDLE INITIAL OR NAME*) (*FAMILY OR LAST NAME*)

Inventor's signature _____

Date _____ **Country of Citizenship** _____

Residence _____

Post Office Address _____

Full name of third joint inventor, if any

(*GIVEN NAME*) (*MIDDLE INITIAL OR NAME*) (*FAMILY OR LAST NAME*)

Inventor's signature _____

Date _____ **Country of Citizenship** _____

Residence _____

Post Office Address _____

(check proper box(es) for any of the following added page(s) that form a part of this declaration)

☐ **Signature** for fourth and subsequent joint inventors. *Number of pages added* _____.

* * *

☐ **Signature** by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. *Number of pages added* _____.

* * *

☐ **Signature** for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. *Number of pages added* _____

* * *

☐ Added page for **signature** by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)

* * *

☐ Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.

☐ Number of pages added _____

* * *

☐ Authorization of practitioner(s) to accept and follow instructions from representative.

* * *

(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)

☒ This declaration ends with this page.

Attorney's Docket No. 16153-5587 **PATENT**

☒ Applicant ☐ Patentee _____

☐ Application No. ☐ Patent No. _____

☐ Filed on ☐ Issued on _____

Title: Inhibiting Apoptosis with Adenovirus RID Protein

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27(d))—NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

Name of Nonprofit Organization Saint Louis University

Address of Nonprofit Organization 221 N. Grand
St. Louis, Misouri 63103

TYPE OF NONPROFIT ORGANIZATION

☒ University or Other Institution of Higher Education

☐ Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3))

☐ Nonprofit Scientific or Educational Under Statute of State of the United States of America

(Name of State _____)

(Citation of Statute _____)

☐ Would Qualify as Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3)), if Located in the United States of America

☐ Would Qualify as Nonprofit Scientific or Educational Under Statute of State of the United States of America if Located in the United States of America

(Name of State _____)

(Citation of Statute _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees to the United States Patent and Trademark Office under Sections 41(a) and (b) of Title 35, United States Code, with regard to the invention described in

☒ the specification filed herewith, with title as listed above.

☐ the application identified above.

☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to, and remain with, the nonprofit organization, with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. 1.9(c), if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e)

*NOTE: *Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).*

Each such person, concern or organization having any rights in the invention is listed below:

☒ No such person, concern, or organization exists.

☐ Each such person, concern or organization is listed below.

Name _____

Address _____

_____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

Name _____

Address _____

_____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any charge in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Name of Person Signing Robert M. Swanson, Ph.D.

Title in Organization Associate Provost

Address of Person Signing 3556 Caroline Street

St. Louis, Missouri 63104

SIGNATURE _____ Date 7/7/98

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
   - ☐ All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2"x 11". Pages _____ do not meet these requirements.
   - ☐ Papers are not flexible, strong, smooth, non-shiny, durable, and white.
   - ☐ Papers are not typewritten or mechanically printed in permanent ink on one side.
   - ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
   - ☐ Papers contain hand lettering.

2. Drawings are not in compliance and were not scanned because:
   - ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
   - ☐ All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
   - ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").

3. Page(s) 6,9,11,12,24,25 are not of sufficient clarity, contrast and quality for electronic reproduction.

4. Page(s)_____ are missing.

5. OTHER:_____